

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Université du Québec
Institut National de la Recherche Scientifique
INRS-Institut Armand-Frappier

Production de composés bioactifs par des levures et évaluation de leurs propriétés biologiques envers le cancer colorectal

Par
Olivier Fortin

Mémoire présentée pour l'obtention du grade de Maître ès sciences (M.Sc.) en
microbiologie appliqué

46

Jury d'évaluation

47

48

Président de Jury

Dr. Marie-Élise Parent
INRS-Institut Armand-Frappier

49

50

51

52

53

54

Examineur externe

Dr. George Szatmari
Université de Montréal

55

56

57

58

59

Examineur interne

Dr. Marie-Élise Parent
INRS-Institut Armand-Frappier

60

61

62

63

64

Directeur de recherche

Dr. Monique Lacroix
INRS-Institut Armand-Frappier

65

66

67

68

69

Codirecteur de recherche

Dr. Blanca Rosa Aguilar-Uscanga
Universidad de Guadalajara

70

71

72

© Droits réservés de Olivier Fortin, 2016

73

74

75

76

77

78

79

80

81

82

83

84

85

À la douce mémoire de ma mère

86

87

88 **REMERCIEMENTS**

89 La réalisation de ce mémoire a été possible grâce à la contribution d'un grand nombre de personnes.
90 En tout premier lieu, j'aimerais remercier Dr. Monique Lacroix pour m'avoir donné l'opportunité
91 de travailler au sein de son groupe de recherche et de m'avoir supervisé tout au long de mon passage
92 à la maîtrise. De plus, j'aimerais remercier ma co-directrice Dr. Blanca Rosa Aguilar-Uscanga pour
93 ses nombreux conseils et sa grande disponibilité malgré l'éloignement géographique. J'aimerais
94 aussi remercier Dr. Khanh Dang Vu et Mr. Stéphane Salmieri pour leur grande écoute ainsi que
95 pour les nombreuses discussions scientifiques que nous avons eues. Finalement, je me dois de
96 remercier mon amoureuse ainsi que mes parents et ma tante qui m'ont épaulé tout au long de mon
97 parcours académique et qui me sont très chers.
98

TABLE DES MATIÈRES

100	REMERCIEMENTS	iv
101	TABLE DES MATIÈRES.....	v
102	RÉSUMÉ.....	x
103	LISTE DES ABRÉVIATIONS	xi
104	LISTE DES FIGURES	xiii
105	CHAPITRE 1 – INTRODUCTION	1
106	Revue bibliographique	2
107	1.1. Généralités sur le cancer colorectal (CCR)	2
108	1.2. Aperçu des traitements contre le CCR disponible au Canada	3
109	1.3. L’option de la chimioprévention	5
110	1.3.1. Les enzymes de phase II.....	5
111	1.3.2. Les espèces réactives de l’oxygène (ERO).....	6
112	1.3.3. La cytotoxicité cellulaire et les tests antiprolifératifs	6
113	1.3.4. La mort cellulaire programmée (apoptose)	7
114	1.3.5. Le microbiote intestinal et les enzymes fécales.....	7
115	1.4. Les parois cellulaires de levures.....	8
116	1.4.1. L’architecture et la composition des parois cellulaires de levures	9
117	1.4.2. Propriétés anticancer et chimiopréventives des parois cellulaires de levures et de	
118	ces composantes	11
119	1.5. Les huiles essentielles (HE).....	13
120	1.5.1. Les constituants chimiques des HE	13
121	1.5.2. L’activité anticancer et chimiopréventive des HE.....	14
122	1.5.3. Les HE de <i>Boswellia</i> spp.....	14
123	1.5.4. Activités anticancer des huiles de <i>Boswellia carterii</i> et de <i>B. sacra</i>	15
124	1.6. Les traitements combinés dans la lutte contre le cancer.....	18
125	1.6.1. Les β -glucanes de levures utilisées en combinaison dans la lutte contre le cancer	
126	19	
127	1.6.2. Les HE utilisées en combinaison dans la lutte contre le cancer	19

128	2. But, hypothèses et objectifs.....	20
129	CHAPITRE 2 - PUBLICATION 1.....	22
130	2.1. Contribution des auteurs.....	24
131	2.2. Résumé en français.....	25
132	2.3. Abstract	27
133	2.4. Introduction	28
134	2.5. Material and methods	30
135	2.5.1. Material	30
136	2.5.2. Yeast strains and growth conditions.....	31
137	2.5.3. Growth kinetics	32
138	2.5.4. Biomass collect and cell wall preparation	32
139	2.5.5. Extraction of yeast glucan and mannoprotein extracts	33
140	2.5.6. Total sugars quantification	33
141	2.5.7. Glucan and mannan quantification by HPLC.....	34
142	2.5.8. Chitin quantification.....	34
143	2.5.9. Molecular weight determination by gel permeation chromatography (GPC)	35
144	2.5.10. Cancerous cell lines and cell maintenance	36
145	2.5.11. NAD(P)H:QR assay	37
146	2.5.12. Antiradical assay (O_2^- anion scavenging activity)	38
147	2.5.13. Antiproliferative assay.....	39
148	2.5.14. Statistical analysis	40
149	2.6. Results	41
150	2.6.1. Growth kinetics	41
151	2.6.2. Solubility and visual appearances of yeast cell wall extracts.....	41
152	2.6.3. Quantification of total sugars, chitin, glucan, mannan in the extracts and Mw	
153	determination.....	42
154	2.6.4. Determination of relative concentrations in total sugars, chitin, glucan and mannan	
155	content in the extracts.....	43
156	2.6.5. Biological activities of commercial β -glucan.....	44
157	2.6.6. Cancer chemopreventive activity of yeast cell wall extracts.....	45
158	2.6.7. Antiradical activity of yeast cell wall extracts.....	45
159	2.6.8. Antiproliferative activity of yeast cell wall extracts.....	46

160	2.6.9. Relationship between the contents of yeast cell wall polysaccharide and their	
161	biological activities.....	47
162	2.7. Discussion	48
163	2.8. Acknowledgements	56
164	CHAPITRE 3 – PUBLICATION 2.....	66
165	3.1. Contribution des auteurs.....	68
166	3.2. Résumé en français.....	69
167	3.3. Abstract	71
168	3.4. Introduction	72
169	3.5. Methods.....	74
170	3.5.1. Materials.....	74
171	3.5.2. Extraction of insoluble glucan and mannoprotein extracts from yeast cell walls and	
172	their preparation for administration by gavage.....	75
173	3.5.3. Animals, housing and diet	76
174	3.5.4. Experimental design	76
175	3.5.5. Aberrant crypt analysis.....	77
176	3.5.6. Liver and caecum processing	78
177	3.5.7. Protein estimation.....	78
178	3.5.8. QR assay.....	79
179	3.5.9. β -glucosidase and β -glucuronidase assay	79
180	3.5.10. Statistical analysis	80
181	3.6. Results	80
182	3.6.1. Determination of total number of aberrant crypt (AC) and aberrant crypt foci (ACF)	
183	per colon.....	80
184	3.6.2. Determination of the number of aberrant crypt foci (ACF) containing a multiplicity of	
185	aberrant crypt (AC).....	81
186	3.6.3. Induction of QR activity determined in liver supernatant	82
187	3.6.4. β -glucuronidase and β -glucosidase activities determined in caecum content	83
188	3.7. Discussion	84
189	3.8. Acknowledgements	89
190	CHAPITRE 4 - PUBLICATION 3.....	97
191	4.1. Contribution des auteurs.....	99

192	4.2. Résumé en français.....	100
193	4.3. Abstract	101
194	4.4. Introduction	102
195	4.5. Method.....	105
196	4.5.1. Chemicals	105
197	4.5.2. EOs preparation	106
198	4.5.3. Extraction of insoluble glucan from <i>S. boulardii</i> cell wall.....	106
199	4.5.4. Cancerous cell lines and cells maintenance.....	107
200	4.5.5. Antiradical assays (O_2^- and DPPH radicals scavenging activity).....	107
201	4.5.6. NAD(P)H: QR assay	108
202	4.5.7. Molecular weight determination by gel permeation chromatography (GPC)	109
203	4.5.8. Antiproliferative assay.....	110
204	4.5.9. Assessing interaction between EOs and insoluble glucan regarding antiproliferative	
205	and NAD(P)H: QR assays	111
206	4.5.10. Apoptosis assay	112
207	4.5.11. Statistical analysis	113
208	4.6. Results	113
209	4.6.1. Evaluation of the antiradical properties of EOs.....	113
210	4.6.2. Effect of EOs in combination with insoluble glucan on the induction of NAD(P)H: QR	
211	and molecular weight	114
212	4.6.3. Effect of EOs in combination with insoluble glucan on the cellular proliferation of	
213	different cell lines	115
214	4.6.4. Effect of essential oils on the level of apoptosis in human colorectal cancer cells ...	117
215	4.7. Discussion	118
216	4.7.1. Evaluation of the antiradical properties of EOs.....	118
217	4.7.2. Effect of EOs in combination with insoluble glucan on the induction of NAD(P)H: QR	
218	and Mw determination.....	119
219	4.7.3. Effect of EOs in combination with insoluble glucan on the cellular proliferation of	
220	different cell lines	121
221	4.7.4. Effect of EOs on the level of apoptosis in human colorectal cancer cells.....	123
222	4.8. Conclusion.....	124
223	4.9. Acknowledgements	125
224	CHAPITRE 5 – DISCUSSION ET CONCLUSION GÉNÉRALES	132

225 5.1. Discussion générale 133

226 5.2. Conclusion générale 140

227 BIBLIOGRAPHIE 142

228 ANNEXE I : VERSION SOUMISE DE LA PUBLICATION 1 152

229 ANNEXE II : COLLABORATION 185

230

231

232 RÉSUMÉ

233 La chimioprévention est un processus par lequel l'utilisation d'agent chimiopréventif naturel ou
234 synthétique permet de prévenir la progression du cancer. Son importance dans la lutte contre le
235 cancer colorectal est justifiée par le fait que cette maladie représente le troisième cancer le plus
236 répandu au Canada malgré les différents traitements offerts et plus d'une décennie de recherche. Il
237 a été démontré que l'alimentation est liée à l'incidence d'environ 70% des cancer colorectaux.
238 Donc, la consommation d'agents à fort potentiel chimiopréventif pourrait conduire à une réduction
239 de l'incidence de ce cancer.

240 Les parois cellulaires de levures sont étudiées pour leurs différentes propriétés anticancer et
241 immunomodulatrices en plus de démontrer un potentiel d'application dans les domaines
242 pharmaceutiques, médical et alimentaires. Nonobstant plusieurs décennies de recherche
243 investiguant leurs capacités thérapeutiques, relativement peu d'études ont rapporté le potentiel
244 chimiopréventif des composantes de parois cellulaires de levures envers le cancer colorectal
245 humain.

246 Cette étude avait pour but de démontrer le potentiel chimiopréventif des composantes de parois
247 cellulaires de levures en modèle *in vitro* et *in vivo* envers le cancer colorectal. En premier lieu, il a
248 été démontré que les β -glucanes insolubles de *Saccharomyces cerevisiae* var. *boulardii* possédaient
249 une excellente capacité à induire la quinone réductase (enzyme impliquée dans la prévention du
250 cancer) et démontraient une meilleure capacité à inhiber la croissance de cellules du cancer
251 colorectal humain en comparaison aux autres extraits de *S. boulardii* et que ceux de *Kluyveromyces*
252 *marxianus*. De plus, l'extrait de mannoprotéines de *S. boulardii* a présenté une excellente capacité
253 antiradicalaire et antiproliférative envers les cellules cancéreuses. La quantification des
254 polysaccharides au sein des échantillons suggère que les β -glucanes ont constitué la composante
255 contribuant le plus significativement à l'activité biologique observée.

256 En second lieu, le potentiel chimiopréventif de ces deux meilleurs extraits a été évalué chez des
257 rats traités au 1,2-diméthylhydrazine. Les résultats ont démontré que seuls les β -glucanes insolubles
258 de *S. boulardii* étaient en mesure de réduire le nombre de lésions précancéreuses (cryptes
259 aberrantes) considérées comme étant la première étape de la carcinogenèse du cancer colorectal.
260 L'étude du mécanisme sous-jacent suggère une diminution du temps de transit des carcinogènes au
261 sein du tractus digestif via une modulation de l'activité spécifique de la quinone réductase au niveau
262 hépatique et d'une enzyme fécale (β -glucuronidase).

263 Finalement, des huiles essentielles de *Boswellia carterii* (Frankincense) et de *B. sacra* (Sacrée) ont
264 été ajoutées aux extraits de β -glucanes insolubles de *S. boulardii* afin d'évaluer la possibilité d'une
265 synergie potentielle pour les propriétés chimiopréventives entre les types de composés. Alors que
266 l'huile Sacrée a démontré un effet cytotoxique spécifique aux cellules cancéreuses, la combinaison
267 entre les β -glucanes insolubles de *S. boulardii* a induit la perte de cette activité. De plus, l'huile
268 Frankincense combinée aux β -glucanes insolubles a été en mesure de démontrer une induction de
269 la quinone réductase supérieure via un effet additif en comparaison avec celle de cette même huile
270 testée séparément. Cette étude a permis de démontrer que les β -glucanes insolubles extraient de la
271 paroi cellulaire de *S. boulardii*, souche de levure considérée comme probiotique et à fort potentiel
272 industriel, pourraient être utilisés dans la fabrication d'un produit nutraceutique ou comme
273 ingrédient fonctionnel dans une optique de prévention du cancer colorectal humain ou même sous
274 la forme de fibre naturelle.

275

LISTE DES ABRÉVIATIONS

AK-BA	acétyl-keto- β -acide boswellique
AB	acide boswellique
CCR	cancer colorectal
CD	concentration doublant le niveau d'induction de la NAD(P)H : quinone réductase
CI	combinatory index
DMH	N,N-diméthylhydrazine
DMSO	Diméthylsulfoxyde
DPPH	α,α -diphényl- β -picrylhydrazil
EDTA	acide éthylènediaminetétraacétique
EOs	essential oils
FCA	foyers de cryptes aberrantes
HE	huile essentielle
IC ₅₀	concentration inhibant 50% de la croissance cellulaire
IP	inhibition percentage
kDa	kilo Dalton
K-AB	keto- β -acide boswellique
NMP	N-méthylpyrrolidone
PMMA	polyméthyl méthacrylate
QR	NAD(P)H : quinone réductase
SC ₅₀	concentration captant 50% l'accumulation de radicaux libre formée
Tween-80	polyoxyéthylène sorbitan monooléate
Mw	molecular weight
X/XO	xanthine/xanthine oxydase
5-FU	5-fluorouracil

LISTE DES TABLEAUX

Tableau 1.1	Résumé des traitements contre le CCR disponible au Canada accompagnés de leurs effets secondaires courants	4
Tableau 1.2	Teneurs relatives des différentes composantes typiquement retrouvées dans les parois cellulaires de levures (<i>S. cerevisiae</i>)	11
Tableau 2.1	Solubility and visual appearance of yeast cell wall extracts obtained after single hot-alkaline extraction for both strains.	57
Tableau 2.2	Sugars quantification and Mw range determination of extracts.	58
Tableau 2.3	Ratios in glucan, mannan and chitin regarding all extracts.	59
Tableau 4.1	Effect of EOs used separately and in combination with insoluble glucan on the induction of QR	127
Tableau 4.2	Effect of EOs used separately and in combination with insoluble glucan on the cellular proliferation of different cell lines	128
Tableau A.1	Solubility and visual appearance of yeast cell wall extracts obtained after single hot-alkaline extraction for both strains.	181
Tableau A.2	Sugar quantification and Mw range determination of extracts.	182
Tableau A.3	Ratios in glucan, mannan and chitin regarding all extracts.	183
Tableau A.4	Effect of yeast cell wall extracts on quinone reductase induction, superoxide anion scavenging capacity and antiproliferative property.	184

LISTE DES FIGURES

Figure 1.1	Carcinogénèse du cancer colorectal. L'inhibition ou l'atténuation de la formation des foyers de cryptes aberrantes (flèche rouge) constitue une approche clef dans la prévention du CCR.	2
Figure 1.2	Organisation typique des parois cellulaires de levures (<i>S. cerevisiae</i>). Les termes <i>outside</i> et <i>inside</i> réfèrent au milieu externe et interne de la cellule respectivement. CWP; Cell Wall Proteins. GPI; Ancre de glycosylphosphatidylinositol. ASL; Alkali-Sensitive Linkage.	10
Figure 1.3	Apparence d'une gomme de résine utilisée pour produire les huiles Frankincenses.	15
Figure 2.1	Growth kinetics of <i>S. boulardii</i> and <i>K. marxianus</i> based on dry biomass in time function. (■) <i>S. boulardii</i> , (□) <i>K. marxianus</i> .	60
Figure 2.2	Induction of NAD(P)H: quinone reductase of untreated cells, negative control, β -Naphthoflavone and commercial insoluble glucan extracted from <i>S. cerevisiae</i> (bakery strain) using alkaline extraction method. (□) β -Naphthoflavone (β -NF), (■) Untreated cells, (▣) 1% DMSO + 20 ppm sodium azide (NC), (▤) Commercial glucan.	61
Figure 2.3	Antiproliferative assay against HT-29 cells using increasing concentration of commercial insoluble glucan from <i>S. cerevisiae</i> . (▥) Commercial glucan.	62
Figure 2.4	Induction of NAD(P)H quinone reductase concerning increasing concentration of all extracts obtained from both yeast strains. (▧) <i>S. boulardii</i> soluble extract, (■) <i>S. boulardii</i> insoluble extract, (▣) <i>S. boulardii</i> mannoprotein extract, (▩) <i>K. marxianus</i> soluble extract, (□) <i>K. marxianus</i> insoluble extract, (▨) <i>K. marxianus</i> mannoprotein extract.	63
Figure 2.5	Percentage of scavenging activity of increasing concentration of all extracts obtained from both yeast strains against superoxide anion. (▧) <i>S. boulardii</i> soluble extract, (▣) <i>S. boulardii</i> mannoprotein extract, (▩) <i>K. marxianus</i> soluble extract, (▨) <i>K. marxianus</i> mannoprotein extract.	64
Figure 2.6	Growth inhibition of HT-29 cell line using a) increasing concentration of extracts obtained from <i>S. boulardii</i> and b) from <i>K. marxianus</i> along with c) IC ₅₀ values for each extracts. (▧) <i>S. boulardii</i> soluble extract, (■) <i>S. boulardii</i> insoluble extract, (▣) <i>S. boulardii</i> mannoprotein extract, (▩) <i>K. marxianus</i> soluble extract, (□) <i>K. marxianus</i> insoluble extract, (▨) <i>K. marxianus</i> mannoprotein extract, (▥) Commercial glucan.	65

Figure 3.1	Diagram representing the experimental design. Forty-eight rats were divided in 6 groups and were fed with high fat low fibre diet for 13 weeks. After one acclimation week, all rats were injected with saline water (G1) or DMH (G2 to G6) and received by gavage Tween-80 solution (G1 and G2) or different concentration of insoluble glucan (G3 and G4) and mannoprotein extract (G5 and G6). At the 13 th week, all rats were sacrificed then colon, caecum and liver were collected for subsequent analysis.	90
Figure 3.2	Numbers (n) of precancerous lesions induced by DMH in rats treated with insoluble glucan and mannoprotein extracts regarding a) total number of aberrant crypt (AC) and b) total aberrant crypt foci (ACF) per colon. NC: Saline + Tween only, PC: Saline + Tween + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour mannoprotein extract.	91
Figure 3.3	Numbers (n) of precancerous lesions induced by DMH in rats treated with insoluble glucan and mannoprotein extracts regarding number of aberrant crypt foci (ACF) containing a multiplicity of AC per focus. (■) ACF containing two to three AC, (□) ACF containing four to five AC. NC: Saline + Tween only, PC: Saline + Tween + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour mannoprotein extract.	93
Figure 3.4	Induction of QR activity in liver supernatant of DMH treated rats treated with insoluble glucan and mannoprotein extracts. NC: Saline + Tween only, PC: Saline + Tween + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour mannoprotein extract	94
Figure 3.5	β -glucuronidase assay in caecum content of DMH treated rats treated with insoluble glucan and mannoprotein extracts. NC: Saline + Tween only, PC: Saline + Tween + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour mannoprotein extract.	95
Figure 3.6	β -glucosidase assay in caecum content of DMH treated rats treated with insoluble glucan and mannoprotein extracts. NC: Saline + Tween only, PC: Saline + Tween + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan, G5: DMH + 0.3	96

mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour mannoprotein extract.

- Figure 4.1** Effect of increasing concentration of Frankincense and Sacred EOs on the percentage of (A) O₂- and (B) DPPH radical inhibition using xanthine/xanthine oxidase (X/XO) and DPPH methods respectively. Asterisk (*) indicates the concentration that scavenged 50% of radicals formed (SC50 value) above respective EO. Error bars represent the standard deviation of the mean of at least 3 independent experiments. 126
- Figure 4.2** Effect of increasing concentration of Frankincense and Sacred EOs surrounding IC₅₀ values on the percentage of (A) apoptotic cells (Annexin V+ PI- cells) and (B) necrotic cells (Annexin V+ PI+ cells) in human colorectal cancer HT-29 cells determined by flow cytometry using Annexin V-FITC and PI double staining method after 48 h of treatment. Positive control (PC) and Negative control (NC) consisted in cells treated with 500 µg/ml of 5-fluorouracil and emulsifying solution respectively. Error bars represent the standard deviation of the mean of at least 3 independent experiments. Means followed by different letters are significantly different ($p \leq 0.05$). 130
- Figure A.1** Growth kinetics of *S. boulardii* and *K. marxianus* based on dry biomass in time function. 180

283

CHAPITRE 1 – INTRODUCTION

284

285 Revue bibliographique

286

287 1.1. Généralités sur le cancer colorectal (CCR)

288 Le CCR reste toujours un enjeu de taille en matière de santé au Canada malgré plusieurs années de
289 recherches intensives. En 2014, ce cancer fût reconnu comme étant le second cancer le plus
290 meurtrier chez les hommes et le troisième chez la femme en plus d'être le troisième plus répandu
291 chez les deux sexes (Canadian Cancer Society's Advisory *et al.*, 2014, Canadian Digestive Health
292 Foundation, 2016). Le CCR est le résultat d'une série de changements histopathologiques débutant
293 par l'apparition de foyers de cryptes aberrantes et aboutissant généralement à un adénocarcinome
294 (Figure 1.1) (Karoui *et al.*, 2007). La carcinogenèse du CCR s'explique par plusieurs facteurs de
295 risque dont la plupart sont environnementaux et/ou liés au mode de vie. Parmi ces derniers notons
296 un régime alimentaire constitué principalement de viande rouge et pauvre en fibres, fruits et
297 légumes ainsi qu'un trop faible niveau d'activité physique (Hagggar *et al.*, 2009, Stevens *et al.*,
298 2007). Nonobstant ces facteurs de risque bien identifiés, le CCR représente encore aujourd'hui une
299 dépense économique importante pour le Canada sans parler des dommages émotionnels infligés
300 aux familles canadiennes.

301



302 **Figure 1.1** : Carcinogenèse du cancer colorectal. L'inhibition ou l'atténuation de la formation des foyers de
303 cryptes aberrantes (flèche rouge) constitue une approche clef dans la prévention du CCR. Image modifiée
304 de Karoui *et al.* (2007).

305

306

307 **1.2. Aperçu des traitements contre le CCR disponibles au Canada**

308 Les traitements contre le CCR sont soit de nature local ou systémique. Les traitements locaux
309 impliquent essentiellement en la chirurgie et la radiothérapie et visent l’ablation ou la destruction
310 des cellules cancéreuses dans la région touchée. En contrepartie, les traitements systémiques
311 englobent les chimiothérapies et les thérapies ciblées. Le choix du traitement à accepter peut-être
312 un fardeau pour le patient (et sa famille), et dépend fortement de la taille, du site et de l’étendue de
313 la tumeur ou du polype. De plus, différentes variantes de chaque traitement existent et visent soit
314 la guérison, la prolongation de la vie ou la limitation des effets secondaires (traitements du contrôle
315 ou maintient) ou plutôt à l’amélioration de la qualité de la vie du patient (traitement palliatif)
316 (Colorectal Cancer Association of Canada, 2017).

317 Parmi tous les traitements disponibles, la chirurgie constitue encore le principal traitement utilisé
318 contre le CCR (toutes méthodes confondues) et est envisageable à différents stades de la
319 carcinogenèse, soit l’ablation du polype bénin ou une colectomie qui vise à enlever une section
320 complète du colon. Alors que la chirurgie permet d’éliminer la tumeur ou le polype, la principale
321 limite de ce traitement est l’impossibilité de s’assurer de l’élimination de toutes les cellules
322 cancéreuses en périphérie de la zone atteinte. La radiothérapie, tant qu’à elle, agit en endommageant
323 l’ADN des cellules cancéreuses visées ce qui limite leur division cellulaire mais est aussi connue
324 pour atteindre les cellules normales ce qui constitue la principale limite de ce traitement. Les
325 traitements de radiothérapies sont soit externe, interne ou peropératoire. La radiothérapie externe,
326 souvent utilisé en combinaison avec la chimiothérapie, est le type de radiothérapie la plus commune
327 et consiste à faire pénétrer des rayons de fortes énergies au travers de la peau en direction des
328 cellules cancéreuses à partir d’une source externe. La radiothérapie interne, utilisé chez les patients
329 qui ne pourront pas supporter la chirurgie, consiste à implanter ou à injecter un composé radioactif
330 à proximité de la tumeur et contraste avec la radiothérapie peropératoire qui est administré durant
331 une chirurgie et consiste, tant qu’à elle, en une seule dose massive de radiothérapie externe
332 (Canadian Cancer Society, 2017a, Colorectal Cancer Association of Canada, 2017).

333 Les produits utilisés dans le cadre des traitements systémiques sont essentiellement administrés via
334 le sang ou de manière orale et consiste en des molécules anticancéreuses qui inhibent la croissance
335 cellulaire (arrêt du cycle cellulaire, apoptose) ou induit un effet cytotoxique chez les cellules
336 cancéreuses ciblées. Même si l’effet cytotoxique est ciblé envers les cellules cancéreuses, il n’en
337 reste pas moins que les cellules saines en sont affectées puisque plusieurs composés

338 chimiothérapeutiques ciblent en fait les cellules à forte division cellulaire (ex. cellules des follicules
 339 pileux) ce qui se traduit en de très lourds effets secondaires. En revanche, les traitements de thérapie
 340 ciblés impliquent l'utilisation de composés (ex. anticorps monoclonaux) qui tentent d'intervenir au
 341 niveau d'une étape ou d'une composante spécifique à la biologie des cellules cancéreuses
 342 diminuant ainsi les effets secondaires. Cependant, de tels traitements ne sont disponibles que pour
 343 les cas de CCR métastatiques. En plus d'être dispendieux, ils nécessitent d'être combinés à des
 344 traitements de chimiothérapies pour en augmenter leur efficacité (Canadian Cancer Society, 2017b,
 345 Colorectal Cancer Association of Canada, 2017).

346 **Tableau 1.1** : Résumé des traitements contre le CCR disponible au Canada accompagnés de leurs effets
 347 secondaires courants

Traitement	Exemples	Objectif	Effets secondaires courants
Chirurgie	Excision locale, résection intestinale, colostomie, iléostomie, exentération pelvienne	Ablation de la tumeur	Douleur, saignement, infection, problème de digestion et urinaire, fatigue, etc.
Chimiothérapie	5-fluorouracil, Capécitabine, Oxaliplatine, Irinotécan, Raltitrexed	Éliminer chimiquement les cellules cancéreuses	Perte de cheveux, faiblesse, vomissement, étourdissement, atteinte de la moelle osseuse, constipations, perte d'appétit, diarrhée/constipation, douleur musculaire, etc.
Radiothérapie	Radiothérapie externe, interne et peropératoire	Destruction des cellules cancéreuses par rayons X	Brûlure (douleur), fatigue, problème d'intestin et de vessie, atteinte de la moelle osseuse, cicatrice sur la peau, etc.
Traitements ciblés (biothérapies)	Bévacizumab, Cétuximab, Panitumumab, Régorafénib	Attaquer une cible ou une étape particulière du processus tumorigénèse	Réaction cutanée, asthénie et fatigue physique, faibles taux de minéraux dans le sang, perte d'appétit, réaction à la perfusion (fièvre, maux de tête, frisson, démangeaisons, urticaire, nausée, dyspnée, anomalies aux ongles des mains ou des pieds pouvant entraîner leur chute

348

349 Le Tableau 1.1 présente une liste non exhaustive des effets secondaires des différents traitements
 350 mentionnés ci-haut. C'est donc de dire que les traitements utilisés contre le CCR sont synonymes
 351 d'effets secondaires majeurs, en plus d'être invasif, coûteux, et éprouvant pour le patient et ces
 352 proches. En ce sens, une approche préventive et naturelle semble être une meilleure option qu'une
 353 approche thérapeutique dans la lutte contre le CCR.

354

355 **1.3. L'option de la chimioprévention**

356 Bien que la détection précoce d'un CCR ne prévienne pas nécessairement son développement,
357 plusieurs études ont été menées sur la prévention primaire de cette maladie (tabagisme, mode de
358 vie, alimentation, activité physique, etc.) dans l'optique de réduire l'incidence de ce cancer.
359 Cependant, plusieurs études ont souvent débouché sur des conclusions contradictoires ouvrant ainsi
360 la voie à l'option de la chimioprévention dans la lutte contre le CCR (Manzano *et al.*, 2012). La
361 chimioprévention est un processus par lequel l'utilisation d'agents chimiopréventifs naturels ou
362 synthétique permet de prévenir la progression du cancer (Hakama, 1998). Il est estimé qu'environ
363 200 composés ont été identifiés comme étant potentiellement chimiopréventifs envers le CCR dont
364 les fibres diététiques, les probiotiques ainsi que les antioxydants (Czadek, 2016). Le caractère
365 chimiopréventif d'un composé implique souvent plus d'un mécanisme sous-jacent et est propre à
366 lui-même justifiant l'importance d'avoir une large gamme de tests pour démontrer son potentiel
367 chimiopréventif. La première étape de la carcinogenèse du CCR implique, entre autres, l'exposition
368 des cellules saines à des carcinogènes et à des espèces chimiques réactives de l'oxygène (ERO)
369 ainsi qu'à la perte des équilibres entre apoptose/mitose, enzymes de phase I/phase II et bactéries
370 bénéfiques/nocives de l'environnement intestinal (Caillet *et al.*, 2012, Hanahan *et al.*, 2011,
371 Prochaska *et al.*, 1988b, Simon *et al.*, 1986).

372 **1.3.1. Les enzymes de phase II**

373 Les enzymes de détoxification cellulaire de phase II, telles que la NAD(P)H quinone réductase
374 (QR), sont connues pour protéger le milieu intracellulaire des métabolites électrophiliques toxiques
375 directement impliqués dans les premières étapes de la carcinogenèse. En ce sens, la QR réduit ou
376 inhibe la toxicité des carcinogènes chimiques via leur transformation en une forme moins toxique
377 ou en un métabolite inerte (Kang *et al.*, 2004). L'activité de la QR est régulée par les protéines
378 Keap1/Nrf2/ARE où l'inducteur potentiel, possédant une fonction (α - β)-cétone insaturée, permet
379 l'alkylation des résidus cystéines hautement réactifs au niveau de la protéine Keap1. L'activation
380 de Kelch-like ECH-Associated Protein 1 (Keap1) permet à son tour l'entrée de Antioxydant
381 Response Element (ARE) dans le noyau cellulaire et induit alors la transcription des gènes codant
382 pour la QR (Dinkova-Kostova *et al.*, 2002). Par la suite, l'enzyme résultante pourra servir à
383 détoxifier le milieu intracellulaire. Depuis plusieurs années, les analyses d'induction de la QR en

384 système *in vitro* représentent une manière efficace, facile et rapide pour la découverte de nouvelles
385 molécules possédant des propriétés chimiopréventives potentielles (Cuendet *et al.*, 2006, Kang *et*
386 *al.*, 2004, Misico *et al.*, 2002).

387 **1.3.2. Les espèces réactives de l'oxygène (ERO)**

388 Les ERO sont des espèces chimiques possédant au moins un atome d'oxygène ou appartenant à
389 une forme chimique de l'oxygène et qui ont une activité chimique supérieure à celle de l'oxygène.
390 L'anion superoxide (anion O₂⁻) et l'anion oxyde nitrique figurent parmi les ERO les plus
391 importants, de par le fait qu'ils représentent des précurseurs aux espèces chimiques responsables
392 des transformations cellulaires, tel le peroxyde d'hydrogène, le radical hydroxyde et l'anion
393 peroxydinitrite. L'effet négatif des ERO, connu sous le terme du stress oxydatif, survient lorsque la
394 formation intracellulaire de ces espèces surpasse les capacités de défense du système antioxydant
395 cellulaire. L'effet du stress oxydatif dans le milieu intracellulaire mène à la peroxydation des
396 lipides, des dommages aux barrières de la muqueuse intestinale et à l'ADN ainsi qu'à des réponses
397 inflammatoires pro-tumorale pouvant résulter en l'augmentation des risques de développer un CCR
398 (Hanahan *et al.*, 2011, Wang *et al.*, 2016, Young *et al.*, 2001). En ce sens, un composé pouvant
399 réduire ou empêcher la formation ou l'accumulation des ERO démontre un potentiel
400 chimiopréventif pertinent.

401 **1.3.3. La cytotoxicité cellulaire et les tests antiprolifératifs**

402 Depuis quelques dizaines d'années, l'établissement d'un système de criblage de composés
403 anticancers devient une nécessité face à l'augmentation des cas de cancer répertorié. En ce sens,
404 l'*US National Cancer Institute* (NCI) a développé une méthode pour cribler un grand nombre de
405 composés potentiellement cytotoxiques envers les cellules cancéreuses. Un composé cytotoxique
406 peut essentiellement induire la mort cellulaire par nécrose ou apoptose conduisant en une
407 diminution de la prolifération cellulaire de la population. Alors que la nécrose implique souvent
408 une perte d'intégrité membranaire, l'apoptose consiste en la mort cellulaire programmée (voir
409 section 1.2.4). Les tests antiprolifératifs, maintes fois optimisés dans la littérature, sont souvent
410 basés sur la capacité des cellules métaboliquement active après traitement à cliver le sel de
411 tétrazolium (MTT) en cristaux de formazan violet permettant de quantifier l'effet antiprolifératif
412 d'un composé en comparaison avec des cellules non traitées. Cette méthode *in vitro* facile et rapide
413 permet de cribler un grand nombre de composés à de multiples concentrations envers différents

414 types de lignées cellulaires cancéreuses humaines. En ce sens, les tests antiprolifératifs tels que
415 celui-ci basés sur le MTT renseignent davantage sur les propriétés anticancer et thérapeutiques que
416 sur leurs propriétés chimiopréventives. Les tests antiprolifératifs peuvent aussi bien être réalisés
417 sur des cellules saines que sur des cellules cancéreuses. Dans cette optique, il est possible d'évaluer
418 la toxicité d'un composé en déterminant ces valeurs IC_{50} (concentration d'échantillon pouvant
419 inhiber la croissance cellulaire de 50%) envers des cellules saines et des cellules cancéreuses. Un
420 composé possédant une faible toxicité ($IC_{50\text{cancéreux}} > IC_{50\text{non-cancéreux}}$) est considéré comme intéressant
421 dans une approche thérapeutique (Alley *et al.*, 1988, Boyd, 1997, Denizot *et al.*, 1986, van Meerloo
422 *et al.*, 2011, Vistica *et al.*, 1991).

423 **1.3.4. La mort cellulaire programmée (apoptose)**

424 L'apoptose est définie comme un processus de mort cellulaire hautement régulé et organisé chez
425 les organismes multicellulaires œuvrant à plusieurs stades du développement. Parmi les
426 phénomènes apoptotiques les plus connus notons l'élimination des lymphocytes autoréactifs ainsi
427 que l'élimination de cellules infectées par des virus et des cellules malignes. Ce phénomène naturel
428 forme une balance homéostatique avec le processus de mitose. Une perte de l'équilibre fragile entre
429 ces deux processus est en partie à l'origine de la transformation cellulaire, de la carcinogenèse et
430 de la formation de tumeurs. Le phénomène d'apoptose est donc une barrière au développement du
431 cancer (Hanahan *et al.*, 2011, Matsuzawa *et al.*, 2001). En ce sens, un composé en mesure de réduire
432 la viabilité des cellules cancéreuses et d'induire le processus d'apoptose dans les cellules
433 cancéreuses démontre des propriétés à la fois chimiopréventives et anticancer.

434 **1.3.5. Le microbiote intestinal et les enzymes fécales**

435 Le côlon contient le plus grand nombre de bactéries métaboliquement actives chez l'humain adulte
436 en plus de représenter un écosystème des plus complexes et en constante évolution. Nonobstant
437 l'existence de variabilité intrinsèque dans la composition des microbiotes humains, l'alimentation
438 semble être une des causes majeures de changement dans la proportion des genres bactériens chez
439 l'adulte. De plus en plus d'études rapportent de fortes corrélations entre des profils spécifiques de
440 microbiotes intestinaux et l'augmentation de l'incidence de plusieurs maladies et syndromes dont
441 le CCR (Louis *et al.*, 2014). Les composantes non digérées du régime alimentaire, comme par
442 exemple les polysaccharides non amylacés, peuvent se retrouver intactes au niveau du côlon et ainsi
443 permettre de faire varier la capacité de fermentation du microbiote intestinal, la durée du transit et

444 le pH intestinal aboutissant à un changement dans la composition des espèces bactériennes
445 présentes dans le côlon. Cette composition du microbiote intestinal a une importance cruciale dans
446 la nature des métabolites retrouvés dans le côlon. En effet, plusieurs espèces bactériennes
447 endogènes du microbiote sont reconnues pour produire des acides gras à courtes chaînes (AGCC)
448 considérés comme des métabolites protecteurs envers le CCR principalement de par leurs actions
449 anti-inflammatoires (Chang *et al.*, 2014, Fung *et al.*, 2012, Louis *et al.*, 2014, Smith *et al.*, 2013).

450 En contrepartie, certaines enzymes bactériennes telles que la β -glucuronidase et la β -glucosidase
451 sont connues pour déconjuguer les toxines et les carcinogènes qui ont été préalablement détoxifiés
452 dans le foie pour être sécrétés dans l'intestin via la bile. En ce sens, l'effet de ces enzymes
453 bactériennes constitue la contrepartie des enzymes de détoxification cellulaire telle que la QR. La
454 β -glucuronidase et la β -glucosidase sont produites dans le côlon par une large gamme de bactéries
455 nocives : *Clostridium sp.* (*C. paraputrificum*, *C. clostridioforme*, *C. perfringens*), *Bacteroides sp.*
456 (*B. vulgatus*, *B. uniforme*, *B. fragilis*), *Enterococcus sp.*, *Peptostreptococcus sp.*, *Staphylococcus*
457 *sp.*, *Ruminococcus (gnavus)*, *Eubacterium sp.* et *Escherichia coli*. La présence de ces enzymes peut
458 mener à une forte concentration localisée de carcinogènes au niveau du côlon ayant pour effet
459 d'augmenter le risque de développer un CCR. De manière générale, la détoxification d'un composé
460 toxique ou carcinogène débute dans le foie où le composé est conjugué à un acide glucuronique ou
461 un autre composé glyconé par les enzymes de phase II pour être ensuite excrété dans le côlon via
462 la bile. À ce niveau, la β -glucuronidase et la β -glucosidase agissent à contresens en déconjuguant
463 ces composés nocifs préalablement détoxifiés (Dabek *et al.*, 2008, Louis *et al.*, 2014, McBain *et*
464 *al.*, 1998, Simon *et al.*, 1986). Plus spécifiquement, la β -glucuronidase hydrolyse l'acide
465 glucuronique du conjugué relâchant ainsi le métabolite nocif. Pour sa part, la β -glucosidase
466 hydrolyse les liens glycosidiques unissant le métabolite hétéroside détoxifié produisant un résidu
467 glucosyl terminal non réducteur et le métabolite nocif. Dans tous les cas, la détoxification d'un
468 carcinogène augmente le temps de transit de ce dernier dans le côlon augmentant ainsi les risques
469 de carcinogénèse (Gill *et al.*, 2002, Ketudat Cairns *et al.*, 2010, Mroczynska *et al.*, 2013). D'un
470 point de vue clinique, une plus grande activité enzymatique de la β -glucuronidase a été reportée
471 chez des patients atteints du CCR en comparaison avec des patients sains démontrant ainsi
472 l'importance de ces enzymes bactériennes (Kim *et al.*, 2001). La présence d'une faible activité de
473 ces enzymes bactériennes découlant en grande partie de la composition du microbiote intestinal et
474 donc de la balance entre les bactéries bénéfiques et néfastes est d'une grande importance dans la
475 prévention du CCR.

476 1.4. Les parois cellulaires de levures


477 Les levures ont depuis toujours été utilisées par l'humain pour leur capacité à produire de l'alcool
478 ainsi qu'à apporter des arômes aux matrices alimentaires. L'industrie alimentaire moderne utilise
479 largement les levures dans plusieurs domaines. Cependant, la biomasse de levures ainsi que leur
480 paroi cellulaire sont souvent considérées comme un déchet industriel. Cet état des faits a amené, il
481 y maintenant quelques décennies, la communauté scientifique à se pencher sur le potentiel bioactif
482 de la biomasse de levures et de leur paroi cellulaire dans les domaines médicaux et des suppléments
483 alimentaires naturels (dos Santos Mathias *et al.*, 2014, Giavasis, 2014, Laroche *et al.*, 2007). Ces
484 années de recherches ont permis, entre autres, de soulever une attention accrue à différents types
485 de polysaccharides présents dans la paroi cellulaire de levures notamment de par leurs propriétés
486 antitumorales et immunomodulatrices chez l'humain.

487 **1.4.1. L'architecture et la composition des parois cellulaires de levures**

488 Les levures sont considérées comme des champignons unicellulaires et eukaryotiques (diamètre
489 d'environ 8µm) se reproduisant par reproduction sexuée et par bourgeonnement. Les levures
490 industrielles appartiennent majoritairement au genre *Saccharomyces* (par exemple, *S. cerevisiae* et
491 *S. cerevisiae* var. *boulardii*) alors que des membres du genre *Kluyveromyces* (par exemple, *K.*
492 *marxianus*) sont surtout utilisés dans l'industrie laitière. Les parois cellulaires de levures assurent
493 quatre fonctions majeures au sein de la cellule : i) pression osmotique interne, ii) protection contre
494 les stress mécaniques en agissant comme une couche protectrice, iii) maintien de la forme cellulaire
495 elle-même changeante selon les conditions de croissance, le cycle cellulaire ainsi que les réponses
496 aux phéromones, IV) échafaudage formé de polysaccharides permettant la présence d'une couche
497 de protéines à la face extérieure de la cellule (Klis *et al.*, 2006). Les parois cellulaires de levures
498 sont des structures dynamiques et sensibles aux conditions de croissance ainsi qu'aux stress
499 (Aguilar-Uscanga *et al.*, 2003). Cela dit, ces structures cellulaires sont typiquement composées des
500 mêmes polysaccharides échafaudés dans un ordre relativement redondant. En effet, les parois
501 cellulaires de levures sont typiquement composées de chitine, de (1→3)-β-D-glucanes possédant
502 des ramifications (1→6)-β-D-glucanes et de mannoprotéines reliés par des liaisons covalentes
503 (figure 1.2).

504

505



506

507

508 **Figure 1.2** : Organisation typique des parois cellulaires de levures (*S. cerevisiae*). Les termes outside et inside
 509 réfèrent au milieu externe et interne de la cellule respectivement. CWP; Cell Wall Proteins. GPI; Ancre de
 510 glycosylphosphatidylinositol. ASL; Alkali-Sensitive Linkage. Image modifiée de Klis et al. (2006).

511

512 Typiquement, les parois cellulaires de levures sont formées de trois épaisseurs de β-glucanes ; une
 513 couche interne insensible aux traitements alcalins connectée à la chitine, une couche intermédiaire
 514 sensible aux traitements alcalins et une couche externe de glycoprotéines possédant des résidus
 515 mannoses phosphorylés. La teneur en ces macromolécules (tableau 1.2) varie énormément selon
 516 différents paramètres tels que la souche de levure, les conditions et la phase de croissance ainsi que
 517 la méthode d'extraction (Aguilar-Uscanga *et al.*, 2003, Ahmad *et al.*, 2012, Klis *et al.*, 2002,
 518 Mantovani *et al.*, 2008, Pinto *et al.*, 2014). Alors que les β-glucanes et la chitine sont des polymères
 519 de glucose et de N-acétyl-glucosamine respectivement, les mannoprotéines sont typiquement
 520 constituées de mannanes (polymère de mannose) et de protéines reliées par des liaisons
 521 glycosidiques (tableau 1.2).

522

523 **Tableau 1.2** : Teneurs relatives des différentes composantes typiquement retrouvées dans les parois
524 cellulaires de levures (*S. cerevisiae*)

Composante	Masse sèche relative au poids des parois cellulaires (%)
(1→3)-β-D-glucanes	30-55
(1→6)-β-D-glucanes	5-10
Mannoprotéines	30-50
Chitine	1.5-6

525 Données compilées d'après Klis *et al.* (2006) et Kwiatkowski *et al.* (2012).

526

527 Les β-glucanes adoptent une structure en hélice triple maintenue par des liaisons hydrogènes et
528 possédant des ramifications habituellement formées de (1→6)-β-D-glucanes. La structure en hélice
529 triple et le taux de ramification des β-glucanes ainsi que leur poids moléculaire, leurs charges et
530 leurs degrés de polymérisations (longueur du polymère) dictent la solubilité de ce polysaccharide
531 une fois en solution. Tous ces paramètres ont une importance dans l'activité biologique et
532 dépendent de la méthode d'extraction utilisée. De manière générale, une méthode d'extraction rude
533 affectera l'intégrité de la structure des β-glucanes diminuant aussi leurs activités biologiques
534 (Mantovani *et al.*, 2008, Zekovic *et al.*, 2005). Malgré sa faible teneur, la chitine est souvent
535 reconnue comme étant responsable de la nature insoluble des parois cellulaires. Le rôle de ce
536 polysaccharide est d'ancrer la paroi cellulaire à la membrane plasmique. Cependant, la faible
537 quantité de chitine présente dans la paroi cellulaire est principalement retrouvée au niveau des
538 cicatrices de bourgeonnements. De plus, sa teneur est connue pour augmenter grandement en
539 condition de stress. Finalement, la nature des protéines retrouvées au niveau des mannoprotéines
540 est très large et dynamique. La majorité des mannoprotéines sont modifiées par une ancre GPI et
541 sont donc liées de manière covalente aux (1→6)-β-D-glucanes. Une faible proportion des protéines
542 de la paroi cellulaire est directement liée aux (1→3)-β-D-glucanes via une liaison sensible aux
543 traitements alcalins.

544 **1.4.2. Propriétés anticancer et chimiopréventives des parois cellulaires de**
545 **levures et de ces composantes**

546 Puisque le traitement du CCR peut s'avérer coûteux, invasif et douloureux pour les patients et les
547 gouvernements, il semblerait que la prévention soit l'approche la plus efficace. En ce sens, l'impact
548 du CCR sur la santé publique au Canada et aux États-Unis a soulevé une demande pour la
549 consommation de produits naturels dans la lutte pour la prévention de cette maladie. Dans cette
550 optique de prévention du CCR, la biomasse de levures ainsi que toutes ses composantes cellulaires
551 furent intensivement étudiées. Cet engouement pour la biomasse de levures et ses parois cellulaires
552 est justifié par sa facilité d'obtention, sa disponibilité ainsi que son caractère naturel en plus d'être
553 d'actualité scientifique.

554

555 Étant initialement des déchets de l'industrie agroalimentaire, les parois cellulaires de levures furent
556 utilisées pour nourrir le bétail où ils démontrèrent des capacités à renforcer le système immunitaire
557 des animaux. Il est maintenant accepté que les polysaccharides contenus dans les parois cellulaires
558 soient majoritairement responsables de l'activité biologique de ces dernières. Plus particulièrement,
559 les β -glucanes et les mannoprotéines sont reconnus pour leurs propriétés anticancer,
560 immunomodulatrices et antiradicalaires (Aguilar *et al.*, 2012, Bohn *et al.*, 1995, Chan *et al.*, 2009,
561 Falch *et al.*, 2000, Jaehrig *et al.*, 2008, Kobayashi *et al.*, 2005, Luhm *et al.*, 2006, Oliveira *et al.*,
562 2013, Rand *et al.*, 2010, Stier *et al.*, 2014, Yoon *et al.*, 2008). Les propriétés immunomodulatrices
563 des β -glucanes sont explicables par le fait que cette macromolécule soit absente chez les cellules
564 des mammifères. Or, les macrophages reconnaissent les β -glucanes comme des motifs moléculaires
565 caractéristiques des pathogènes (MMCP) via le récepteur dectin-1 ce qui induit leur activation et
566 conduit à une réponse immunitaire innée (Rand *et al.*, 2010, Tsoni *et al.*, 2008). En ce sens,
567 l'activité anticancer *in vitro* des β -glucanes est due à l'implication des cellules immunitaires,
568 notamment à l'augmentation de l'infiltration des cellules T activées dans l'environnement tumoral
569 ainsi qu'à l'augmentation de l'activité antitumorale des « cellules tueuses naturelles » dites cellules
570 NK (Adams *et al.*, 2008). De plus, il a été rapporté que les β -glucanes sont en mesure d'induire des
571 phénomènes d'apoptose au niveau des cellules humaines du cancer colorectal pouvant aussi
572 expliquer leurs propriétés anticancer et chimiopréventives (Kim *et al.*, 2009).

573

574 Les mannoprotéines de levures ont, quant à eux, démontré des capacités à ralentir la croissance de
575 différentes lignées cellulaires cancéreuses humaines en plus de démontrer des propriétés
576 antiradicalaires. Ces dernières sont probablement dues à la présence de résidus aromatiques et de
577 groupes thiols au sein des glycoprotéines leurs conférant des propriétés antiradicalaires (Jaehrig *et*

578 *al.*, 2007, Liu *et al.*, 2011). Finalement, des complexes de protéines-polysaccharides (CPP) furent
579 souvent rapportés comme ayant des propriétés antitumorales où un phénomène de cytotoxicité
580 direct serait en cause davantage qu'un effet de réponse immunitaire (Moharib *et al.*, 2014, Ooi *et*
581 *al.*, 2000, Wang *et al.*, 1995).

582 **1.5. Les huiles essentielles (HE)**

583 Une huile essentielle (HE) est un mélange complexe de composés chimiques au sein duquel les
584 différentes composantes agissent ensemble procurant un effet biologique. Ce mélange, obtenu des
585 plantes, forme un liquide hydrophobe contenant des composés aromatiques volatiles propres à la
586 plante en question et typiquement obtenu par hydro-distillation ou par distillation à la vapeur. Au
587 sein de la plante, les HE ont un rôle antibactérien, antiviral, antifongique, insecticide en plus
588 d'attirer certains insectes pollinisateurs. Dès le Moyen Âge, les HE ont déjà commencé à être
589 utilisées en raison de leurs propriétés médicinales (i.e. antiseptique, anti-inflammatoire,
590 analgésique local), ainsi que dans les pratiques d'embaumement et dans la préservation des
591 aliments. De nos jours, les HE et leurs constituants sont utilisés dans plusieurs produits ainsi que
592 dans une large gamme d'applications ; parfums, maquillages, produits sanitaires, dentisterie,
593 agriculture, préservatif alimentaire ainsi que comme remède naturel. L'utilisation de certaines HE
594 dans le domaine de la médecine semble encore être sujet de discordes dans la communauté
595 scientifique. Plusieurs HE ou bien leurs composantes majoritaires ont démontré des effets
596 anticancer et chimiopréventives très intéressantes qui seront développés dans les sections 1.4.2. et
597 1.4.3. du présent document (Bakkali *et al.*, 2008, Burt, 2004, Gautam *et al.*, 2014).

598 **1.5.1. Les constituants chimiques des HE**

599 Les différents effets biologiques connus des HE sont attribuables aux espèces chimiques qui les
600 composent. Les HE étant des mélanges complexes, il n'est pas rare d'observer qu'une HE possède
601 une activité biologique supérieure à celle de son composé majoritaire ce qui témoigne d'un effet
602 synergique entre ses composantes. Plusieurs paramètres peuvent faire varier la composition d'une
603 même HE; l'espèce végétale, la partie de l'arbre utilisée, la méthode d'extraction, la composition
604 du sol, l'étape du cycle végétatif de la plante, la saison, le climat et le lieu géographique de la
605 récolte. Par contre, certaines familles de composés chimiques sont en grande partie responsables
606 des propriétés biologiques des HE. En effet, les terpènes (mono, di et sesquiterpènes), les cétones,
607 les esters, les phénols et les lactones ont largement été cités en ce sens (Bakkali *et al.*, 2008).

608

1.5.2. L'activité anticancer et chimiopréventive des HE

609 Plusieurs HE ainsi que leurs constituants majoritaires ont démontré des propriétés anticancer et
610 chimiopréventives. La nature lipophile de plusieurs composantes des HE leur permettent de
611 facilement traverser la membrane plasmique des cellules leur donnant ainsi accès au cytosol. L'effet
612 des HE sur les cellules cancéreuses peut impliquer différents mécanismes de nature nécrotique,
613 apoptotique ou induire l'arrêt du cycle cellulaire. Les effets nécrotiques des HE dans les cellules
614 eukaryotiques sont dus à une dépolarisation de la membrane mitochondriale affectant la chaîne de
615 protons des électrons ainsi que les réserves d'ATP. De plus, les HE peuvent augmenter la
616 perméabilité des membranes cellulaires et mitochondriales résultant en une perte de fluide. Les
617 mitochondries contiennent différentes ERO dans le but d'accomplir leurs fonctions cellulaires. En
618 ce sens, la perturbation de la membrane mitochondriale mène à une perturbation des flux
619 d'électrons et donc à une accumulation de ERO qui résulte en une oxydation et endommage les
620 lipides, les protéines et l'ADN causant la mort cellulaire. En revanche, certaines HE ont démontré
621 la capacité à induire des phénomènes d'apoptose dans différentes lignées cellulaires cancéreuses.
622 En effet, la modulation des gènes reliés à l'apoptose, l'arrêt du cycle cellulaire ainsi que la
623 modulations de plusieurs protéines ou complexes protéiques intimement impliquées dans les
624 différentes voies signalétiques du mécanisme apoptotique (l'activation des protéines caspases,
625 BCL-2, MAPK et l'inactivation de la protéine AKT) font partie des manifestations les plus
626 fréquentes des HE aboutissant à l'apoptose (Gautam *et al.*, 2014).

627 Certaines HE démontrent aussi des propriétés chimiopréventives *in vitro* et *in vivo* notamment
628 envers la capacité à capter les radicaux libres (DPPH, O₂⁻, OH⁻) et à agir comme inducteur des
629 enzymes de phase II. Nonobstant du fait qu'il est complexe d'attribuer la responsabilité d'une
630 composante d'une huile à une activité biologique spécifique, il n'en reste pas moins que de telles
631 propriétés augmentent le potentiel chimiopréventif d'une huile essentielle.

632

1.5.3. Les HE de *Boswellia spp.*

633 Les HE du genre *Boswellia spp* (famille des *Burséracées*), aussi connues comme « arbre à encens
634 », sont traditionnellement utilisées en médecine, en aromathérapie et en soins cosmétiques ainsi
635 que dans plusieurs pratiques religieuses. Les HE produites par la résine de ces arbres (Figure 1.3)
636 sont connues sous le nom de Frankincense et possèdent une odeur de bois épicée et sont
637 généralement transparentes ou légèrement jaunâtres. L'utilisation de ces HE dans les populations
638 humaines remonte à l'Égypte antique où elles étaient utilisées en embaumement et sont encore

639 largement utilisées dans les cérémonies religieuses modernes juives, catholiques romaines et grecs
640 orthodoxes jusqu'à devenir encore aujourd'hui un des huiles essentielles les plus
641 commercialisées au niveau du marché international (Van Vuuren *et al.*, 2010).



642

643 **Figure 1.3 :** Apparence d'une gomme de résine utilisée pour la production des huiles Frankincenses. Figure
644 modifiée de Woolley *et al.* (2012).

645

646 Les HE de *Boswellia spp.* sont riches en monoterpènes (α/β -pinène, limonène, α -thujène, sabinène,
647 myrcène, p-cymène, α -copaène, δ -cadiène) ainsi qu'en triterpène tel que l'acide boswellique (BA),
648 l'acide keto boswellique (K-BA) et l'acide acétyl-keto boswellique (AK-BA). Cependant, des
649 variations importantes dans la composition de ces huiles provenant de différentes espèces de
650 *Boswellia spp* furent rapportées (Woolley *et al.*, 2012). Dans ce contexte, plusieurs botanistes,
651 scientifiques et gouvernements considèrent toujours *B. carterii* et *B. sacra* comme étant une seule
652 et même espèce alors que certaines études tentent de prouver le contraire. En effet, Woolley *et al.*
653 (2012) ont rapporté que l'huile essentielle de *B. sacra* diffère de celle de *B. carterii* de par les
654 valeurs supérieures de rotation optique (+30.1 et -13.3° respectivement), les ratios énantiomériques
655 et les teneurs en α -pinène (79.0 et 48.2% respectivement). Ces variations dans la composition de
656 ces deux huiles ne sont pas seulement attribuables au fait qu'elles proviennent de deux espèces
657 différentes, mais aussi au fait que ces arbres ne poussent pas dans la même région géographique.
658 En effet, il est généralement accepté que *B. carterii* est retrouvé en Somalie alors que c'est au
659 Yémen et en Oman que l'on retrouve *B. sacra*.

660

1.5.4. Activités anticancer des huiles de *Boswellia carterii* et de *B. sacra*.

661 Une riche littérature démontre les propriétés pharmaceutiques des huiles essentielles de *B. sacra* et
662 *B. carterii*. En effet, ces huiles sont utilisées pour leurs propriétés anti-inflammatoires,
663 immunomodulatrices ainsi qu'en santé cutanée et plus récemment pour leurs propriétés anticancer.
664 La capacité des huiles essentielles de *B. carterii* et de *B. sacra* à inhiber ou ralentir la croissance de
665 différentes lignées cellulaires cancéreuses a été rapportée maintes fois dans la littérature (Chen *et*
666 *al.*, 2013, Dozmorov *et al.*, 2014, Frank *et al.*, 2009, Hakkim *et al.*, 2015, Ni *et al.*, 2012, Suhail *et*
667 *al.*, 2011, Xia *et al.*, 2016). Par exemple, Hakkim *et al.* (2015) ont démontré qu'une huile essentielle
668 de *Boswellia* obtenu en Oman fût en mesure d'inhiber totalement la croissance de cellule humaine
669 du cancer du sein jusqu'à une concentration de 1 :3250 (265 ppm) via un test antiprolifératif au
670 MTT. Les auteurs ont en plus démontré un changement dans la morphologie cellulaire des cellules
671 après traitement résultant en une perte de leur adhérence ainsi qu'à l'adoption d'une morphologie
672 sphérique ce qui témoigne d'un arrêt de leurs cycles cellulaires. Les composantes majoritaires de
673 leurs huiles furent l' α -pinène (61.56%) et l' α -amyrine (20.60%). Toujours à titre d'exemple, Ni *et*
674 *al.* (2012) ont démontré qu'une huile essentielle de *B. sacra* fût en mesure d'inhiber efficacement
675 la viabilité cellulaire de différentes lignées humaines du cancer du pancréas. Les auteurs ont
676 rapporté des valeurs d'IC₅₀ variant de 1:240 (3583 ppm) à 1:1560 (551 ppm) en plus d'identifier
677 les composantes majoritaires comme étant l' α -pinène, la limonène, la myrcène et l'acide
678 boswellique. Alors que ces études renseignent sur la capacité des huiles à inhiber la croissance de
679 cellules cancéreuses, elles n'indiquent pas leurs effets sur les cellules saines. En ce sens, un
680 composé affectant de manière similaire des cellules cancéreuses et des cellules saines dans un
681 contexte *in vitro* pourrait s'avérer nocif lorsque administré en modèle *in vivo*. En revanche, un
682 composé présentant des valeurs d'IC₅₀ supérieures envers des cellules saines en comparaison à des
683 cellules cancéreuses démontre un excellent potentiel anticancer *in vitro* et serait donc un candidat
684 de choix pour des analyses *in vivo*. Les HE de *Boswellia* spp. sont reconnues pour démontrer une
685 cytotoxicité spécifique aux cellules cancéreuses. En effet, Suhail *et al.* (2011) ont démontré qu'une
686 HE extraite de *B. sacra* est en mesure d'inhiber plus efficacement la croissance de cellules
687 humaines du cancer du sein en comparaison à des cellules du sein non-cancéreuses. Dans le même
688 ordre d'idées, Frank *et al.* (2009) ont démontré qu'une HE de *B. carterii* fût aussi en mesure
689 d'inhiber plus efficacement la croissance de cellules humaines du cancer de la vessie en
690 comparaison avec des cellules saines témoignant de la capacité de cette huile à avoir une spécificité
691 cytotoxique pour les cellules cancéreuses.

692 Une telle activité antiproliférative spécifique aux cellules cancéreuses a fait l'objet de plusieurs
693 études dans le but de déterminer le mécanisme sous-jacent. Alors qu'une sensibilité des cellules
694 pourrait être responsable d'une telle spécificité envers les cellules cancéreuses, plusieurs études ont

695 rapporté l'importance de l'apoptose dans ce phénomène. En effet, Dozmorov *et al.* (2014) ont testé
696 la capacité d'une HE extraite de *B. carterii* à induire un effet pro-apoptotique dans des cellules
697 humaines du cancer de la vessie via l'étude de l'expression des gènes modulés par cette huile. Après
698 avoir confirmé la spécificité de l'huile pour les cellules cancéreuses, les auteurs ont observé une
699 modulation de plusieurs gènes reliés aux voies moléculaires de l'apoptose. Frank *et al.* (2009) ont
700 aussi démontré que l'activité anticancer spécifique aux cellules cancéreuses de la vessie était due à
701 un phénomène d'apoptose par une analyse de micromatrice d'ADN (microarray) confirmant qu'un
702 grand nombre de gènes furent modulés par l'huile de *B. carterii*. Finalement, Ni *et al.* (2012) ont
703 démontré que l'HE de *B. sacra* était en mesure d'induire l'apoptose dans des cellules humaines du
704 cancer du pancréas via la voie dépendante de caspase, via une induction rapide et transitoire des
705 protéines AKT (Protéine Kinase B) et Erk1/2 (Extracellular signal-regulated kinases 1 and 2) ainsi
706 que via la diminution de l'expression de complexe protéique lié au cycle cellulaire (D1/cdk4).

707 Tenter de déterminer la/les composante(s) responsable(s) de l'activité cytotoxique et apoptotique
708 des EHs de *Boswellia spp.* est un sujet d'actualité scientifique. Tel que discuté, les terpènes seraient
709 principalement responsables de l'activité biologique des EHs. Or, ceux de *Boswellia spp.* ne font
710 pas exception. En effet, quelques études semblent démontrer que l'acide boswellique (BA) et ses
711 dérivés seraient responsables des propriétés apoptotiques des EHs de *Boswellia spp.* Liu *et al.*
712 (2002) ont démontré que BA, K-BA et AK-BA sont en mesure d'induire l'apoptose en une réponse
713 de dose-dépendance via l'activation des caspases dans des cellules humaines du cancer colorectal.
714 Les auteurs ont rapporté que cette activité apoptotique était observable à des concentrations en BA,
715 K-BA et en AK-BA supérieures à 25µM. De plus, Ni *et al.* (2012) ont clairement démontré que la
716 méthode d'extraction à une profonde influence sur la composition de l'huile essentielle obtenue et
717 donc sur l'activité biologique. En effet, les auteurs ont obtenu 4 HE à partir de la résine de *B. sacra*
718 en utilisant 4 températures d'hydrodistillation différentes pour ensuite tester la capacité des extraits
719 à inhiber la croissance de cellules cancéreuses humaines du pancréas et à induire l'apoptose. Il en
720 a résulté que les deux extraits contenant la plus forte teneur en BA et en composés à hauts poids
721 moléculaires présentaient de meilleures valeurs d'IC₅₀ en plus d'induire l'apoptose. Les auteurs
722 n'ont cependant pas trouvé de corrélation entre l'activité biologique et la teneur en monoterpènes,
723 ce qui contraste avec les études de Bhattacharjee *et al.* (2013), Chen *et al.* (2015) et de Kusuhara
724 *et al.* (2012) qui ont tous démontré des effets anticancer ou chimiopréventif de l' α -pinène. Cette
725 différence dans les corrélations entre les activités biologiques et la composition des HE témoigne
726 de l'effet synergique des composantes de l'huile. En ce sens, il est juste d'avancer que les terpènes
727 sont majoritairement responsables de l'activité anticancer des HE de *Boswellia* puisqu'ils
728 constituent les composantes majoritaires. Par contre, déterminer le composé exact donnant aux

729 huiles de *Boswellia* leurs propriétés anticancer peut s'avérer ardu. De plus, la présence d'une
730 synergie entre les composantes des HE peut être la clef de l'explication de leurs propriétés
731 biologiques. En effet, Turgis *et al.* (2009) ont montré qu'une HE de thym contenant des teneurs en
732 carvacrol, en γ -terpinène et en p-cymène de 23.25%, 18.09% et de 20.38% respectivement était
733 plus efficace pour ces propriétés antimicrobiennes que le carvacrol pur.

734 Les HE de *Boswellia spp.* ont aussi une activité antiradicalaire. Bien que celle-ci soit modeste, il
735 n'en reste pas moins que les composantes de ces huiles sont en mesure de capter l'anion O_2^- ainsi
736 que le radical DPPH (Al-Harrasi *et al.*, 2013, Mohamed *et al.*, 2015).

737 Les HE de *Boswellia* ont aussi démontré des effets thérapeutiques chez l'humain. Deux rapports de
738 cas cliniques ont utilisé l'huile essentielle de *B. sacra* dans le but de réduire ou d'éliminer
739 totalement des tumeurs chez des patients. La première étude rapporte la capacité de l'huile à
740 éliminer totalement une lésion carcinomateuse sur le bras gauche ainsi qu'une régression
741 significative d'une seconde lésion au niveau de la poitrine d'un patient mâle âgé de 56 ans traité
742 pendant 20 semaines à raison de plusieurs applications cutanées par jour (Fung *et al.*, 2013). La
743 seconde étude suggère que la même huile a été en mesure d'éliminer complètement un carcinome
744 à grade supérieur invasif de la vessie chez un patient mâle âgé de 52 ans traité pendant 2 ans à
745 raison d'une prise orale (3 ml) par jour. Ces deux cas cliniques témoignent donc du fort potentiel
746 anticancer des huiles de *Boswellia spp.* (Xia *et al.*, 2016).

747 **1.6. Les traitements combinés dans la lutte contre le cancer**

748 L'utilisation d'une combinaison de composés dans une optique médicale est utilisée dans la lutte
749 contre plusieurs maladies complexes telles que le SIDA et le cancer. Dans ce dernier cas, les
750 tumeurs sont souvent constituées d'une hétérogénéité de types cellulaires cancéreux. Alors que
751 l'utilisation d'un seul composé sera en mesure de bloquer une voie moléculaire bien précise
752 résultant en une résistance de la tumeur envers le traitement, une combinaison de composés pourra
753 agir de concert pour ainsi bloquer plusieurs voies moléculaires et donc atteindre la viabilité d'un
754 plus grand nombre de cellules au sein de la tumeur. Alors que cette rationnelle explique le grand
755 succès de la chimiothérapie combinatoire, cette approche semble maintenant standard dans la lutte
756 contre le cancer (National Library of Medicine, 2003).

757 L'utilisation de composés anticancers en combinaison avec des produits naturels a déjà été
758 rapportée dans la littérature. En effet, Baldwin *et al.* (2010) ont démontré qu'un mélange de
759 bactéries probiotiques (*Lactobacillus acidophilus* et *L. casei*) en combinaison avec le 5-Fluouracil

760 (5-FU), un agent chimiothérapeutique, fût en mesure d'induire l'apoptose dans des cellules
761 humaines du cancer colorectal plus efficacement que le mélange probiotique utilisé seul. Cette
762 étude démontre donc le potentiel et de la pertinence d'utiliser des produits naturels en traitement
763 combinatoire dans la lutte contre le cancer.

764 **1.6.1. Les β -glucanes de levures utilisées en combinaison dans la lutte contre** 765 **le cancer**

766 Les β -glucanes de levures sont utilisés comme adjuvants en combinaison avec des anticorps
767 monoclonaux (ACm) dans la lutte contre le cancer mettant ainsi à profit leurs propriétés
768 immunomodulatrices. En effet, les ACm sont utilisés dans une optique d'induire un mécanisme de
769 cytotoxicité au niveau de la cellule cancéreuse. Les mécanismes *in vitro* sous-jacents impliquent
770 une cytotoxicité cellulaire dépendante aux anticorps et une cytotoxicité dépendante du complément.
771 Cependant, les ACm utilisés seuls sont peu efficaces pour induire une cytotoxicité dépendante au
772 récepteur du complément 3 (CD11b/CD18) puisque ce mécanisme est normalement induit par des
773 levures et certains microorganismes exposant des molécules de β -glucanes à leur surface. En ce
774 sens, les β -glucanes permettent d'induire un troisième mécanisme de cytotoxicité cellulaire dans
775 les cellules cancéreuses et donc d'agir comme adjuvant lorsque utilisés en combinaison avec des
776 ACm (Akramiene *et al.*, 2007, Chan *et al.*, 2009). Dans la lutte contre le cancer, les β -glucanes sont
777 donc typiquement utilisés en traitement combinatoire.

778 **1.6.2. Les HE utilisées en combinaison dans la lutte contre le cancer**

779 Les HE sont de plus en plus utilisées en combinaison avec des agents thérapeutiques dans le but de
780 combattre la multi résistance de certains cancers aux médicaments et de réduire les effets
781 secondaires du traitement en soi. En effet, les HE sont de plus en plus utilisées comme suppléments
782 diététiques dans une optique de chimiothérapie combinatoire en raison de l'importante quantité de
783 composés chimiques. Leurs constituants peuvent ainsi agir en synergie (Gautam *et al.*, 2014). Dans
784 cette optique, Chen *et al.* (2013) ont démontré qu'un mélange composé d'huiles de l'arbre à myrrhe
785 et de *B. carterii* (en ratio 1 :1) présente un effet synergique envers la capacité d'induire l'apoptose
786 dans des cellules humaines du cancer du sein. Aucune étude à ce jour n'a été réalisée pour évaluer
787 la synergie potentielle entre des composantes membranaires de levures et des HE.

788

789

2. But, hypothèses et objectifs

790 Le développement et la mise en marché de composés bioactifs et naturels ayant des effets
791 bénéfiques pour la santé sont des avenues très importantes pour l'industrie alimentaire considérant
792 l'impact du cancer colorectal en Amérique du nord. En ce sens, ce travail a pour but d'étudier le
793 potentiel chimiopréventif et anticancer des extraits de parois cellulaires de levures et des huiles
794 essentielles de *Boswellia carterii* et de *B. sacra* envers le cancer colorectal.

795 Les hypothèses de ce travail sont les suivantes :

- 796 i) Les extraits de parois cellulaires de levures et les huiles essentielles de *Boswellia* ont
797 des propriétés chimiopréventives et anticancer envers le cancer colorectal,
- 798 ii) Les β -glucanes et les mannoprotéines contribuent significativement à l'activité
799 biologique des extraits de levures,
- 800 iii) Les extraits de levures et les huiles essentielles de *Boswellia* utilisées en combinaison
801 démontrent un effet synergique

802 Les objectifs de ce travail sont :

- 803 i) Déterminer le potentiel chimiopréventif et anticancer des extraits de parois cellulaires
804 de levures (Chapitre 2) ainsi que des huiles essentielles de *Boswellia* (Chapitre 4) en
805 en modèle *in vitro*,
- 806 ii) Déterminer la/les composante(s) contribuant significativement à l'activité biologique
807 des extraits de parois cellulaires de levures (Chapitre 2),
- 808 iii) Déterminer le potentiel chimiopréventif des meilleurs extraits de parois cellulaires de
809 levures en modèle *in vivo* (Chapitre 3),
- 810 iv) Évaluer la capacité du meilleur extrait de paroi cellulaire à améliorer le potentiel
811 chimiopréventif et anticancer des huiles essentielles de *Boswellia* en modèle *in vitro*
812 (Chapitre 4)

813

814 Les moyens utilisés pour atteindre les objectifs sont :

- 815 i) Les extraits de parois cellulaires de levures ont été obtenus par autolyse de la biomasse
816 levurienne suivie d'une étape d'extraction à l'eau chaude alcaline et d'une précipitation
817 à l'éthanol selon une méthode modifiée de Nguyen *et al.* (1998) et de Supphantharika
818 *et al.* (2003)(Chapitre 2),

- 819 ii) La démonstration du potentiel chimiopréventif et anticancer *in vitro* des extraits de
820 parois cellulaires de levures a été effectuée avec les tests d'activité de la quinone
821 réductase, de captation de l'anion superoxide et des tests antiprolifératifs sur cellules
822 cancéreuses en utilisant des méthodes spectrophotométriques tel que décrit par
823 Prochaska *et al.* (1988a), Gerhäuser *et al.* (2003) ainsi que Vistica *et al.* (1991)
824 (Chapitre 2),
- 825 iii) Le poids moléculaire des extraits de parois cellulaires de levures ainsi que leurs teneurs
826 en sucres totaux, en β -glucanes, en mannanes et en chitine ont été déterminés par HPLC
827 et par des méthodes colorimétriques tel que décrit par Dubois *et al.* (1956), Pérez *et al.*
828 (1983) et basé sur les travaux réalisés à Industrial Microbiology laboratory de CUCEI-
829 UdG (Mexique). La mise en relation de la caractérisation des extraits avec leurs
830 activités biologiques a été réalisée dans le but de déterminer le(s) composante(s)
831 contribuant significativement à leurs activités (Chapitre 2),
- 832 iv) La démonstration du potentiel chimiopréventif et anticancer *in vivo* des extraits de
833 parois cellulaires de levures a été effectuée par l'administration orale des meilleurs
834 extraits à des rats traités au 1,2-diméthylhydrazine suivi du compte des cryptes
835 aberrantes au niveau de leurs côlons selon les travaux de Bird (1995). Le mécanisme
836 sous-jacent à la réduction du nombre de cryptes aberrantes a été déterminé par le
837 dosage de l'activité de la quinone réductase au niveau du foie ainsi que le dosage de
838 deux enzymes bactériennes (β -glucuronidase et β -glucosidase) au niveau du caecum
839 basé sur des versions modifiées des travaux décrits par Prochaska *et al.* (1988a) et Park
840 *et al.* (1998)(Chapitre 3),
- 841 v) La démonstration du potentiel chimiopréventif et anticancer *in vitro* des huiles
842 essentielles de *Boswellia* a été effectuée avec les tests d'activité de la quinone
843 réductase, de captation des radicaux O_2^- et DPPH, des tests antiprolifératifs sur cellules
844 cancéreuses ainsi que leurs capacités à induire l'apoptose en utilisant des méthodes
845 spectrophotométriques et la cytométrie en flux tel que décrit par Prochaska *et al.*
846 (1988a), Gerhäuser *et al.* (2003), Blois (1958) et Vistica *et al.* (1991) (Chapitre 4),
- 847 vi) La capacité du meilleur extrait de paroi cellulaire à améliorer le potentiel
848 chimiopréventif et anticancer *in vitro* des huiles essentielles de *Boswellia* a été mesurée
849 par les tests d'activité de la quinone réductase et les tests antiprolifératifs sur cellules
850 cancéreuses en utilisant des méthodes spectrophotométriques tel que décrit par
851 Prochaska *et al.* (1988a) et Vistica *et al.* (1991) (Chapitre 4)

852

853

CHAPITRE 2 - PUBLICATION 1

854

855 Cancer chemopreventive, antiproliferative and superoxide anion

856 scavenging properties of yeast cell wall components

857

858 Running headline: Chemoprevention of yeast cell wall

859

860

861 **Cancer chemopreventive, antiproliferative and superoxide anion scavenging**
862 **properties of yeast cell wall components**

863

864 O. Fortin¹, B. Aguilar-Uscanga², K.D. Vu¹, S. Salmieri¹, M. Lacroix^{1†}

865

866 ¹INRS-Institut Armand-Frappier, Research Laboratories in Sciences Applied to Food, 531

867 boul. des Prairies, Laval, QC, Canada.

868 ²Laboratorio de Microbiología Industrial, Centro Universitario de Ciencias Exactas e

869 Ingenierías, Universidad de Guadalajara (UdG). 1425 Blvd. Marcelino García Barragan

870 Guadalajara, Jalisco, Mexico.

871 † Address correspondence to Monique Lacroix. INRS-Institut Armand-Frappier,
872 Research Laboratories in Sciences Applied to Food, Canadian Irradiation Centre, The
873 Institute of Nutraceutical and Functional Foods (INAF), 531, Boulevard des Prairies,
874 Laval, Québec, Canada H7V 1B7. Tel.: +450 687 5010 #4489; fax: +450 686 5501. E-
875 mail address: monique.lacroix@iaf.inrs.ca (M. Lacroix).

876

877 La publication 1 a été soumise le 17 Janvier 2017 dans le journal Nutrition and Cancer. En ce sens,
878 la version longue et originale est présentée au chapitre 2 alors que la version courte et nouvellement
879 soumise dans le Journal Nutrition and Cancer est présentée en annexe 1. Cette version courte a été
880 préparée afin de répondre aux exigences du journal.

881

882 **2.1. Contribution des auteurs**

883 J'ai réalisé toutes les expériences, mis sur pied le protocole de captation de l'anion
884 superoxide, rédigé le manuscrit scientifique et supervisé 6 stagiaires qui m'ont assisté dans
885 les analyses préliminaires et finales qui ont mené à la réalisation de ces résultats. Dr.
886 Aguilar-Uscanga m'a supervisé dans la caractérisation des extraits en plus d'avoir participé
887 aux discussions scientifiques ainsi que d'avoir révisé le manuscrit. Dr. Vu m'a montré les
888 différentes méthodes pour quantifier l'activité biologique des extraits, en plus de m'avoir
889 supervisé durant l'élaboration du protocole de captation de l'anion superoxide, d'avoir
890 participé aux discussions scientifiques et d'avoir révisé le manuscrit. Mr. Salmieri m'a aidé
891 dans la rédaction du manuscrit en plus d'avoir participé à quelques discussions
892 scientifiques et d'avoir révisé le manuscrit. Dr. Lacroix, coordonnatrice et responsable du
893 projet, a supervisé l'élaboration du protocole de captation de l'anion superoxide et les
894 discussions scientifiques entourant ce projet en plus d'avoir révisé le manuscrit.

895

896

897

898

899

900

901

902

903

904

905

906

907 **2.2. Résumé en français**

908

909 **Propriétés chimiopréventives, antiprolifératives et de captation de l'anion**

910 **superoxyde des composantes de la paroi cellulaire de levure envers le cancer**

911 **colorectal**

912

913 Objectif : Cette étude a investigué les propriétés chimiopréventives, antiprolifératives et
914 antiradicalaires d'extraits de polysaccharides provenant de *Saccharomyces boulardii* et de
915 *Kluyromyces marxianus*. Les teneurs en β -glucanes, mannanes et chitines ont été
916 quantifiées pour identifier le(s) polysaccharide(s) responsable(s) de l'activité biologique
917 observée.

918 Méthodes et résultats : Des extraits de β -glucanes solubles, β -glucanes insolubles et de
919 mannoprotéines ont été obtenus de la paroi cellulaire via une extraction unique à l'eau
920 chaude alcaline. La quantification des sucres totaux, β -glucanes, mannanes et de la chitine
921 présents dans les extraits a été réalisée par des méthodes spectrophotométriques et par
922 chromatographie liquide à haute performance. La captation de l'anion superoxyde (capacité
923 antiradicalaire) ainsi que des tests d'induction de la quinone réductase (QR) et
924 antiprolifératif sur cellules cancéreuses ont été réalisés pour déterminer les propriétés
925 biologiques des extraits. Les résultats ont montré que les β -glucanes insolubles de *S.*
926 *boulardii* ont été en mesure d'augmenter l'activité de la QR de manière dose-dépendante
927 en plus de présenter la meilleure inhibition de croissance contre des cellules humaines du
928 cancer colorectal.

929 Conclusion : Les β -glucanes insolubles et les mannoprotéines de *S. boulardii* ont démontré
930 les propriétés biologiques les plus pertinentes. De plus, de fortes teneurs en β -glucanes, des

931 ratios β -glucanes/sucres totaux élevés et des ratios chitine/ β -glucanes faibles se sont avérés
932 avoir un impact sur l'augmentation des propriétés chimiopréventives et antiprolifératives
933 des extraits.

934 Importance et impact de l'étude : À notre connaissance, cette étude est la première à
935 démontrer une induction de la QR par des composantes de la paroi cellulaire de levures.
936 Cette découverte enrichit les applications potentielles des parois cellulaires de levures dans
937 le domaine médical.

938 Mot clé : β -Glucanes, chimioprévention, antiradicalaire, antiprolifératif, levure, paroi
939 cellulaire, caractérisation

940

941

942 **2.3. Abstract**

943 Aim: This study investigated the cancer chemopreventive, the antiradical and the
944 antiproliferative properties of polysaccharide extracts from the cell wall of *Saccharomyces*
945 *boulardii* and *Kluyromyces marxianus*. β -glucan, mannan and chitin were also quantified
946 to identify the most important extract responsible for these biological properties.

947 Method and results: Soluble and insoluble β -glucans as well as mannoprotein were
948 extracted from cell walls the using single hot-alkaline method. Quantification of total
949 sugars, glucan, mannan and chitin of those extracts were performed using
950 spectrophotometric methods and high-performance liquid chromatography (HPLC).
951 Superoxide anion (O_2^-) scavenging (antiradical capacity), quinone reductase (QR)
952 induction and antiproliferative assays were done for evaluation of biological properties of
953 those extracts. Results showed that the insoluble glucan from *S. boulardii* increased QR
954 activity as a dose-dependent function and exhibited the highest growth inhibition against
955 colorectal cancer cells.

956 Conclusion: Insoluble glucan and mannoprotein of *S. boulardii* exhibited the most relevant
957 biological properties. Moreover, high amount of glucan, high glucan/total sugars ratios and
958 low chitin/glucan ratios were shown to have an impact on enhancing cancer
959 chemopreventive and antiproliferative properties.

960 Significance and Impact Study: To our knowledge, this is the first study that demonstrates
961 an induction of QR activity by yeast cell wall components. This evidence enriched the
962 potential applications of the yeast cell wall in the medical field.

963 Keywords: β -Glucan, chemoprevention, antiradical, antiproliferative, yeast, cell wall,
964 characterisation

965 **2.4. Introduction**

966 Colorectal cancer (CRC) is the second leading cause of deaths due to cancer in males and
967 the third in females (Canadian Cancer Society's Advisory *et al.*, 2014). It is also the third
968 most prevalent cancer in Canada (Canadian Digestive Health Foundation, 2016). Since
969 treatment for CRC can be expensive and invasive for patients, prevention methods still
970 seem to be the most efficient approach. It has been shown that life style plays an important
971 role in the incidence of many cancers and diet has been related to almost 70 % of CRC
972 incidence (Aggarwal *et al.*, 2013). Thus, the consumption of a diet containing agents with
973 CRC preventive properties could reduce the risks of CRC incidence. The impact of CRC
974 on the health population in Canada and USA triggered a demand of natural products with
975 CRC preventive properties to prevent or reduce the development of this disease. Among
976 natural agents, yeast cell wall components have shown increased interest due to their
977 anticancer and immunomodulatory properties which can be utilized in nutrition, in
978 pharmaceutical and in medical applications (Laroche *et al.*, 2007).

979

980 Yeasts are largely used in industrial domains especially in the food industry. However, cell
981 walls of spent yeasts are often discarded after the collection of fermented broth or used in
982 many applications such as the production of yeast extract or nutraceutical food supplements
983 (dos Santos Mathias *et al.*, 2014, Giavasis, 2014). Many studies have investigated the
984 natural properties of yeast cell walls and demonstrated that there are strong
985 immunomodulatory properties of yeast glucan in *in vitro* and *in vivo* models in addition to
986 their ability to prevent DNA damage which is the first step in carcinogenesis (Karoui *et al.*,
987 2007, Oliveira *et al.*, 2013). These properties depend on the physicochemical nature and

988 integrity of the glucan structure (Akramiene *et al.*, 2007, Chan *et al.*, 2009, Volman *et al.*,
989 2008) which varies according to growth conditions, extraction methods and yeast species
990 (Aguilar-Uscanga *et al.*, 2003, Ahmad *et al.*, 2012, Akramiene *et al.*, 2007, Chan *et al.*,
991 2009, Klis *et al.*, 2006, Mantovani *et al.*, 2008, Pinto *et al.*, 2014, Stier *et al.*, 2014).

992

993 Yeast cell walls are organized with approximatively the same polysaccharides consisting
994 of mannoprotein, chitin and (1→3)-β-D-glucan with (1→6)-β-D-glucan ramifications
995 (Klis *et al.*, 2006). The sugar composition of the cell walls is mainly responsible for their
996 biological and chemical properties (Aguilar *et al.*, 2012).

997

998 *Saccharomyces boulardii* (*S. cerevisiae* var. *boulardii*) and *Kluyveromyces marxianus* are
999 well-known yeasts with diverse industrial applications and relevant biological properties.

1000 Indeed, *S. boulardii* is considered as a probiotic strain known to generate preventive effects
1001 on the occurrence of antibiotic-associated diarrhoea, beneficial effects against different
1002 enteric pathogens and the production of different anti-inflammatory molecules including
1003 *Saccharomyces* anti-inflammatory factor (Czerucka *et al.*, 2007, Kelesidis *et al.*, 2012).

1004 Otherwise, *K. marxianus* is known to possess a relevant potential in biotechnology due to
1005 its capacity to synthesis β-galactosidase and pectinase in addition to the reduction of lactose
1006 content in food products. Furthermore, *K. marxianus* exhibits a higher ethanol production
1007 compared to *S. cerevisiae* due to its highly thermotolerant properties (Anderson *et al.*,
1008 1986, Falcão Moreira *et al.*, 1998, Fonseca *et al.*, 2008).

1009

1010 Since the immunomodulatory properties of cell wall extracts (glucan, chitin and
1011 mannoprotein) of *S. cerevisiae* are well characterized, this study focused on the
1012 chemopreventive, antiradical and antiproliferative properties of cell wall extracts of *S.*
1013 *boulardii* and *K. marxianus*. First, the content, the relative concentrations and the molecular
1014 weight of the polysaccharides typically found in yeast cell wall were determined. Then, the
1015 cancer chemopreventive potential of the extracts was investigated and compared with
1016 commercial insoluble glucans of *S. cerevisiae*. The nicotinamide adenine dinucleotide
1017 phosphate hydrogen: quinone reductase (NAD(P)H:QR) assay was been selected as a
1018 cancer chemopreventive test for the role of its phase II detoxification enzyme known to
1019 protect against toxic electrophilic metabolites directly involved in the very first stage of
1020 carcinogenesis whereas O_2^- anion was selected since it is one of the most important reactive
1021 oxygen species (ROS) due to its possibility to generate hydrogen peroxide and $OH\cdot$ radicals
1022 (Young *et al.*, 2001). The determination of NAD(P)H:QR activity using murine hepatoma
1023 1c1c7 cell line, the antiradical activity by measurement of O_2^- anion scavenging capacity
1024 and the antiproliferative potential against human CRC cell line HT-29 was evaluated in
1025 order to reveal structure-function relationships between the cell wall composition and their
1026 biological activities.

1027

1028 **2.5. Material and methods**

1029 **2.5.1. Material**

1030 Chemicals and media were obtained as follows: dextrose, essential amino acids, sodium
1031 pyruvate, fetal bovine serum (FBS), minimum essential medium-Earle's balanced salt
1032 solution (MEM-EBSS), Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12

1033 (MEMF/12), Hank's balanced salt solutions (HBSS), trypsin, Pierce®BCA Protein assay,
1034 glycine, N-methylpyrrolidone (NMP) and 96-wells microplates were purchased from
1035 Fisher Scientific (Ottawa, ON, Canada). Commercial insoluble β -glucan, activated carbon,
1036 β -naphthoflavone, digitonin, bovine serum albumin (BSA), glucose-6-phosphate, thiazolyl
1037 blue tetrazolium bromide (MTT), menadione, glucose-6-phosphate dehydrogenase, 2,3-
1038 *Bis*(2-methoxy-4-nitro-5-sulfohenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT),
1039 xanthine, sodium carbonate buffer (pH 10.2), xanthine oxydase, superoxide dismutase,
1040 phenol, sulphuric acid, lyticase from *Arthrobacter luteus*, chitinase from *Streptomyces*
1041 *griseus*, tetraporate potassium, 4-(dimethylamino)benzaldehyde, N-acetylglucosamine,
1042 mannan, lithium chloride (LiCl), nicotinamide adenine dinucleotide phosphate (NADP),
1043 dimethyl sulfoxide DMSO) and flavin adenine dinucleotide (FAD) were purchased from
1044 Sigma-Aldrich (Oakville, ON, Canada). Yeast extract, bacterial peptone and agar were
1045 purchased from Alpha Bioscience (Baltimore, MD, USA). Polyethylene glycol and
1046 polymethyl methacrylate (PMMA) were purchased from Agilent technologies
1047 (Mississauga, ON, Canada).

1048

1049 **2.5.2. Yeast strains and growth conditions**

1050 *Kluyveromyces marxianus* ATCC 10022 and *Saccharomyces cerevisiae* var. *boulardii*
1051 ATCC MYA-796 were purchased from the American type culture collection (ATCC)
1052 (Manassas, VA, USA). The yeast strains were stored at -80°C in sterile yeast peptone
1053 dextrose (YPD) (10 g/l dextrose, 5 g/l yeast extract, 3 g/l, bacterial peptone, 0.8 g/l, MgSO₄,
1054 1 g/l KH₂PO₄) containing 10% (w/v) sterile glycerol. One ml of culture cells in cryovials
1055 (10⁸ cells/ml) from each strain were thawed and inoculated in 25 ml of YPD medium then

1056 incubated for 18 h at 30°C under agitation at 200 RPM (Forma Scientific, Orbital shaker,
1057 Model; EQ-069, USA). 2.5 ml of the resulting cell suspension was inoculated in a final
1058 volume of 50 ml of YPD medium for 24 h at 30°C under agitation. Finally, 12.5 ml of this
1059 second cell suspension was inoculated in a final volume of 250 ml of YPD using the latter
1060 conditions. At the end of second and third fermentation, 1 ml of fermented broth was
1061 serially diluted in sterile peptone water and plated on YPD agar in order to confirm lack of
1062 contamination in cell suspension.

1063

1064 **2.5.3. Growth kinetics**

1065 To determine the growth phase of the yeast species, optical density and dry biomass weight
1066 were monitored for 24 h. The fermentation was conducted using the same growth
1067 conditions as mentioned above except that 1 ml of cell suspension was collected every 2 h
1068 and diluted in sterile medium, to measure growth by optical density at 600 nm (Varian
1069 Canada inc., Mississauga, ON, Canada). In parallel, 1 ml of cell suspension was also
1070 collected every 2 h and placed in sterile preweighted tubes then centrifuged at 2000 g for
1071 10 min at 4°C. The supernatant was discarded and the pellet was washed with sterile water.
1072 Finally, the washed biomass was dried at 60°C for 48 h and the tubes were weighted. A
1073 linear relation (equation) of dry biomass weight and optical density was established and
1074 the resulting equation was used to estimate the dry biomass in time function.

1075

1076 **2.5.4. Biomass collect and cell wall preparation**

1077 Fermented broths were centrifuged at 9000 g for 10 min at 4°C. The supernatant was
1078 discarded and the pellet was washed twice with sterile phosphate buffer 50 mmol/l, pH 7.2.

1079 To extract sugars from cell walls with respect to its integrity, yeasts cells were autolyzed
1080 by suspending the wet biomass in 15% (w/v) sterile water and were autolyzed for 24 h at
1081 50°C with agitation at 200 rpm. Autolyzed cells were then centrifuged at 9000 g for 10 min
1082 at 4°C. The supernatant was discarded and the autolyzed cells were entirely used for glucan
1083 and mannoprotein extraction.

1084

1085 **2.5.5. Extraction of yeast glucan and mannoprotein extracts**

1086 The method of extraction of β -glucan and mannoprotein was based on work of Nguyen *et*
1087 *al.* (1998) and Supphantharika *et al.* (2003) with some modifications. A quantity of 500 ml
1088 of 1 mol/l NaOH was mixed with 100 g of autolysed cells for 1 h at 90°C without stirring
1089 in order to avoid glucan degradation. Then, the suspension was centrifuged at 9000 g for
1090 10 min at 4°C. The precipitate was washed twice with distilled water, freeze-dried and the
1091 resulting extract was considered as insoluble glucan. The supernatant was mixed with 95%
1092 ethanol in 1:4 proportions, left overnight at 4°C and centrifuged. The resulting pellet was
1093 washed twice with distilled water, then freeze-dried and the obtained extract was referred
1094 to as soluble glucan. Finally, ethanol in the supernatant was evaporated using a vacuum
1095 concentrator (Savant, Automatic environmental speedVac® system, Model; AES1010,
1096 Farmingdale, NY, USA) under full vacuum, low speed and at ambient temperature for 8 h
1097 and then freeze-dried to obtain the mannoprotein extract.

1098

1099 **2.5.6. Total sugars quantification**

1100 The total sugars content in each extract was determined following a method of Dubois *et*
1101 *al.* (1956). Briefly, 10 mg of freeze-dried samples were mixed with 1 ml of milli-Q water.
1102 Then, 200 μ l of this solution were mixed with 200 μ l of 5% phenol and 2 ml of sulphuric

1103 acid. The mixture was roughly vortexed and left 5 min at room temperature before reading
1104 absorbance at 490 nm with a Cary 1 spectrophotometer (Varian). A standard curve was
1105 made using a sugar solution (ranging from 0.02 to 0.1 g/l) which contained 40% mannose
1106 and 60% dextrose in order to roughly imitate sugar proportion in the *S. cerevisiae* cell wall.
1107 The resulting equation was used to extrapolate the total sugars content in the extracts. All
1108 quantifications were made in triplicate (n=3) and results were expressed as average \pm
1109 standard deviation (SD).

1110

1111 **2.5.7. Glucan and mannan quantification by HPLC**

1112 Glucan and mannan were quantified by HPLC (Varian Pro Star 210) equipped with a
1113 refractive index detector (RID). Polysaccharides were separated in a Metacarb CA-PLUS
1114 (30 cm x 7.8 mm) isothermal column at 90°C, using water as mobile phase and a flow rate
1115 of 0.6 ml/min. A calibration curve was performed at concentrations between 1 to 0.1 g/l of
1116 glucan and mannan. All quantifications were made in triplicate (n=3) and results were
1117 expressed as average \pm SD. This method was established for analysis of polysaccharides in
1118 Industrial Microbiology laboratory of CUCEI-UdG (México).

1119

1120 **2.5.8. Chitin quantification**

1121 The quantification of chitin in cell wall extracts was done using a modified method of Pérez
1122 *et al.* (1983) and Roncero *et al.* (1988). Briefly, 100 mg of freeze-dried extracts were
1123 suspended in test tubes containing 5 ml of 6% KOH, heated at 80°C for 90 min and cooled
1124 on ice for 1 min. Afterwards, 500 μ l of acetic acid was added and the tubes were centrifuged
1125 at 1500 g for 2 min. The resulting pellet was washed twice with distilled water and once
1126 with 50 mmol/l phosphate buffer (pH 6.3). Then, 500 μ l of phosphate buffer, 50 μ l of 5

1127 U/ml lyticase and 50 μ l of 5 U/ml chitinase were added to the pellet and incubated at 37°C
1128 for 20 h at 200 rpm. Afterward, 100 μ l of this solution was mixed with 150 μ l of Milli-Q
1129 water and with 250 μ l of 0.27 mol/l potassium tetraborate (pH 9). Tubes were boiled for 8
1130 min and cooled down on ice for 2 min. Finally, 3 ml of Reissig reagent 1X (1% (w/v) 4-
1131 (Dimethylamino)-benzaldehyde, 0.12 mol/l HCl and 1.52 mol/l glacial acetic acid) was
1132 added to each tube and incubated for 40 min at 37°C. Absorbencies were read at 585 nm
1133 (Varian). A standard curve of N-acetylglucosamine ranging from 20 to 100 mmol/l was
1134 made and resulting equation was used to calculate the amount of chitin in tested samples.
1135 All quantifications were made in triplicate (n=3) and results were expressed as average \pm
1136 SD.

1137

1138 **2.5.9. Molecular weight determination by gel permeation chromatography** 1139 **(GPC)**

1140 The molecular weights (Mw) of polysaccharides was analysed by gel permeation
1141 chromatography (GPC) using an Agilent HPLC (Agilent Technologies 1260 infinity series,
1142 Waldbronn, BW, Germany), equipped with a quaternary pump (Model G1311B), a manual
1143 injector with a sample loop of 20 μ l and a refractive index detector (Model G1362A).
1144 Insoluble glucan was treated separately from soluble glucan and mannoprotein extracts.
1145 For soluble glucan and mannoprotein extracts, two identical PL Aquagel-OH mixed-M 8
1146 μ m 300 X 7.5 mm columns were used in series to increase resolution. Water containing
1147 0.02% (w/v) sodium azide was used as mobile phase with a flow rate of 1 ml/min and both
1148 columns and detector were set at 30°C. Freeze-dried mannoprotein and soluble glucan were
1149 rehydrated by solubilizing 2.5 mg/ml in mobile phase and filtered through a 0.2- μ m filter.

1150 Polyethylene glycol was used as a standard and prepared as recommended by the
1151 manufacturer. Concerning insoluble glucan, 2 identical PLgel 5 μ m Mixed-D 300 X 7.5
1152 mm columns were used in series as explained above. The mobile phase consisted of 100%
1153 NMP containing 5% (w/v) LiCl was used with a flow rate of 0.5 ml/min and both columns
1154 and detector were set at 60°C. The method for preparation of insoluble glucan for injection
1155 was mainly based on Austin (1977), Yilmaz *et al.* (2003) and Chakrabandhu *et al.* (2008)
1156 with some modifications due to the insoluble properties of chitin. Freeze-dried insoluble
1157 glucan was mixed in NMP at a concentration of 2.5 mg/ml into a glass bottle. The
1158 suspension was stirred for 48 h at 60°C and filtered through a 0.2- μ m nylon filter. PMMA
1159 was used as a standard for insoluble glucan and was prepared as indicated by the
1160 manufacturer. The equation obtained by plotting Mw with retention times of standards was
1161 used to calculate the Mw of each peak obtained by GPC of the extracts. All extracts were
1162 injected in triplicate (n=3) and expressed as Mw range.

1163

1164 **2.5.10. Cancerous cell lines and cell maintenance**

1165 Hepa 1c1c7 (ATCC CRL-2026) and HT-29 (ATCC HTB-38) cell lines were purchased
1166 from the American type culture collection (ATCC) (Manassas, VA, USA). The cell lines
1167 were cultivated in 25 cm² cellular flasks (Corning, Manassas, VA, USA) in a humidified
1168 incubator at 37°C in an atmosphere of 5% CO₂ and 95% air. Hepa 1c1c7 cells were grown
1169 in complete MEM-EBSS medium which contained 0.1% essential amino acids, 0.1%
1170 sodium pyruvate, 10% (v/v) FBS and completed with MEM-EBSS solution whereas HT-
1171 29 cells were grown in complete MEMF/12 medium which contained 0.1% essential amino
1172 acid, 0.1% sodium pyruvate, 10% (v/v) FBS and completed with MEMF/12 solution. The

1173 maintenance of cells was performed at a confluence of 80-90% by discarding cultured
1174 medium and washing adherent cells with HBSS solution. Then, cells were treated with 1.5
1175 ml of 1X trypsin for exactly 30 s. Trypsin was poured off and cells were incubated for
1176 exactly 12 min in a humidified incubator at 37°C in an atmosphere of 5% CO₂ and 95%
1177 air. Finally, 2 ml of respective medium was added to trypsinized cells and 1 ml of cell
1178 suspension was used to inoculate into 5 ml of fresh completed medium.

1179

1180 **2.5.11. NAD(P)H:QR assay**

1181 The NAD(P)H:QR (QR) assay was based on studies from Prochaska *et al.* (1988a) and
1182 Talalay (1989) with some modifications. The aim of this assay was to determine the
1183 concentration of extracts required to double the QR induction (CD) since a basal expression
1184 level of QR occurs in Hepa 1c1c7 cells. Freeze-dried extracts were rehydrated in 10% (v/v)
1185 dimethyl sulfoxide (DMSO) containing 20 ppm of sodium azide (as antimicrobial agent)
1186 in order to avoid sterilization of extract solution by filtration or by heating which could
1187 lead to a loss of biological activities. A 96-well plate was seeded with Hepa 1c1c7 cells at
1188 a density of 10⁴ cells/ml (200 µl per well) in completed MEM-EBSS medium. This
1189 microplate, named QR plate, was then incubated in a humidified incubator at 37°C for 24
1190 h in an atmosphere of 5% CO₂ and 95% air. Afterward, different concentrations of extracts
1191 previously serial diluted were added and each well was completed to 200 µl with carbon
1192 activated MEM-EBSS cells for 48 h. Cells were then washed with HBSS solution and 50
1193 µl of 1.6% (w/v) digitonin were added in each well. The microplate was incubated for 10
1194 min at 37°C, then placed on an orbital shaker for 10 min at room temperature. A 20 µl
1195 sample of this suspension was added to a new 96-well microplate for further total protein

1196 determination. Then, 200 μ l of complete reaction mixture (0.25 mol/l Tris-HCl pH 7,
1197 4.67% (w/v) BSA, 0.01% tween-20, 5 mol/l FAD, 1 mmol/l glucose-6-phosphate, 30 mol/l
1198 NADP, 34.8 μ mol/l MTT, 50 μ mol/l menadione and 2 mU/ μ l glucose-6-phosphate
1199 deshydrogenase in distilled water) was added to each well of the QR plate and optical
1200 densities were read after 5 min at 595 nm using a microplate reader (Biotek, Model EL800,
1201 Winooski, VT, USA). Protein assays were made using Pierce[®]BCA reagents and was
1202 performed as suggested by the manufacturer. Negative and positive controls consisted of
1203 1% (v/v) DMSO containing 20 ppm sodium azide and 2 μ mol/l β -naphthoflavone
1204 respectively whereas medium was used as blank. Specific activity of QR was defined as
1205 nmol of blue formazan formed per mg protein per minute. Fold induction of QR was
1206 calculated as follow:

1207

1208 QR Fold Induction (treated on control) = Specific activity of QR in treated group / Specific
1209 activity of QR in negative control group

1210

1211 Fold induction ≥ 2 was considered as relevant in order to determine whether extracts can
1212 induce QR. All measurements were done in triplicate (n=3) and results were presented as
1213 average \pm SD.

1214

1215 **2.5.12. Antiradical assay (O_2^- anion scavenging activity)**

1216 The capacity of samples to scavenge O_2^- was measured using xanthine/xanthine oxydase
1217 system (XTT color assay) based on the method of Gerhausser et al. (2003). This assay aims
1218 to determine whether soluble sugars extracts possess radical scavenging properties by

1219 quantifying their ability to scavenge O_2^- anion. Freeze-dried samples of yeast cell wall
1220 extracts were rehydrated in 10% (v/v) DMSO at desired concentrations. Then, serial
1221 dilutions of extracts were performed in 10% (v/v) DMSO and 20 μ l of those extracts were
1222 loaded in 96-well microplates. Then, each well was completed to 200 μ l with reactional
1223 mix (1 mmol/l XTT, 1 mmol/l EDTA, 1 mmol/l xanthine, 50 mmol/l sodium carbonate
1224 buffer (pH 10.2) and 3 mU/ml xanthine oxydase) and the optical density was read at 490
1225 nm (Biotek) after 20 min. The negative control consisted of DMSO 1% (v/v) whereas the
1226 positive control corresponded to 30 U/ml of superoxide dismutase. Scavenging activity (%)
1227 was calculated as follows:

1228

1229 Scavenging Activity (%) = [(sample OD - Negative control OD) / (Positive control OD -
1230 Negative control OD)] X 100

1231

1232 Concentrations exhibiting a scavenging activity of 50% were referred to as SC_{50} values.
1233 Insoluble glucan was not used for this assay since perfectly soluble samples were required.
1234 All measurements were done in triplicate (n=3) and results were presented as average \pm
1235 SD.

1236

1237 **2.5.13. Antiproliferative assay**

1238 The antiproliferative effect of different yeast cell wall extracts against the HT-29 cell line
1239 was measured using MTT color assay based on the method of Vistica *et al.* (1991). The
1240 cell proliferation was determined by the ability of the metabolically active cells to cleave
1241 the tetrazolium salt to purple formazan crystals. Concentrations that inhibiting 50% of the

1242 cellular growth (IC₅₀ values) were calculated for all extracts. In a 96-well plate, HT-29
1243 cells were seeded at 2 x 10⁴ cells per 200 µl of complete MEMF/12 medium. After 24 h of
1244 incubation at 37°C under an atmosphere of 5% CO₂ and 95% air, the medium was replaced
1245 with 100 µl of fresh medium containing 10 µl of each extract previously serial diluted. The
1246 negative control consisted of 1% (v/v) DMSO containing 20 ppm sodium azide and the
1247 blank consisted of 100µl of fresh medium. After 48 h of incubation, the culture medium
1248 was decanted and replaced with 200 µl of fresh MEMF/12 containing 25 µl of 0.5% (w/v)
1249 MTT. The microplate was incubated for 4 h at 37°C in an atmosphere of 5% CO₂ and 95%
1250 air. Then, the medium was carefully removed and 200 µl of DMSO plus 25 µl of Sorensen
1251 buffer pH 10.5 (0.1 mol/l glycine, 0.1 mol/l NaCl) were added to each well. Absorbencies
1252 were measured at 562 nm (Biotek) and the cellular growth inhibition was calculated as
1253 follows:

1254

1255 Cellular Growth Inhibition (%)= 100 - [(Sample OD / Negative control OD) X 100]

1256

1257 Equations obtained by plotting the linear portion of growth inhibition versus concentrations
1258 of extracts were used to determinate IC₅₀ values. All measurements were done in triplicate
1259 (n=3) and results were presented as average ± SD.

1260

1261 **2.5.14. Statistical analysis**

1262 Amounts of total sugar content, chitin, glucan and mannan in extracts as well as IC₅₀ values
1263 were analyzed by one-way analysis of variance (ANOVA) using PASW statistics 18
1264 software (IBM Corporation, Somers, NY, USA) and differences between samples were

1265 analyzed with post hoc Duncan's multiple-range test. Significance was considered at $P \leq$
1266 0.05.

1267

1268 **2.6. Results**

1269 **2.6.1. Growth kinetics**

1270 Growth kinetics of yeasts was performed to collect yeast biomass in stationary phase in
1271 order to reflect spent yeast at the end of industrial fermentation processes. As presented in
1272 Figure 2.1, the initial amounts of biomass from *K. marxianus* (0.8 g/l) and *S. boulardii* (1.0
1273 g/l) were similar. Afterwards, dry biomass of both *K. marxianus* and *S. boulardii* was
1274 increased to 1.5 g/l after 8 h and 10 h respectively, indicating that *K. marxianus* presented
1275 a shorter latency phase than *S. boulardii*. Despite the fact that *K. marxianus* produced more
1276 biomass than *S. boulardii* (6.3 and 3.2 g/l respectively), both species biomass were
1277 collected in stationary phase after 24 h growth. Since growth phase is a major factor in
1278 terms of biological activity and composition of yeast cell wall, these results indicate that
1279 further comparisons between *S. boulardii* and *K. marxianus* should be carried out.

1280

1281 **2.6.2. Solubility and visual appearances of yeast cell wall extracts**

1282 The solubility of these extracts is briefly described in Table 2.1 Results showed that
1283 insoluble glucan was partially soluble in high concentrations of DMSO whereas it were
1284 totally soluble in pure NMP after stirring and heating for 48 h in presence of 5% (w/v)
1285 lithium chloride. Soluble glucan and mannoprotein were readily soluble in water and at all
1286 concentrations of DMSO. In 10% DMSO, insoluble glucan yielded a white and turbid
1287 suspension; soluble glucan yielded a transparent solution whereas mannoprotein yielded a
1288 transparent and yellow solution.

1289

1290 **2.6.3. Quantification of total sugars, chitin, glucan, mannan in the extracts and**

1291 **Mw determination**

1292 The quantification of total sugars is presented in Table 2.2 Results showed that the content
1293 of insoluble glucan, soluble glucan and mannoprotein of *S. boulardii* (42.73%, 39.13% and
1294 0.4% respectively) are similar to their respective counterparts in *K. marxianus* (51.38%,
1295 32.55% and 0.52% respectively) suggesting that both species possessed a similar amount
1296 of total sugars in cell walls. Results also showed that insoluble glucan from both species
1297 contained significantly more total sugars than all other extracts evaluated in this study (P
1298 ≤ 0.05). Also, insoluble extracts of both species contained the highest amounts of glucan
1299 (49.17 and 40.54% for *K. marxianus* and *S. boulardii* respectively) whereas the soluble
1300 glucan of *S. boulardii* contained the lowest amount of glucan (23.99%). Furthermore,
1301 combined amounts of glucan in soluble and insoluble extracts represented 65% and 80%
1302 for *S. boulardii* and *K. marxianus* respectively, which demonstrates a noticeable difference
1303 in their cell wall composition. The content of mannoprotein is presented in Table 2.2 The
1304 results showed that the content of mannoprotein of *S. boulardii* contained significantly less
1305 mannan (3.17%) than their *K. marxianus* counterparts (9.14%) ($P \leq 0.05$). Moreover, each
1306 extract contained 4-10 times less mannan than glucan. These observations may be due to
1307 the presence of mannan covalently bound to glucan despite the extraction. The total content
1308 of chitin found in the three extracts of *S. boulardii* (1.51%) was found to be higher than
1309 content found in all extracts of *K. marxianus* (0.89%), which also demonstrated typical
1310 differences in cell wall composition between each strain. Finally, higher chitin contents
1311 were found in both soluble and insoluble extracts of *S. boulardii* (0.66 and 0.58%

1312 respectively) as compared to 0.30 and 0.35% in *K. marxianus*. The GPC analysis showed
1313 that the Mw range in insoluble glucan of *S. boulardii* is 1921 kDa and 2085 kDa in *K.*
1314 *marxianus* showing higher Mw than soluble glucan and mannoprotein extracts, which
1315 corroborates the fact that solubility partially depends on Mw (Table 2.2). Mannoprotein
1316 extracts of *K. marxianus* showed a Mw from 0.48-77 kDa and from (0.72-87 kDa) in *S.*
1317 *boulardii*. Also, Table 2.2 indicates that insoluble glucan in both strains showed a high
1318 amounts of total sugars and glucan in addition to high Mw.

1319

1320 **2.6.4. Determination of relative concentrations in total sugars, chitin, glucan and** 1321 **mannan content in the extracts**

1322 Determination of relative concentration using ratios may lead to a better analysis of extracts
1323 composition and to a better understanding of their structure-function relationship. Table
1324 2.3 shows that insoluble glucan of *S. boulardii* possessed a glucan/total sugars ratio (0.94)
1325 that was significantly higher ($P \leq 0.05$) than their soluble counterparts (0.61) whereas no
1326 differences ($P > 0.05$) in the glucan/total sugar ratios were observed between insoluble and
1327 soluble glucan of *K. marxianus*. Mannan/total sugars ratios were higher in mannoprotein
1328 of *S. boulardii* (7.03) and *K. marxianus* (24.94) whereas mannan/glucan the ratios showed
1329 no significant differences ($P > 0.05$) between soluble and insoluble glucan of both strains.
1330 In addition, chitin/total sugars ratios in insoluble glucans of both yeast strains (6.83×10^{-3}
1331 and 13.66×10^{-3} for *S. boulardii* and *K. marxianus* respectively) were the lowest as
1332 compared to other extracts whereas the ratios in mannoprotein of both strains were the
1333 highest (471.85×10^{-3} and 685.14×10^{-3} for *S. boulardii* and *K. marxianus* respectively),
1334 hence suggesting the presence of a higher amount of chitin in mannoprotein extracts which

1335 does not corroborate with the information in Table 2.2 More importantly, the insoluble
1336 glucan of both strains exhibited low chitin/glucan ratios compared to other extracts whereas
1337 this ratio was significantly higher ($P \leq 0.05$) regarding soluble glucan of *S. boulardii* (27.40
1338 $\times 10^{-3}$), hence suggesting that soluble extract of *S. boulardii* possessed more chitin and less
1339 glucan than both insoluble extracts. Also, the chitin/mannan ratios suggest that the
1340 insoluble glucan of both strains contains high amounts of chitin whereas the soluble glucan
1341 of *S. boulardii* exhibited the highest chitin/mannan ratio, which is in agreement with Table
1342 2.2 Analysis of all ratios for each extract and each strain suggests that insoluble glucan
1343 possesses high glucan/total sugars ratios, low chitin/total sugars ratio and low chitin/glucan
1344 ratios for both strains. By contrast, soluble glucan of *S. boulardii* exhibited the lowest
1345 glucan/total sugars ratio and the highest chitin/glucan ratio therefore suggesting a low
1346 proportion of glucan in this extract. Finally, the results presented in Table 2.3 suggest a
1347 lack of direct correlation regarding mannan/glucan ratio and mannan/total sugars ratio in
1348 all extracts, which is congruent with results in Table 2.2.

1349

1350 **2.6.5. Biological activities of commercial β -glucan**

1351 The QR activity, antiradical and antiproliferative tests were conducted to evaluate some
1352 biological activities of all extracts to estimate the chemopreventive potential of the yeast
1353 cell wall. In this aspect, commercial insoluble glucan from *S. cerevisiae* was used for QR
1354 and antiproliferative assays for comparison purposes and results which are presented in
1355 Figures 2.2 and 2.3 respectively. Figure 2.2 indicates that negative control (1% DMSO +
1356 20 ppm sodium azide) and untreated cells did not induce any QR activity (1.0 fold
1357 induction) whereas β -naphthoflavone (positive control) quadrupled the QR activity (3.9

1358 fold induction). Figure 2.2 also shows that commercial insoluble glucan from *S. cerevisiae*
1359 induced QR activity in a dose-dependent manner and possessed a CD value of around 125
1360 µg/ml. Figure 2.3 showed that commercial insoluble glucan from *S. cerevisiae* inhibited
1361 the growth of HT-29 cells following a dose-dependent function and reached an IC₅₀ value
1362 of 344.2 µg/ml. Therefore, results from Figure 2.2 and 2.3 demonstrate relevant biological
1363 activities of commercial yeast β-glucan and will further be used for comparison with the
1364 yeast cell wall extract obtained in this study.

1365

1366 **2.6.6. Cancer chemopreventive activity of yeast cell wall extracts**

1367 Results of QR assay and CD values of the yeast cell wall extracts are presented in Figure
1368 2.4. Results show that only insoluble glucan from both yeast species could induce QR
1369 activity and reach CD values of 500 µg/ml. Also, Figure 2.4 shows that both insoluble
1370 glucans exhibited a dose-dependent response. Moreover, Figure 2.4 suggests that the CD
1371 value of the commercial insoluble glucan (125 µg/ml) is 4 times lower than those obtained
1372 for the insoluble extracts of *S. boulardii* and *K. marxianus* (500 and 500 µg/ml
1373 respectively), which might be explained by a higher purity of the commercial glucan. Those
1374 results show that the insoluble glucan of *S. boulardii* and *K. marxianus* possess a relevant
1375 chemoprevention potential since these extracts were able to increase the specific activity
1376 of the NAD(P)H quinone reductase.

1377

1378 **2.6.7. Antiradical activity of yeast cell wall extracts**

1379 The capacity of water-soluble extracts (soluble glucan and mannoprotein extracts) of yeast
1380 cell walls to scavenge O₂⁻ anion was determined and results are presented in Figure 2.5.

1381 Results show that soluble glucan of *K. marxianus* reached a SC₅₀ value of 3000 µg/ml as
1382 opposed to soluble glucan of *S. boulardii* that did not reached an SC₅₀ value. Mannoprotein
1383 of *K. marxianus* reached a SC₅₀ value (1500 µg/ml) twice as low as found for
1384 mannoproteins of *S. boulardii* (3000 µg/ml). Finally, Figure 2.5 also demonstrates that all
1385 extracts exhibited a dose-dependent response to scavenge O₂⁻ anion except for the soluble
1386 glucan of *S. boulardii*. Those results demonstrate that mannoprotein and soluble glucan of
1387 *K. marxianus* scavenged O₂⁻ species more efficiently as compared to their *S. boulardii*
1388 counterparts.

1389

1390 **2.6.8. Antiproliferative activity of yeast cell wall extracts**

1391 The antiproliferative activities of cell wall extracts of *S. boulardii* and *K. marxianus* against
1392 HT 29 cells are presented in Figure 2.6. Results show that all extracts were able to reach
1393 50% of growth inhibition at the tested concentrations (ranging from 3000 to 125 µg/ml).
1394 Results also show that all extracts exhibited a dose-dependent response (Figures 2.6a and
1395 2.6b). Figure 2.6c indicates that extracts of *S. boulardii* showed lower IC₅₀ values than their
1396 *K. marxianus* counterparts. Indeed, the insoluble extract of *S. boulardii* possessed the
1397 lowest IC₅₀ value (108.3 µg/ml) among glucan extracts whereas mannoprotein of *S.*
1398 *boulardii* possessed the lowest IC₅₀ value (251.0 µg/ml) among mannoprotein extracts. In
1399 fact, only the insoluble glucan of *S. boulardii* exhibited an IC₅₀ value significantly (P ≤
1400 0.05) lower than the commercial insoluble glucan (344.2 µg/ml) whereas soluble glucan
1401 and mannoprotein of *K. marxianus* were found to possess the highest IC₅₀ values (856.0
1402 and 1403.0 µg/ml respectively) as compared to all extracts.

1403

1404 **2.6.9. Relationship between the contents of yeast cell wall polysaccharide and**
1405 **their biological activities**

1406 Figure 2.4, 2.5 and 2.6 indicate that insoluble glucan from both yeast strains constitute the
1407 most relevant extract regarding biological activities. The insoluble glucan of *S. boulardii*
1408 is the most relevant extract based on its QR inductive activity with the CD value of 500
1409 µg/ml and its antiproliferative activity against HT 29 cells with the lowest IC₅₀ values of
1410 108.3 µg/ml. However, soluble glucan of *S. boulardii* exhibited the lowest biological
1411 activities based on an IC₅₀ value of 356.1 µg/ml against HT 29 cells as the unique detected
1412 biological activity.

1413

1414 Determining the combination of polysaccharides found in the yeast cell wall that are
1415 potentially responsible for cancer chemopreventive, antiradical and antiproliferative
1416 properties is essential to understand the major component involved in the biological
1417 activities of extracts. Overall, results from characterization and biological activities
1418 suggested that insoluble glucan possessed the most relevant biological activities which
1419 correspond to high contents in total sugars, glucan and chitin as well as a high Mw, a high
1420 glucan/total sugars ratio, low chitin/total sugars and chitin/glucan ratios. In contrast, the
1421 soluble extract of *S. boulardii* presented the weakest biological activity and corresponded
1422 to a low content in glucan, low glucan/total sugars ratio and high chitin/glucan ratio. These
1423 assessments suggest a typical relationship between biological activities and sugars
1424 quantification that aims to determine the relative importance of each polysaccharide in
1425 biological activities: % chitin < % glucan ≈ % total sugars. This relation shows that extracts
1426 majorly need to contain glucan to possess biological properties whereas chitin seems to be

1427 statistically less influential on chemopreventive and anticancer properties against CRC *in*
1428 *vitro*. Finally, this relation suggests that mannan was not responsible for the biological
1429 activities of the extracts.

1430

1431 **2.7. Discussion**

1432 Since growth phase can modulate the yeast cell wall composition drastically, biomass was
1433 collected in stationary phase in this study in order to reflect the cellular state of spent yeasts.
1434 Hudson *et al.* (2014) observed that wild type *S. boulardii* MYA-797 grown in YPD medium
1435 containing 2% dextrose reached the very late exponential phase after 24 h of growth. In
1436 this study, *S. boulardii* reached stationary phase (Figure 2.1) after approximately 24 h of
1437 fermentation. This could be due to the fact that only 1% dextrose was used instead of 2 %
1438 dextrose as used by Hudson *et al.* (2014). Moreover, Mitterdorfer *et al.* (2001)
1439 demonstrated that a strain of *S. boulardii* reached the early stationary phase after
1440 approximately 25 h of growth using Sabouraud media containing 1% dextrose which is
1441 also comparable with our results.

1442

1443 Similarly, the growth kinetics of *K. marxianus* obtained in this study is comparable with
1444 the results of Falcão Moreira *et al.* (1998) considering growth conditions. The authors
1445 reported that *K. marxianus* ATCC 10022 cells entered stationary phase after approximately
1446 28 h of growth using YPD medium containing 2% dextrose and a growth temperature of
1447 26°C. It has been demonstrated that growth temperature and dextrose concentration lower
1448 than 30°C and 2% can lead to a decrease of biomass and thus to a reduction of the time
1449 needed to enter stationary phase (Margaritis *et al.*, 1983, Rodrussamee *et al.*, 2011).

1450 Consequently, time needed for *K. marxianus* to enter stationary phase as found in the
1451 present study is in good agreement congruent with the scientific literature.

1452

1453 In general, cell walls obtained from yeast biomass collected in stationary phase consists
1454 mainly of 3 biopolymers: chitin, mannan and (1→3)-β-D-glucan and (1→6)-β-D-glucan.

1455 Their proportions change according to many parameters such as strains, growth conditions,
1456 growth phase, method of cell wall preparation, extraction and chemical derivatization of
1457 natural biopolymers (Aguilar-Uscanga *et al.*, 2003, Klis *et al.*, 2006, Zekovic *et al.*, 2005).

1458 Glucan amounts found in soluble and insoluble extracts obtained in this study are similar
1459 to those obtained by Suphantharika *et al.* (2003). These authors used a single hot alkaline

1460 extraction approach to recover glucan from baker's yeast cell wall and obtained insoluble
1461 extracts constituted of approximately 50% of glucan. Moreover, the theoretical amount of

1462 total β-glucans represents between 58 to 72% of yeast cell wall dry weight (Kwiatkowski
1463 *et al.*, 2012), which is in accordance with the total amount of β-glucan obtained in this

1464 study. In contrast with glucan quantification, the total amount of mannans in extracts was
1465 inferior for both yeast strains as compared to mannoprotein complex found in the literature

1466 (35 to 40%) (Klis *et al.*, 2002, Kwiatkowski *et al.*, 2012). This divergence might be due to
1467 the relatively important content of proteins in the complex which was not quantified since

1468 this study focused on polysaccharide characterization. Klis *et al.* (2006) suggested that *S.*
1469 *cerevisiae*'s cell wall contains between 1 and 6% of chitin which is congruent with our

1470 results. The presence of chitin in soluble and insoluble glucan extracts might be due to
1471 residual N-acetyl-glucosamine branched to (1→3)-β-D-glucan and (1→6)-β-D-glucan.

1472 Indeed, chitin in stressed cell walls tends to branch directly with (1→6)-β-D-glucan instead
1473 of the typical (1→3)-β-D-glucan (Fontaine *et al.*, 2000, Klis *et al.*, 2006).

1474

1475 The content of chitin, glucan and mannan revealed the divergence in cell wall composition
1476 of *S. boulardii* and *K. marxianus* which has already been reported elsewhere (Backhaus *et*
1477 *al.*, 2010). The authors concluded that *S. cerevisiae* tends to decrease the amount of glucan
1478 in the cell wall under stress conditions whereas a member of *Kluyveromyces spp.* Shows
1479 unchanged glucan content under the same conditions. Those observations seem to be in
1480 agreement with our results, since the amounts of glucan and glucan/total sugars ratios were
1481 significantly higher for *K. marxianus*. Moreover, chitin/total sugars ratios were lower in
1482 soluble/insoluble glucan as compared to mannoprotein extracts, hence suggesting the
1483 presence of a higher amount of chitin in mannoprotein extracts. This inconsistency might
1484 arise from the phenol-sulfuric acid method used to quantify neutral sugars. Indeed, it may
1485 be that sugars in mannoprotein extracts are mainly charged, which could explain the low
1486 total sugars contents and high chitin/total sugars ratios.

1487

1488 Glucans with a Mw between 100 and 200 kDa are known to exhibit important biological
1489 activities such as tumor growth inhibition *in vivo* and antiproliferative effect on cancerous
1490 cells *in vitro* (Mantovani *et al.*, 2008, Saitô *et al.*, 1991, Wang *et al.*, 2004). In the present
1491 study, the Mw of insoluble glucan from *S. boulardii* (1921 kDa) and *K. marxianus* (2085
1492 kDa) was found to be higher when compared to other extracts and also exhibited the most
1493 relevant biological activities (i.e., exhibited CD values and lowest IC₅₀ values). High Mw
1494 β-glucan has been reported to possess biological activities. Using hot-alkaline extraction,

1495 Mork *et al.* (1998) produced a soluble β -glucan that exhibited a Mw of approximately
1496 1000 kDa and showed capacity in activating macrophages. In addition, Kelly (2001)
1497 described an insoluble glucan that presented a Mw range of 1000-3000 kDa and exhibited
1498 a capacity to heal skin wounds in rats. These studies confirmed that insoluble glucan with
1499 molecular weights higher than 1000 kDa possesses biological activities and thus
1500 corroborates findings from the present study.

1501

1502 The determination of polysaccharides mainly responsible for biological activities observed
1503 in this study revealed that β -glucan was the principal component of yeast cell walls that
1504 exhibited important biological activities whereas chitin was important to a lesser extent.
1505 Those results corroborate results obtained by others investors. Indeed, *S. cerevisiae*'s β -
1506 glucan is known to exhibit antimutagenic and antigenotoxic effects *in vivo* (Oliveira *et al.*,
1507 2013), to inhibit the cellular growth of colorectal cancer cells *in vivo* (Yoon *et al.*, 2008)
1508 and to exhibit apoptosis properties in colorectal cancer cells *in vitro* (Kim *et al.*, 2009).
1509 Furthermore, β -glucan immunomodulation properties have been intensively reported for
1510 many decades. For example, it was shown to increase NK cell activity and T cells-mediated
1511 cytotoxicity, trigger inflammatory response, strong interferon (IFN) and interleukin (IL)
1512 release, enhance phagocytic activity of neutrophils and stimulate macrophages (Aguilar *et*
1513 *al.*, 2012, Bohn *et al.*, 1995, Chan *et al.*, 2009, Falch *et al.*, 2000, Luhm *et al.*, 2006, Rand
1514 *et al.*, 2010, Stier *et al.*, 2014).

1515

1516 Chitin covalently bound to glucan in soluble/insoluble extracts might have led to a decrease
1517 of glucan biological function. Indeed, glucan branched to chitin or mannan above certain

1518 proportions might cause a decrease in glucan's biological properties, which could explain
1519 the importance of high chitin/glucan ratio in the soluble glucan of *S. boulardii*. However,
1520 the chitin content was found to be high in insoluble glucan which demonstrated the
1521 importance of the relative concentration of chitin and glucan. In this regard, Zhang *et al.*
1522 (2004) extracted different water-soluble polysaccharides from fungal sources and
1523 determined the amount of N-acetyl glucosamine, glucose and total sugars in extracts and
1524 then investigated their effect on growth inhibition of HL-60 leukemic cells and antitumor
1525 activities *in vivo*. The authors observed that extracts with higher glucose/total sugars ratios
1526 and lower N-acetyl glucosamine/glucose ratios exhibited the most relevant anticancer
1527 properties both *in vivo* and *in vitro*, which is in good agreement with our findings.

1528

1529 Since our results suggested the importance of glucan in reaching relevant CD, SC₅₀ and
1530 IC₅₀ values, the mechanism of glucan in such activities is worth further discussion. QR is
1531 a phase II detoxification enzyme recognized to protect against toxic electrophilic
1532 metabolites directly involved in the very first stage of carcinogenesis. QR decreases
1533 chemical carcinogenicity by transforming those compounds into a less toxic form or into
1534 inactive metabolites (Kang *et al.*, 2004). The capacity of cell wall extracts obtained from
1535 *S. boulardii* and *K. marxianus* to induce QR activity seems to be a novel biological activity
1536 highlighted in the present study. Despite the fact that compounds exhibiting a CD value
1537 below 10 µg/ml are considered as highly relevant inducers (Kang *et al.*, 2004), high CD
1538 values obtained by insoluble glucan (500 µg/ml) can be considered as medium and even
1539 low inducers for *in vivo* studies using yeast cell wall compound (Li *et al.*, 2010, Samuelsen
1540 *et al.*, 2014). The mechanism of induction depends on whether the inducer is mono- or

1541 bifunctional inducer. Monofunctional inducers increase the specific activity of phase II
1542 enzymes whereas bifunctional inducers increase both phase I and phase II specific activities
1543 (Prochaska *et al.*, 1988b). Further studies will be needed to determine whether insoluble
1544 glucan is a mono or bifunctional inducer.

1545

1546 As opposed to the QR assay, several studies demonstrated the antiradical scavenging
1547 activity of polysaccharides from fungal and yeast sources (Jaehrig *et al.*, 2007, Krizkova
1548 *et al.*, 2006, Saiki *et al.*, 2011, Tsiapali *et al.*, 2001). The dose-dependent response of
1549 soluble glucan and mannoprotein extracts might be explained by a hydrogen atom transfer
1550 (HAT) mechanism of anomeric hydrogen (Tsiapali *et al.*, 2001). Indeed, Tsiapali *et al.*
1551 (2001) demonstrated that antiradical activities of glucan are higher than dextrose and
1552 mannose most probably due to the greater abstraction lability of the anomeric hydrogen
1553 from internal glucose units rather than from the reducing end. In addition, the presence of
1554 a substituted carboxymethyl group in gluco-pyranose structure could also explain the
1555 antiradical scavenging activity observed in the present study (Saiki *et al.*, 2011). Our results
1556 also demonstrated that mannoprotein of *K. marxianus* exhibited the most relevant SC₅₀
1557 value. This observation might be due to a higher presence of aromatic amino acids and
1558 thiol groups in mannoprotein which are known to exhibit high antioxidant activities
1559 (Jaehrig *et al.*, 2007). Moreover, those antioxidant residues in the mannoprotein extract of
1560 *K. marxianus* may be more accessible than in other extracts due to an increased sensitivity
1561 of proteins denaturation during extraction. Indeed, Jaehrig *et al.* (2007) revealed that the
1562 treatment of mannoprotein with dithiothreitol released free thiol and aromatic side chains
1563 which increased the antioxidant activities compared to untreated mannoprotein whereas

1564 native cell walls of *S. cerevisiae* did not generate antioxidant activities. In contrast, all
1565 soluble extracts obtained in the present study revealed relatively high SC₅₀ values and thus
1566 can be considered to possess a low antiradical potential, which is in accordance with the
1567 literature since sugar compounds were reported to exhibit low antiradical properties
1568 (Machová *et al.*, 2013, Tsiapali *et al.*, 2001). Finally, it has been reported that yeast glucan
1569 possesses a weaker antiradical scavenging capacity compared to mannoprotein extracts
1570 (Jaehrig *et al.*, 2007, Jaehrig *et al.*, 2008), which is congruent with our results.

1571

1572 Proliferation of cancerous cells can be inhibited through different mechanisms including
1573 cell cycle arrest, apoptosis and necrosis (Hanahan *et al.*, 2011, Ren *et al.*, 2012). Although
1574 further investigation will be necessary to investigate whether necrosis or apoptosis was
1575 involved in growth inhibition of HT-29 cells observed in this study, the fact that all extracts
1576 exhibited antiproliferative activities is in agreement with the literature (Zekovic *et al.*,
1577 2005). Indeed, lentinan, a well-known β -glucan from fungi, was reported to inhibit 50% of
1578 the growth of sarcoma 180 solids tumors *in vitro* at a concentration of approximately 500
1579 $\mu\text{g/ml}$ (Zhang *et al.*, 2005). Moreover, β -glucan derived from a mutant strain of
1580 *Aureobasidium* inhibited 52.6% of the cellular growth of human colon cancer cells SNU-
1581 C4 at a concentration of 150 $\mu\text{g/ml}$ and triggered apoptosis at 100 $\mu\text{g/ml}$ (Kim *et al.*, 2009).
1582 These biological activities can be linked to β -glucan insolubility, molecular weight, nature
1583 of branching, presence of glycoprotein bound to glucan and triple-helix structure of glucan
1584 (Wang *et al.*, 2004, Zhang *et al.*, 2005). Indeed, schizophyllan, a homopolysaccharide of
1585 glucose from fungal sources, possesses a triple-helix structure and demonstrates the
1586 capacity to inhibit tumor growth. However, alkaline-treated schizophyllan adopted a

1587 single-helix structure and showed a reduced ability to inhibit tumor growth as compared to
1588 its unmodified counterpart suggesting that the triple-helix structure plays an important role
1589 for antitumor activities (Ooi *et al.*, 2000, Ren *et al.*, 2012). Zhang *et al.* (2005) also
1590 proposed that triple-helix of β -glucan presents a stiff chain conformation which provides a
1591 greater growth-inhibition effect *in vivo*.

1592

1593 The relative proportion of polysaccharides and proteins is also an important factor and has
1594 been intensively reported to explain the antiproliferative properties of yeast cell wall
1595 extracts. In this context, Wang *et al.* (1995) prepared a polysaccharide-peptide (PSP)
1596 complex of *Tricholoma sp.* that exhibited immunomodulatory and anticancer activities at
1597 a higher level than crude powder from fruiting bodies. A more recent study isolated
1598 polysaccharides from *Pleurotus sajor-caju*, an edible mushroom, which induced excellent
1599 cytotoxic activities against human colon cancer HCT 116 cells *in vitro*. After partial
1600 characterization of the named polysaccharides PS1, the authors detected significant
1601 amounts of proteins and lipids which might have been responsible for these observed
1602 anticancer properties (Moharib *et al.*, 2014). Finally, Ooi *et al.* (2000) reviewed the
1603 antitumor mechanisms of polysaccharide-protein complexes (PSK) both *in vitro* and *in vivo*
1604 with a focus on fungi. The authors found that homopolysaccharides and PSK used different
1605 antitumor mechanisms. Typically, lentinan and schizophyllan are triggered by
1606 macrophages and T-cells whereas the mechanism of PSK is more direct with no substantial
1607 effect on immune responses, hence suggesting that the unique feature of both PSP and PSK
1608 is possibly due to the involvement of proteins that increases the structural diversity between
1609 active components (Ooi *et al.*, 2000). Conjointly, these investigations brought evidence

1610 indicating that the integrity of the glucan network and the glucan-protein complex might
1611 be highly relevant in anticancer properties of yeast's cell walls. Thus, further studies on the
1612 structure of glucan to find relation with biological properties are necessary.

1613

1614 This study demonstrated that extracts obtained via a simple and fast extraction method from
1615 cell walls of *S. boulardii* and *K. marxianus* suitable for industrial applications exhibited
1616 cancer chemoprevention, antiradical and antiproliferative properties in a dose-dependent
1617 manner. In addition, this study also revealed for the first time the capacity of insoluble
1618 glucan from *S. boulardii* and *K. marxianus* to induce QR activity, a phase II detoxification
1619 enzyme. Our results suggested that insoluble glucan and mannoprotein extracts from *S.*
1620 *boulardii* exhibited relevant biological activities toward CRC. Finally, the characterization
1621 of extracts demonstrated that high amounts of glucan, high glucan/total sugars ratios and
1622 low chitin/glucan ratios in extracts have a major impact in biological properties of yeast
1623 cell wall extracts. Thus, insoluble glucan and mannoprotein extracts of *S. boulardii* could
1624 be used in animal models in order to investigate their CRC chemopreventive properties in
1625 *in vivo* experiments.

1626

1627 **2.8. Acknowledgements**

1628 This work was supported by the Ministère de l'Économie, de l'Innovation et de
1629 l'Exportation du Québec (MEIE). Olivier Fortin is a scholarship recipient of Fondation
1630 Armand-Frappier.

1631

1632 **Table 2.1:** Solubility and visual appearance of yeast cell wall extracts obtained after
 1633 single hot-alkaline extraction for *S. cerevisiae* and *K. marxianus*.

1634

Extracts	Solubility in solvents						Appearance in 10% DMSO
	Water	DMSO	DMSO	DMSO	DMSO	NMP*100	
		10%	50%	75%	100%	%	
Insoluble	-	-	-	+/-	+/-	+	White, high turbidity
Soluble	+	+	+	+	+	ND	Transparent
Manno	+	+	+	+	+	ND	Transparent, yellow

1635 * 48 h with agitation at 60°C and additioned with 5% lithium chloride.

1636 (-) Insoluble.

1637 (+/-) Partially soluble.

1638 (+) completely soluble.

1639 ND Not determined, NMP 1-methyl-2-pyrrolidone.

1640 Soluble, insoluble and manno extracts refer to soluble glucan, insoluble glucan and
 1641 mannoprotein respectively.

1642

1643 **Table 2.2:** Sugars quantification and Mw range determination of extracts.

1644

Strain	Extracts	Total sugars (%)	Glucan (%)	Mannan (%)	Chitin (%)	Mw range (kDa)
	Insoluble	51.38±6.02 ^b	49.17±0.13 ^d	3.14±2.78 ^{a,b}	0.35±0.08 ^{a,b}	2085
<i>K. marxianus</i>	Soluble	32.55±2.42 ^b	30.38±0.30 ^b	8.49±3.75 ^{a,b}	0.30±0.03 ^b	0.74-165
	Manno	0.52±0.38 ^a	ND	9.14±0.94 ^b	0.24±0.02 ^a	0.48-77
	Insoluble	42.73±7.64 ^b	40.54±0.07 ^c	9.72±1.96 ^{a,b}	0.58±0.03 ^c	1921
<i>S. boulardii</i>	Soluble	39.13±5.63 ^b	23.99±0.29 ^a	3.99±3.46 ^{a,b}	0.66±0.02 ^c	0.73-160
	Manno	0.45±0.03 ^a	ND	3.17±0.11 ^a	0.27±0.01 ^b	0.72-87

1645 ND Not determined.

1646 Soluble, insoluble and manno extracts refer to soluble glucan, insoluble glucan and
1647 mannoprotein, respectively.

1648 Within each column, means bearing a different lowercase letter are significantly different

1649 ($P \leq 0.05$).

1650

1651 **Table 2.3:** Ratios in glucan, mannan and chitin from all extracts.

1652


Strain	Extracts	glucan / total sugars	mannan / total sugars	mannan / glucan	chitin / total sugars (10 ⁻³)	chitin / glucan (10 ⁻³)	chitin / mannan
	Insoluble	0.96±0.11 ^b	0.06±0.01 ^a	0.06±0.05 ^a	6.83±1.54 ^a	7.12±1.62 ^a	0.112±0.025 ^{c, d}
<i>K. marxianus</i>	Soluble	0.93±0.07 ^b	0.26±0.02 ^b	0.28±0.01 ^a	9.34±0.82 ^a	10.03±0.88 ^{a, b}	0.036±0.003 ^b
	Manno	ND	10.55±1.07 ^c	ND	471.85±38.45 ^c	ND	0.026±0.002 ^a
	Insoluble	0.94±0.16 ^b	0.23±0.04 ^{a, b}	0.24±0.05 ^a	13.66±2.94 ^b	14.38±3.09 ^b	0.059±0.0129 ^{b, c}
<i>S. boulardii</i>	Soluble	0.61±0.09 ^a	0.10±0.01 ^a	0.16±0.14 ^a	16.81±0.48 ^b	27.40±0.79 ^c	0.165±0.005 ^d
	Manno	ND	7.03±0.53 ^c	ND	685.14±14.25 ^d	ND	0.086±0.002 ^c

1653 ND Not determined.

1654 Soluble, insoluble and manno extracts refer to soluble glucan, insoluble glucan and
1655 mannoprotein respectively.

1656 Within each column, means bearing a different lowercase letter are significantly different
1657 (P≤0.05).

1658




1659

1660 **Fig 2.1.** Growth kinetics of *S. boulardii* and *K. marxianus* based on dry biomass in time

1661 function. (■) *S. boulardii*, (□) *K. marxianus*.


1662



1663

1664 **Fig 2.2.** Induction of NAD(P)H: quinone reductase of untreated cells, negative control, β-
 1665 Naphthoflavone and commercial insoluble glucan extracted from *S. cerevisiae* (bakery
 1666 strain) using alkaline extraction method. (□) β-Naphthoflavone (β-NF), (■) Untreated
 1667 cells, (▣) 1% DMSO + 20 ppm sodium azide (NC), (▤) Commercial glucan.


1668



1669

1670 **Fig 2.3.** Antiproliferative assay against HT-29 cells using increasing concentration of
 1671 commercial insoluble glucan from *S. cerevisiae*. (■) Commercial glucan.


1672




1673

1674 **Fig 2.4.** Induction of NAD(P)H quinone reductase with increasing concentration of all
 1675 extracts obtained from both yeast strains. (▨) *S. boulardii* soluble extract, (■) *S. boulardii*
 1676 insoluble extract, (▩) *S. boulardii* mannoprotein extract, (≡) *K. marxianus* soluble extract,
 1677 (□) *K. marxianus* insoluble extract, (▮) *K. marxianus* mannoprotein extract.

1678



1680 **Fig 2.5.** Percentage of scavenging activity of increasing concentration of all extracts
 1681 obtained from both yeast strains against superoxide anion. (▨) *S. boulardii* soluble extract,
 1682 (■) *S. boulardii* mannoprotein extract, (≡) *K. marxianus* soluble extract, (⏏) *K. marxianus*
 1683 mannoprotein extract.
 1684



1685

1686 **Fig 2.6.** Growth inhibition of HT-29 cell line using a) increasing concentration of extracts
 1687 obtained from *S. boulardii* and b) from *K. marxianus* along with c) IC₅₀ values for each
 1688 extract. (▨) *S. boulardii* soluble extract, (■) *S. boulardii* insoluble extract, (▩) *S. boulardii*
 1689 mannoprotein extract, (▤) *K. marxianus* soluble extract, (□) *K. marxianus* insoluble
 1690 extract, (▨) *K. marxianus* mannoprotein extract, (▩) Commercial glucan. Soluble,
 1691 insoluble and manno extracts refer to soluble glucan, insoluble glucan and mannoprotein
 1692 respectively. Different lowercase letter are significantly different (P≤0.05). IC₅₀
 1693 Concentration that inhibits 50% of cellular growth.

1694

1695

CHAPITRE 3 – PUBLICATION 2

1696

1697 Effect of β -glucan and mannoprotein extracted from cell wall of

1698 *Saccharomyces boulardii* on colon cancer prevention in male F344

1699 rats treated with 1,2-dimethylhydrazine.

1700

1701

1702

1703 **Effect of β -Glucan and Mannoprotein Extracted from Cell Wall of**
1704 ***Saccharomyces boulardii* on Colon Cancer Prevention in Male F344 Rats**
1705 **Treated with 1,2-Dimethylhydrazine**

1706

1707 Olivier Fortin¹, Blanca R. Aguilar-Uscanga², Khanh D. Vu¹, Stephane
1708 Salmieri¹ and Monique Lacroix¹

1709

1710 ¹ *INRS-Institut Armand-Frappier, Research Laboratories in Sciences Applied to Food, 531*

1711 *boul. des Prairies, Laval, QC, Canada.*

1712 ² *Laboratorio de Microbiología Industrial, Centro Universitario de Ciencias Exactas e*

1713 *Ingenierías, Universidad de Guadalajara (UdG). 1425 Blvd. Marcelino García Barragan*

1714 *Guadalajara, Jalisco, Mexico.*

1715

1716 Address correspondence to Monique Lacroix. INRS-Institut Armand-Frappier, Research
1717 Laboratories in Sciences Applied to Food, Canadian Irradiation Centre, The Institute of
1718 Nutraceutical and Functional Foods (INAF), 531, Boulevard des Prairies, Laval, Québec,
1719 Canada H7V 1B7. Tel.: +450 687 5010 #4489; fax: +450 686 5501. E-mail address:
1720 monique.lacroix@iaf.inrs.ca (M. Lacroix).

1721

1722 La publication 2 a été soumise le 17 Janvier 2017 dans le Journal Nutrition and Cancer

1723 **3.1. Contribution des auteurs**

1724

1725 J'ai réalisé les expériences et rédigé le manuscrit scientifique. Dr. Aguilar-Uscanga a
1726 participé aux discussions scientifiques et a aussi révisé le manuscrit. Dr. Vu a participé aux
1727 discussions scientifiques et a révisé le manuscrit. Mr. Salmieri m'a aidé dans la rédaction
1728 du manuscrit en plus d'avoir participé à quelques discussions scientifiques et a révisé le
1729 manuscrit. Dr. Lacroix, coordonnatrice et responsable du projet, a supervisé les discussions
1730 scientifiques entourant ce projet en plus d'avoir révisé le manuscrit.

1731

1732 **3.2. Résumé en français**

1733

1734 **L'Effet des β -Glucanes et des Mannoprotéines Obtenus de la Paroi Cellulaire de**
1735 ***Saccharomyces boulardii* Envers la Prévention du Cancer Colorectal Chez des Rats**
1736 **F344 Mâles Traités au 1,2-Diméthylhydrazine.**

1737

1738 L'effet des extraits de la paroi cellulaire de *Saccharomyces boulardii* envers la prévention
1739 du cancer colorectal chez des rats traités au diméthylhydrazine ainsi que les possibles
1740 mécanismes sous-jacents ont été investigués. Des extraits bruts de β -glucanes insolubles
1741 (0.5 et 1.0 mg/kg/jour) ainsi que de mannoprotéines (0.3 et 3.0 mg/kg/jour) ont été
1742 administrés à des rats par gavage pendant 12 semaines, le tout accompagné d'une diète
1743 forte en gras et faible en fibres après quoi les rats furent sacrifiés et les foyers de cryptes
1744 aberrantes (FCA) ont été comptés au niveau du côlon. De plus, les activités enzymatiques
1745 de la NAD(P)H: quinone réductase (QR) et de deux enzymes fécales (β -glucosidase et β -
1746 glucuronidase) furent quantifiées au niveau du foie et du caecum respectivement. Les
1747 résultats ont montré que seuls les rats traités aux β -glucanes insolubles démontraient une
1748 réduction du compte de FCA, une réduction de l'activité de la β -glucuronidase et une
1749 augmentation de celle de la QR. À notre connaissance, cette étude est la première à révéler
1750 qu'un extrait brut de β -glucanes insolubles obtenu à partir de la paroi cellulaire de *S.*
1751 *boulardii* est en mesure de démontrer d'importantes propriétés de prévention du cancer
1752 colorectal en modèle *in vivo* via des modulations enzymatiques.

1753 Mots clés : β -glucanes insolubles de levures, prévention du cancer, foyers de cryptes

1754 aberrantes, NAD(P)H:quinone réductase, β -glucuronidase, cancer colorectal

1755

1756 **3.3. Abstract**

1757 The effect of *Saccharomyces boulardii* cell wall extracts on colon cancer prevention in rats
1758 treated with 1,2-dimethylhydrazine and their possible mechanisms was investigated. A
1759 crude insoluble glucan (0.5 and 1.0 mg/kg/day) and a crude mannoprotein extract (0.3 and
1760 3.0 mg/kg/day) were administered in rats by gavage for 12 weeks along with a high fat low
1761 fiber diet whereupon rats were sacrificed and aberrant crypt foci (ACF) were counted in
1762 the colon. Moreover, NAD(P)H: quinone reductase (QR) and harmful fecal enzymes (β -
1763 glucosidase and β -glucuronidase) were quantified in the liver and in the caecum,
1764 respectively. Results showed that only rats treated with insoluble glucan had a decreased
1765 β -glucuronidase activity and an increased QR activity which led to a reduction in ACF
1766 counts. To our knowledge, this is the first study that demonstrates that crude insoluble
1767 glucan obtained from the *S. boulardii* cell wall exhibited colon cancer prevention properties
1768 *in vivo* via an enzymatic modulation.

1769

1770 Keywords: yeast, β -glucan, cancer prevention, aberrant crypt foci, experimental

1771 **3.4. Introduction**

1772 Colorectal cancer (CRC) is the second most deadly cancer for males and the third for
1773 females (Canadian Cancer Society's Advisory *et al.*, 2014) in addition to being the third
1774 most prevalent cancer in Canada (Canadian Digestive Health Foundation, 2016). Multiple
1775 risk factors are known for CRC. However, it is now well established that environmental
1776 factors and life-styles which include smoking, obesity, physical inactivity, diet rich in
1777 saturated fat and red meat along with a diet low in fiber, fruits or vegetables are involved
1778 in CRC (Hagggar *et al.*, 2009, Stevens *et al.*, 2007). Many studies suggest that diet habits
1779 have an important impact on CRC carcinogenesis (Gill *et al.*, 2002, Hagggar *et al.*, 2009),
1780 therefore, dietary modification by consumption of natural products with cancer
1781 chemopreventive properties could reduce the incidence of CRC.

1782 Polysaccharides represent the major part of the dry weight of yeast cell walls which mainly
1783 consist of mannoprotein, chitin and (1→3)-β-D-glucan with (1→6)-β-D-glucan
1784 ramifications (Klis *et al.*, 2002). Yeast cell walls are usually considered as industrial by-
1785 products and are often discarded after fermentation processes or used in many applications
1786 such as health and food supplements (dos Santos Mathias *et al.*, 2014). For instance,
1787 Dadrass *et al.* (2014) demonstrated that the *S. cerevisiae* cell wall modulates enzymatic
1788 activities in the liver upon chemically-induced CRC. Moreover, yeast cell wall
1789 polysaccharides demonstrated interesting chemopreventive and anticancer properties *in*
1790 *vivo*. Indeed, insoluble (particulate) yeast glucan orally administrated in mice has been
1791 reported to induce IL-12 cytokine production which induced a switch from a T-helper
1792 (Th)2 to Th1 response. Th1 cells can enhance cytotoxic T lymphocyte response resulting
1793 in an improved immunotherapy of cancer (Baran *et al.*, 2007). Moreover, orally

1794 administered insoluble glucan at doses ranging from 100 to 400 μg per day in tumor-
1795 bearing mice could reduce tumor diameter and increase survival rate in a dose-dependent
1796 manner (Li *et al.*, 2010). In contrast, very few studies have focused on *in vivo*
1797 chemoprevention properties of yeast mannoprotein. Liu *et al.* (2011) reported the capacity
1798 of yeast mannoprotein obtained from different extraction methods in exhibiting
1799 antineoplastic effect against several cancerous cell lines (HepG2, HL-60, and Eca109).

1800 In a previous study, Fortin *et al.* (2017a) extracted soluble and insoluble glucan and
1801 mannoprotein from the cell wall of *Saccharomyces boulardii* and *Kluyveromyces*
1802 *marxianus* and their chemopreventive and anticancer potential properties *in vitro* were
1803 determined. It has been reported that *S. boulardii*'s insoluble glucan induced NAD(P)H:
1804 quinone reductase (QR) activity and presented high antiproliferative activity expressing
1805 through a lower concentration required to inhibit 50% cell growth (lower IC_{50} value)
1806 toward CRC cells. Moreover, among mannoprotein extracts, *S. boulardii*'s mannoprotein
1807 exhibited the lower IC_{50} value toward CRC cells in addition to revealing the ability to
1808 scavenge superoxide anion. Thus, those two extracts present excellent chemopreventive
1809 potential.

1810 CRC prevention is typically assessed *in vivo* by the evaluation of the capacity of a bioactive
1811 agent to reduce counts of precancerous lesions known as aberrant crypt foci (ACF) in rat
1812 colon, in which CRC is chemically induced by using 1,2-dimethylhydrazine (DMH). The
1813 formation of precancerous lesions is considered to be the very first stage of CRC
1814 carcinogenesis, thus making ACF an excellent target for CRC prevention (Karoui *et al.*,
1815 2007). The exact mechanisms of chemopreventive effects of dietary agents against
1816 colorectal carcinogenesis are not known; however, some possible mechanisms have been

1817 proposed. For example, it has been suggested that an increase in QR activity could be
1818 responsible for the detoxification and excretion of carcinogens (Kang *et al.*, 2004) or the
1819 decrease of bacterial enzyme activities such as β -glucosidase and β -glucuronidase which
1820 are able to catalyse the conversion of procarcinogenic substances into carcinogenic
1821 substances (Ketudat Cairns *et al.*, 2010, Simon *et al.*, 1986). DMH is metabolized into
1822 azoxymethane (AOM) and methylazoxymethanol (MAM) in the liver. MAM is then
1823 transported to the colon via the bloodstream and the bile where it is transformed into methyl
1824 cation. In the colon, methyl cation targets the colonic mucosa resulting in the formation of
1825 oxidative stress and DNA damage. The severity of that damage partially depends on the
1826 transit time of those carcinogens in the colon which can be lowered by a reduction of β -
1827 glucosidase and β -glucuronidase activities (Fiala, 1977, Rosenberg *et al.*, 2009).

1828 In this context, the aim of this study was to investigate the *in vivo* chemopreventive
1829 potential of insoluble glucan and mannoprotein extracts obtained from the *S. boulardii* cell
1830 wall. It was assessed by the reduction of ACF, the induction of QR activity in liver and to
1831 the decrease β -glucosidase and β -glucuronidase activities in caecum content using male
1832 F344 rats treated with DMH.

1833

1834 **3.5. Methods**

1835 **3.5.1. Materials**

1836 N,N-dimethylhydrazine (DMH), methylene blue, 3-(4,5-dimethylthiazol-2-yl)-2,5-
1837 diphenyltetrazolium bromide (MTT), menadione, glucose 6-phosphate, glucose 6-
1838 phosphate dehydrogenase, ethylenediaminetetraacetic acid (EDTA), flavin adenine di-
1839 nucleotide (FAD), bovine serum albumin (BSA), nicotinamide adenine dinucleotide

1840 phosphate (NADP), Tween 20, Tween-80, NaOH, 4-nitrophenol, p-nitrophenyl β -D-
1841 glucopyranoside, p-nitrophenyl β -D-glucuronide and 10% formalin were purchased from
1842 Sigma-Aldrich Canada Ltd (Oakville, ON, Canada). Dextrose and 96-well microplates
1843 were purchased from Fisher Scientific (Ottawa, ON, Canada). Yeast extract and bacterial
1844 peptone were purchased from Alpha Biosciences (Baltimore, MD, USA).

1845

1846 **3.5.2. Extraction of insoluble glucan and mannoprotein extracts from yeast cell walls** 1847 **and their preparation for administration by gavage**

1848 Extraction of insoluble glucan and mannoprotein extracts was carried out as described in
1849 our previous study (Fortin *et al.*, 2017a). *Kluyveromyces marxianus* ATCC 10022 and
1850 *Saccharomyces cerevisiae* var. *boulardii* ATCC MYA-796 were purchased from American
1851 Type Culture Collection (ATCC) (Corning, Manassas, VA, USA) and were grown in
1852 yeast peptone dextrose (YPD) (10 g/l dextrose, 5 g/l yeast extract, 3 g/l bacterial peptone,
1853 0.8 g/l, MgSO₄, 1 g/l KH₂PO₄) for 24 h at 30°C under 200 rpm agitation. Biomass was
1854 autolysed at 50°C for 24 h at 200 rpm. Then, autolyzed cells were centrifuged at 9000 g for
1855 10 min at 4°C (Thermo Scientific, Sorvall ST16 centrifuge, Langensfeld, Hesse,
1856 Germany) and used for glucan and mannoprotein extraction. The extraction was performed
1857 by single hot alkaline extraction using 1 mol/l NaOH for 1 h at 90°C without stirring
1858 yielding insoluble glucan (precipitate) and soluble glucan-mannoprotein complex
1859 (supernatant). The mannoprotein extract was separated from soluble glucan by alcohol
1860 precipitation using 95% ethanol followed by the evaporation of ethanol residue using a
1861 vacuum concentrator (Savant, Automatic environmental speedVac® system, Model;
1862 AES1010, Farmingdale, NY, USA) under full vacuum, low speed and at ambient
1863 temperature for 8 h. Both insoluble glucan and mannoprotein extracts were freeze-dried

1864 (Labconco, FreeZone® 2.5 Liter Freeze Dry Systems, model 7670521, Kansas City, MO,
1865 USA). To administer both extracts by gavage, freeze-dried glucan and mannoprotein
1866 extracts were stirred for 30 min at desired concentration in 0.9% (w/v) saline containing
1867 Tween-80 in 1:4 proportions.

1868

1869 **3.5.3. Animals, housing and diet**

1870 Forty-eight F344 male rats of five weeks old and with an average weight of 122.85 g were
1871 obtained from Charles River Laboratories (Laval, QC, Canada) and housed 3 rats per cage.
1872 The temperature and the relative humidity were maintained at 22°C and 55% respectively.
1873 The light–dark cycles were 12 h each and all animals had free access to water and rat diet
1874 commercial pellets provided by Envigo (Madison, WI, USA). The composition of the high
1875 fat low fibre diet was 39.8% corn starch, 20% casein, 10% maltodextrin, 10% corn oil,
1876 12% lard, 2% cellulose, 4.375% mineral mixture, 1.25% vitamin mixture, 0.3% choline
1877 bitartrate, 0.3% L-cystine and 0.0044% TBHQ. All experimental animal care and
1878 treatments followed the guidelines set by the Canadian Council on Animal Care (CCAC)
1879 (Desrouillères *et al.*, 2015).

1880

1881 **3.5.4. Experimental design**

1882 The rats received a one-week period of acclimation and were randomly divided into 6
1883 groups of 8 animals. All rats were fed with the high fat low fibre diet (Harlan). Group 1
1884 and 2 served as negative (NC) and positive controls (PC) respectively and received 0.9%
1885 saline water containing Tween-80 (in 1:4 proportion) by gavage. Rats in groups 2 to 6 were
1886 injected with DMH dissolved in saline solution (30 mg/kg subcutaneously) once a week

1887 for six weeks (Desrouillères *et al.*, 2015). In addition to the diet, rats in groups 3 to 6 (G3
1888 to G6) were treated by gavage with different doses of insoluble glucan (G3 and G4) or
1889 mannoprotein extracts (G5 and G6). G3 and G4 were treated with 0.5 and 1.0 mg/kg/jour
1890 of insoluble glucan respectively whereas G5 and G6 received 0.3 and 3.0 mg/kg/jour of
1891 mannoprotein extract respectively. Animals were observed daily for general health and
1892 body weights were documented once a week. After an experimental period of 12 weeks,
1893 rats were sacrificed in a CO₂ chamber (CNBE, Laval, QC, Canada). The entire colon
1894 segment was collected for AC analysis whereas the liver and caecum were collected and
1895 stored at -80°C for subsequent enzymatic assays. Figure 3.1 summarizes the experimental
1896 design used in this study.

1897

1898 **3.5.5. Aberrant crypt analysis**

1899 The count of aberrant crypt (AC) and aberrant crypt foci (ACF) per colon was based on a
1900 procedure described by Bird (1995). The entire colon of each animal was collected and
1901 washed with saline (0.9% NaCl) until no fecal residue were observed. Colons were cut
1902 longitudinally and laid flat on Whatman paper in a Petri dish and fixed in 10% buffered
1903 formalin solution for at least 24 h. Then, colons were stained with 0.2% methylene blue for
1904 exactly 3 min and placed in saline overnight to remove excess staining. Stained colons
1905 were placed on glass slides and examined under a microscope (Carl Zeiss inc., Gottingen,
1906 Basse-Saxe, Germany) using 20 X objective for counting of ACF as well as the number of
1907 AC per focus. Moreover, the number of ACF containing a multiplicity of AC was also
1908 recorded and presented as total ACF containing 2-3 AC or containing 4-5 AC per colon.

1909

1910 **3.5.6. Liver and caecum processing**

1911 Rat livers were weighed and samples ranging from 1.5 to 2 g were cut from each liver. A
1912 volume of 5 ml of sucrose solution (0.25 mol/l) was added into each sample and
1913 homogenization was processed using a tissue homogenizer purchased from Fisher
1914 Scientific (Ottawa, ON, Canada). The homogenized samples were centrifuged at 5000 g
1915 for 30 min at 4 °C. The obtained supernatants were mixed with 1 ml of calcium chloride
1916 solution (0.1 mol/l) and were centrifuged at 27,000 g for 20 min at 4°C. The obtained
1917 supernatants were filtered through a 0.2 µm filter membrane and were used for QR activity
1918 in rat liver (Desrouillères *et al.*, 2015).

1919

1920 Rat caecal contents from different treatment groups were weighed and mixed with 10 ml
1921 of 100 mmol/l phosphate buffered saline. The suspensions were homogenized using a
1922 tissue homogenizer (Fisher Scientific, Ottawa, ON, Canada) and then centrifuged at 1500
1923 g for 15 min at 4°C. The obtained supernatants were centrifuged at 10000 g for 15 min at
1924 4°C. The clear obtained supernatants were filtered throughout a 0.2 µm filter membrane
1925 and used for β-glucosidase and β-glucuronidase activities (Desrouillères *et al.*, 2015).

1926

1927 **3.5.7. Protein estimation**

1928 Supernatants of rat liver and caecum were used for the determination of total proteins
1929 content which is essential for enzymatic assays (Desrouillères *et al.*, 2015). Total proteins
1930 determination was assessed using Pierce BCA protein assay kit (Fisher Scientific, Ottawa,
1931 ON, Canada) according to the manufacturer's protocol. Briefly, 25 µl of each sample were
1932 added into each well of a 96-well microplate and then 200 µl of BCA solution were added

1933 to the samples wells. The blank consisted of 225 μ l of heat-inactivated liver or caecum
1934 supernatants. All microplates were incubated for 30 min at 37°C and the absorbance was
1935 measured at 562 nm using a microplate reader (Biotek, Model EL800, Winooski, VT,
1936 USA). BSA was used as standard to determine protein concentration in samples.

1937

1938 **3.5.8. QR assay**

1939 The QR assay was based on Prochaska *et al.* (1988a) and Talalay (1989) with some
1940 modifications to the *in vivo* assays. Briefly, 30 μ l samples of liver supernatants were placed
1941 in a 96-well microplate. Then, 200 μ l of the reaction mixture (0.25 mol/l Tris-HCl pH 7,
1942 4.67% (w/v) BSA, 0.01% Tween-20, 5 mol/l FAD, 1 mmol/l glucose-6-phosphate, 30 mol/l
1943 NADP, 34.8 μ mol/l MTT, 50 μ mol/l menadione and 2 mU/ μ l glucose-6-phosphate
1944 dehydrogenase) was added into each well. The microplate was incubated for 5 min at room
1945 temperature and absorbance values were measured at 595 nm using a microplate reader
1946 (Biotek). Blank consisted of 30 μ l of heat-inactivated liver supernatants. Specific activity
1947 of QR was defined as nmol of blue formazan formed per mg protein per minute. The
1948 induction activity of QR enzyme was calculated by dividing the enzyme specific activity
1949 of a treated group by the enzyme specific activity of the control group.

1950

1951 **3.5.9. β -glucosidase and β -glucuronidase assay**

1952 β -glucosidase and β -glucuronidase assays were based on Park *et al.* (1998) with some
1953 modifications. Enzymatic activities of β -glucosidase and β -glucuronidase were determined
1954 using *p*-nitrophenyl β -D-glucopyranoside and *p*-nitrophenyl β -D-glucuronide as substrates,
1955 respectively. Briefly, 30 μ l samples from faecal supernatants were added in a 96-well

1956 microplate. A volume of 20 μ l of 2 mmol/l respective substrate was added into each well
1957 and the microplate was incubated at 37°C for 15 min. Then, the reaction was stopped by
1958 adding 250 μ l of 10 mmol/l NaOH. Absorbance values were measured at 405 nm using a
1959 microplate reader (Biotek). Blank consisted of 30 μ l of heat-inactivated caecum
1960 supernatants. Based on the fact that one activity unit is defined as the quantity of enzyme
1961 required to hydrolyse substrate into one μ mol/l of *p*-nitrophenol per minute, a standard
1962 curve of *p*-nitrophenol ranging from 0 to 300 μ mol/l was used to calculate the specific
1963 activities of both enzymes which were expressed as units of *p*-nitrophenol formed per min
1964 per mg protein of caecum supernatant.

1965

1966 **3.5.10. Statistical analysis**

1967 Data were analyzed by one-way analysis of variance (ANOVA), using PASW statistics 18
1968 software (IBM Corporation, Somers, NY, USA) and expressed as means \pm standard
1969 deviation. Differences among the groups were analyzed with a post-hoc Duncan's multiple-
1970 range test.

1971

1972 **3.6. Results**

1973 **3.6.1. Determination of total number of aberrant crypt (AC) and aberrant crypt foci** 1974 **(ACF) per colon**

1975 The cancer preventive effect of yeast cell walls obtained from *S. boulardii* was assessed *in*
1976 *vivo* via the capacity of extracts to prevent the formation of precancerous lesions. As
1977 presented in Figure 3.2, rats in the PC group showed significantly more AC (403.9 AC per
1978 colon) and ACF (263.6 ACF per colon) as compared to rats in NC group (66.1 AC per

1979 colon and 49.6 ACF per colon) ($p \leq 0.05$). Animals treated with insoluble glucan (G3 and
1980 G4) showed a 42% and 45% respective reduction of the total count of AC (Figure 3.2a) per
1981 colon as compared to the PC group. In addition, rats in groups G3 and G4 showed a 40%
1982 and 50% respective total count reduction of ACF (Figure 3.2b) per colon as compared to
1983 the PC group, hence suggesting that insoluble glucan demonstrated cancer prevention
1984 effects toward CRC. In contrast, no reduction in the count of total AC per colon nor in the
1985 count of total ACF per colon was observed in rats treated with mannoprotein extract (G5
1986 and G6) as compared to the PC group. Moreover, Figure 3.2 suggest that animals treated
1987 with high dose of mannoprotein extract (3.0 mg/kg/jour) presented a significantly higher
1988 count of total AC per colon and total ACF per colon as compared to the PC group ($p \leq$
1989 0.05). Also, no significant differences ($p > 0.05$) were observed between animals in groups
1990 G3 and G4 nor between animals in groups G5 and G6 regarding total counts of AC and
1991 ACF.

1992

1993 **3.6.2. Determination of the number of aberrant crypt foci (ACF) containing a** 1994 **multiplicity of aberrant crypt (AC)**

1995 Since there is a direct correlation between the ACF size and the probability of colon
1996 carcinoma development, the number of AC per ACF was also evaluated. As presented in
1997 Figure 3.3, rats in the PC group had significantly more total number of ACF containing 2-
1998 3 AC per focus and containing 4-5 AC per focus ($p \leq 0.05$) as compared to rats in the NC
1999 group which is congruent with results from Figure 3.2, hence confirming the relevance of
2000 the experimental design of this study. Moreover, rats treated with insoluble glucan (G3 and
2001 G4) showed a 38% and 61% respective reduction of the total number of ACF containing

2002 2-3 AC per focus as compared to the PC group. In addition, data from Figure 3.3 also
2003 demonstrated that rats in both groups G3 and G4 showed a 73% significant reduction of
2004 the total number of ACF containing 4-5 AC per focus as compared to the PC group ($p \leq$
2005 0.05). It is of interest to find that there was no significant difference ($p > 0.05$) in the total
2006 number of ACF containing 4-5 AC per focus among G3, G4 and NC groups (Figure 3.3).
2007 These results suggest that insoluble glucan reduced the total number of ACF containing a
2008 multiplicity of AC, hence decreasing the probability of colon carcinoma development in
2009 addition to confirm the cancer prevention effect of insoluble glucan. In contrast, no
2010 reduction in total counts of ACF containing 2-3 AC per focus nor containing 4-5 AC per
2011 focus was observed in animals treated with mannoprotein extract (G5 and G6). Moreover,
2012 animals treated with high dose of mannoprotein extract (3.0 mg/kg/jour) presented a
2013 significantly higher count of ACF containing 2-3 AC per focus as compared to the PC
2014 group ($p \leq 0.05$), hence suggesting a negative effect of this extract on the digestive tracts
2015 at high concentration.

2016

2017 **3.6.3. Induction of QR activity determined in liver supernatant**

2018 Analysis of the reduction of precancerous lesions revealed that insoluble glucan possesses
2019 *in vivo* cancer prevention properties. The mechanism involved in such chemopreventive
2020 properties has been investigated via the effect of insoluble glucan and mannoprotein
2021 extracts on the activity of a phase II detoxification enzyme. Results presented in Figure 3.4
2022 show that only animals in G3 (0.5 mg/kg/jour of insoluble glucan) were able to induce by
2023 68% the QR specific activity as compared to the PC group ($p \leq 0.05$). Animals in group
2024 G4 (1.0 mg/kg/jour of insoluble glucan) showed an increased QR specific activity by 29%

2025 in comparison with the PC group. However, QR induction of animals treated with a high
2026 dose of insoluble glucan (1.04 fold induction) was not statistically different than the QR
2027 induction of animals in the PC group (0.75 fold induction) ($p > 0.05$), hence suggesting
2028 that QR induction might not be the only responsible factor for cancer prevention effect
2029 observed since animal in G3 and G4 similarly reduced ACF counts. Moreover, all rats
2030 treated with mannoprotein extract (G5 and G6) were not able to significantly ($p > 0.05$)
2031 induce QR activity as compared to control groups (G1 and G2) which is congruent with
2032 results from Figures 3.2 and 3.3 where no reduction of AC and ACF were observed for
2033 mannoprotein extract.

2034

2035 **3.6.4. β -glucuronidase and β -glucosidase activities determined in caecum content**

2036 The activities of β -glucuronidase and β -glucosidase were also quantified and results are
2037 presented in Figure 3.5 and 3.6 respectively. Results demonstrated that rats in the NC group
2038 (186.1 units per mg protein of caecum content) presented a β -glucuronidase activity
2039 significantly lower than rats in the PC group (294.2 units per mg protein of caecum content)
2040 ($p \leq 0.05$). Also, data from Figure 3.5 show that rats in groups G3 (168.9 units per mg
2041 protein of caecum content) and G4 (147.9 units per mg protein of caecum content) were
2042 able to significantly reduce ($p \leq 0.05$) the activity of β -glucuronidase in a dose-dependent
2043 manner. A reduction of 43% and 50% was observed in groups G3 and G4, respectively, as
2044 compared to the PC group, hence suggesting that β -glucuronidase was implied in the cancer
2045 prevention effect of insoluble glucan. Moreover, results in Figure 3.5 also demonstrated
2046 that all rats treated with mannoprotein extract (G5 and G6) significantly increased ($p \leq$
2047 0.05) the β -glucuronidase activity (396.5 and 454.5 units per mg protein of Caecum

2048 respectively) as compared to the PC groups, which is also in accordance with results
2049 presented in Figures 3.2 and 3.3 where no reduction of AC and ACF were observed for the
2050 mannoprotein extract. In contrast, results in Figure 3.6 demonstrated that all rats treated
2051 with insoluble glucan (155.1 and 211.0 units per mg protein of caecum content) or
2052 mannoprotein extracts (145.1 and 154.6 units per mg protein of caecum content) did not
2053 significantly reduce ($p > 0.05$) the activity of β -glucosidase activity as compared to the PC
2054 group (190.0 units per mg protein of caecum content), hence suggesting that β -glucosidase
2055 might not be implicated in the cancer prevention effect observed by the reduction of the
2056 count of AC and ACF presented in Figures 3.2 and 3.3.

2057

2058 **3.7. Discussion**

2059 The objectives of this study were to evaluate the effect of the consumption of insoluble
2060 glucan and mannoprotein extracted from the cell walls of *S. boulardii* on the reduction of
2061 ACF formation in male F344 rats treated with DMH. Then, the effects of those extracts on
2062 the QR activity in the rat liver and on two faecal enzymes were evaluated. The results
2063 suggest that only the insoluble glucan was able to reduce the initial step of CRC
2064 development. Several studies presented the effect of β -glucan from different sources to
2065 prevent the formation of precancerous lesions (Lahouar *et al.*, 2012, Watanabe *et al.*, 2013).
2066 For instance, Bobek *et al.* (2001) investigated the effect of pleuran (β -glucan from
2067 *Pleurotus ostreatus*) on DMH-induced precancerous lesions in rat colon and observed a
2068 reduction of ACF count in the group treated with pleuran as compared to a control group.
2069 The authors attributed this effect to the fibrous (insoluble) nature of pleuran which
2070 participates in the sequestration of bile acid and other carcinogens resulting in the

2071 acceleration of their excretion. Moreover, the well-known immunomodulatory properties
2072 of β -glucan may also be responsible for the reduction of ACF. Indeed, the releasing of IL-
2073 12 and IL-10 cytokines induced by β -glucan treatment has been reported to play an
2074 important role in cancer therapy (Chan *et al.*, 2009, Stier *et al.*, 2014). The fact that
2075 mannoprotein extract did not reduce the count of ACF reflects its lack of chemoprevention
2076 effect *in vivo*. Very few studies investigated the *in vivo* chemoprevention of yeast
2077 mannoprotein whereas many studies focused on its anticancer properties *in vitro*. Indeed,
2078 Liu *et al.* (2011) revealed that the molecular weight (Mw) of *S. cerevisiae*'s mannoprotein,
2079 which depends on the extraction method, is important to obtain relevant antineoplastic
2080 activities (inhibition ratios) against cancerous cells. The authors observed the highest
2081 inhibition ratio using hot water extracted *S. cerevisiae* mannoprotein (181·127 kDa). The
2082 mannoprotein extract used in the present study exhibited a Mw range ranging from 720-
2083 87000 Da which is lower than Mw of mannoprotein obtained by Liu *et al.* (2011). In this
2084 respect, the low Mw range of mannoprotein extract used in the present study may explain
2085 the lack of chemoprevention effect observed. Moreover, mannoprotein extracts were found
2086 to have different *in vivo* and *in vitro* antitumor activities, depending on their
2087 monosaccharide composition, protein content, molecular mass and chain conformation
2088 which also vary according to extraction method (Bland *et al.*, 2004).

2089

2090 CRC carcinogenesis is a multistage process that begins with the transformation of crypt
2091 stem cells that remain located at the bottom of crypt while fuelling a growing
2092 microadenoma (Barker *et al.*, 2009). The importance of phase II detoxification enzymes
2093 such as QR in CRC chemoprevention concerns its capacity to decrease chemical

2094 carcinogenicity by transforming those compounds in a less toxic form or into inactive
2095 metabolites (Kang *et al.*, 2004). In this context, an enhancement of QR activity is
2096 considered to enhance excretion of carcinogens. Thus, a bioactive agent with the capacity
2097 to induce QR activity demonstrates a chemopreventive potential. In the present study, rats
2098 treated with insoluble glucan induced QR activity whereas rats treated with mannoprotein
2099 did not show such an effect. These results are in accordance with our previous study in
2100 which those extracts exhibited the same pattern in QR induction *in vitro* (Fortin *et al.*,
2101 2017a). Results from the present study also showed that rats treated with high dose of
2102 insoluble glucan (1.0 mg/kg/jour) showed no significant QR induction whereas rats treated
2103 with low dose (0.5 mg/kg/jour) showed a significant ($p \leq 0.05$) induction of QR induction
2104 as compared to rats in the PC group. This result suggests that QR induction might not be
2105 the only mechanism responsible for ACF reduction in rats treated with insoluble glucan
2106 since both doses similarly reduced the formation of ACF as presented in Figures 3.2 and
2107 3.3. Indeed, it has been reported that QR is interconnected with other phase II enzymes in
2108 the liver (Cuendet *et al.*, 2006, Desrouillères *et al.*, 2015, Kang *et al.*, 2004). Thus, a high
2109 dose of insoluble glucan may trigger the induction of a second phase II enzyme and/or
2110 another chemopreventive mechanism that detoxifies an organism in the sense that if one
2111 can detoxify the organism, no QR induction will be observed. Since this study is the first
2112 time reporting an induction of QR by yeast cell walls *in vivo*, there is a great interest to
2113 investigate the effect of insoluble glucan on other phase II detoxification enzymes using a
2114 wider range of doses ranging from 50 to 400 mg/kg/jour for instance (Samuelsen *et al.*,
2115 2014).

2116

2117 β -glucosidase and β -glucuronidase are two bacterial enzymes who are able to deconjugate
2118 toxins and/or carcinogens that have been previously detoxified in the liver and secreted
2119 into the gut via the bile. Those enzymes may lead to high local concentrations of
2120 carcinogens in the gut, hence increasing risk of CRC carcinogenesis (Dabek *et al.*, 2008,
2121 Simon *et al.*, 1986). More specifically, β -glucuronidase removes glucuronic acid from a
2122 compound detoxified by phase II enzymes hence releasing the carcinogenic compound in
2123 the colon (Gill *et al.*, 2002). Similarly, β -glucosidase hydrolyses glycosidic bonds releasing
2124 non-reducing terminal glucosyl residues from an aglycon compound which may be
2125 carcinogenic or toxic for the colonic environment. Since glycosides are hydrolyzed in the
2126 colon by bacterial β -glucosidases, potentially toxic substances may be formed in the large
2127 intestine (Ketudat Cairns *et al.*, 2010, Mroczynska *et al.*, 2013). Those bacterial enzymes
2128 are mostly produced by many *Clostridium* sp. (*C. paraputrificum*, *C. clostridioforme*, *C.*
2129 *perfringens*), *Bacteroides* sp. (*B. vulgatis*, *B. uniforme*, *B. fragilis*), *Enterococcus* sp.,
2130 *Peptostreptococcus* sp., *Staphylococcus* sp., *Ruminococcus* (gnavus), *Eubacterium* sp. and
2131 *Escherichia coli* (Dabek *et al.*, 2008, de Moreno de LeBlanc *et al.*, 2005, Nakamura *et al.*,
2132 2002). For those reasons, a reduction in the activity of β -glucosidase and β -glucuronidase
2133 can lead to a reduced exposure to carcinogenic substances and thus lead to a reduction in
2134 the incidence of CRC.

2135

2136 Our results demonstrated that rats treated with insoluble glucan significantly had a reduced
2137 activity of β -glucuronidase which is congruent with previous studies by Shen *et al.* (2012).
2138 Indeed, the authors reported that β -glucan present in cereals can decrease β -glucuronidase
2139 activity in a dose-independent manner, increase *Bifidobacteria* and *Lactobacilli* counts in

2140 addition to decrease those of colonic *Enterobacteriaceae*. The authors proposed that
2141 insoluble compounds contained in oat and barley β -glucan may pass in undigested forms
2142 into the large intestine and act as prebiotics, hence stimulating the growth of beneficial
2143 bacteria such as *Bifidobacteria* and *Lactobacilli*. In this context, insoluble glucan may have
2144 acted as a prebiotic in the colon leading to the increase of *Bifidobacteria* and *Lactobacilli*
2145 which may have decreased the bacterial population responsible for β -glucuronidase
2146 production by competitive exclusion. However, our results demonstrated that insoluble
2147 glucan did not reduce bacterial β -glucosidase activity. These results may be due to the
2148 different mechanism that dictated change in β -glucosidase and β -glucuronidase activities.
2149 Relatively to this assessment, McBain *et al.* (1998) reported that β -glucosidase activity is
2150 mostly related to a substrate-induced modulation of bacterial metabolism rather than the
2151 number of bacteria as opposed to β -glucuronidase activity. In this context, insoluble glucan
2152 used in the present study might have enhanced a competitive exclusion phenomenon to the
2153 detriment of β -glucuronidase producing bacteria and might not have acted as a substrate
2154 for β -glucosidase producing bacteria. In contrast, mannoprotein extract did not exhibit the
2155 capacity to reduce bacterial enzymes as compared to the positive control group which is
2156 also congruent with the absence of the capacity to reduce ACF counts. In this perspective,
2157 yeast mannoprotein extract obtained from alkaline extraction did not show any
2158 chemoprevention properties *in vivo* which highly contrasts with the insoluble glucan. This
2159 lack of CRC prevention properties might be due to an intrinsic incapacity of yeast
2160 mannoprotein to exhibit such properties since no study has reported, to our knowledge,
2161 such capacities.
2162


2163 This study demonstrated that a crude extract containing β -glucan as a major polysaccharide
2164 obtained from the cell walls of *S. boulardii* using a single hot alkaline extraction could have
2165 a preventive effect against colon carcinogenesis by decreasing the total number of ACF in
2166 DMH-treated rats. The mechanisms involved in this cancer prevention effect were found
2167 to be the induction of QR activity and the reduction of β -glucuronidase activity which could
2168 result in a reduced retention time of carcinogenic compounds in the organism. These
2169 findings together with our previous work demonstrates that this crude insoluble glucan
2170 from the cell walls of *S. boulardii* possesses both *in vivo* and *in vitro* cancer preventive
2171 effect against CRC, which provides further evidence on the chemopreventive potential of
2172 yeast cell walls. Further studies will be needed to investigate the immunomodulatory
2173 properties of this specific extract which will involve recognizing and eliminating the vast
2174 majority of incipient cancer cells and thus nascent tumors (Hanahan *et al.*, 2011).
2175 Moreover, the apoptosis properties and the underneath mechanisms need to be assessed in
2176 order to determine the specific cytotoxicity of the crude insoluble glucan against cancerous
2177 cells.

2178

2179 **3.8. Acknowledgements**

2180 This work was supported by the Ministère de l'Économie, de l'Innovation et de
2181 l'Exportation du Québec (MEIE). Olivier Fortin is a scholarship recipient of Fondation
2182 Armand-Frappier.

2183




Administrated by Gavage		
Group 1 (G1): Control diet	+ Saline and Tween-80	+ Saline injection (NC)
Group 2 (G2): Control diet	+ Saline and Tween-80	+ DMH injection (PC)
Group 3 (G3): Control diet	+ 0,5 mg/kg/day insoluble glucan	+ DMH injection
Group 4 (G4): Control diet	+ 1 mg/kg/day insoluble glucan	+ DMH injection
Group 5 (G5): Control diet	+ 0,3 mg/kg/day mannoprotein extract	+ DMH injection
Group 6 (G6): Control diet	+ 3 mg/kg/day mannoprotein extract	+ DMH injection

[†] DMH was injected at 30 mg/kg subcutaneous

2184

2185 **Fig 3.1.** Diagram representing the experimental design. Forty-eight rats were divided in 6
 2186 groups and were fed with high fat low fibre diet for 13 weeks. After one acclimation week,
 2187 all rats were injected with saline water (G1) or DMH (G2 to G6) and received by gavage
 2188 Tween-80 solution (G1 and G2) or different concentration of insoluble glucan (G3 and G4)
 2189 and mannoprotein extract (G5 and G6). At the 13th week, all rats were sacrificed then colon,
 2190 caecum and liver were collected for subsequent analysis.

2191




2192

2193 **Fig 3.2.** Numbers (n) of precancerous lesions induced by DMH in rats treated with
 2194 insoluble glucan and mannoprotein extracts regarding a) total number of aberrant crypt
 2195 (AC) and b) total aberrant crypt foci (ACF) per colon. NC: Saline + Tween only, PC: Saline
 2196 + Tween + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour
 2197 insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0
 2198 mg/kg/jour mannoprotein extract. Error bars represent the standard deviation of the mean

2199 total AC and AFC per colon obtained from 8 rats in each group. Different letters are
2200 significantly different ($p \leq 0.05$).


2201



2202

2203 **Fig 3.3.** Numbers (n) of precancerous lesions induced by DMH in rats treated with
 2204 insoluble glucan and mannoprotein extracts regarding number of aberrant crypt foci (ACF)
 2205 containing a multiplicity of AC per focus. (■) ACF containing two to three AC, (□) ACF
 2206 containing four to five AC. NC: Saline + Tween only, PC: Saline + Tween + DMH, G3:
 2207 DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan, G5:
 2208 DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour mannoprotein
 2209 extract. Error bars represent the standard deviation of the mean total AFC containing 2-5
 2210 AC per focus obtained from 8 rats in each group. Lowercase and uppercase letters concerns
 2211 ACF containing 2 to 3 AC per focus and 4 to 5 AC per focus respectively. Different letters
 2212 are significantly different ($p \leq 0.05$).


2213



2214

2215 **Fig 3.4.** Induction of QR activity in liver supernatant of DMH treated rats treated with
 2216 insoluble glucan and mannoprotein extracts. NC: Saline + Tween only, PC: Saline + Tween
 2217 + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour
 2218 insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0
 2219 mg/kg/jour mannoprotein extract. Error bars represent the standard deviation of mean QR
 2220 induction obtained from 8 rats in each group. Different letters are significantly different (p
 2221 ≤ 0.05).


2222



2223

2224 **Fig 3.5.** β -glucuronidase assay in caecum content of DMH treated rats treated with
 2225 insoluble glucan and mannoprotein extracts. NC: Saline + Tween only, PC: Saline + Tween
 2226 + DMH, G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour
 2227 insoluble glucan, G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0
 2228 mg/kg/jour mannoprotein extract. Error bars represent the standard deviation of the mean
 2229 β -glucuronidase activity obtained from 8 rats in each group. Different letters are
 2230 significantly different ($p \leq 0.05$).

2231



2244 **Fig 3.6.** β -glucosidase assay in caecum content of DMH treated rats treated with insoluble
 2245 glucan and mannoprotein extracts. NC: Saline + Tween only, PC: Saline + Tween + DMH,
 2246 G3: DMH + 0.5 mg/kg/jour insoluble glucan, G4: DMH + 1.0 mg/kg/jour insoluble glucan,
 2247 G5: DMH + 0.3 mg/kg/jour mannoprotein extract, G6: DMH + 3.0 mg/kg/jour
 2248 mannoprotein extract. Error bars represent the standard deviation of the mean β -
 2249 glucosidase assay obtained from 8 rats in each group. Different letters are significantly
 2250 different ($p \leq 0.05$).

2251

2252

CHAPITRE 4 - PUBLICATION 3

2253

2254 Chemopreventive, antiradical and antiproliferative properties of
2255 essential oils obtained from *Boswellia carterii* and *B. sacra* in
2256 combination with yeast cell wall extract.

2257

2258

2259 **Chemoprevention, antiradical and antiproliferative properties of essential oils**
2260 **obtained from *Boswellia carterii* and *B. sacra* in combination with yeast cell wall**
2261 **extract.**

2262
2263 Olivier Fortin¹, Blanca Aguilar-Uscanga², Khanh Dang Vu¹, Stéphane Salmieri¹,
2264 Jingcheng Zhao¹, Monique Lacroix¹¹.
2265

2266
2267

2268 ¹INRS-Institut Armand-Frappier, Research Laboratories in Sciences Applied to Food, 531
2269 boul. des Prairies, Laval, QC, Canada.

2270 ² Laboratorio de Microbiología Industrial, Centro Universitario de Ciencias Exactas e
2271 Ingenierías, Universidad de Guadalajara (UdG). 1425 Blvd. Marcelino García Barragan
2272 Guadalajara, Jalisco, Mexico.

2273

2274 La publication 3 a été soumise au Journal of Functional Foods le 17 Janvier 2017.

¹ Corresponding author: Dr. Monique Lacroix, Professor at INRS-Institut Armand-Frappier, Research Laboratories in Sciences Applied to Food, Canadian Irradiation Centre, The Institute of Nutraceutical and Functional Foods (INAF), 531, Boulevard des Prairies, Laval, Québec, Canada H7V 1B7. Tel.: +450 687 5010 #4489; fax: +450 686 5501. E-mail address: monique.lacroix@iaf.inrs.ca (M. Lacroix).

Abbreviations: EOs, essential oils; 5-FU, 5-fluorouracil; BCA, bicinechoninic acid protein; BSA, bovine serum albumin; CRC, colorectal cancer; FAD, flavin adenine dinucleotide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NADP, nicotinamide adenine dinucleotide phosphate; QR, NAD(P)H: quinone reductase; Tween-80, polyoxyethylene sorbitan monooleate; FBS, fetal bovine serum; MEM-EBSS, minimum essential medium-Earle's balanced salt solution; HBSS, Hank's balanced salt solutions; X/XO, Xanthine/Xanthine Oxidase; DPPH, α,α -diphenyl- β -picrylhydrazyl; PI, propidium iodide; CI, combination index; IC₅₀, concentration that inhibits 50% of the cellular growth; SC₅₀, concentration that scavenges 50% of formed radicals; MIC, minimal inhibitory concentration; BA, boswellic acid; K-BA, keto- β -boswellic acid, AK-BA, acetyl-keto- β -boswellic acid

2275 **4.1. Contribution des auteurs**

2276

2277 J'ai réalisé les expériences et rédigé le manuscrit scientifique. Dr. Aguilar-Uscanga a
2278 participé aux discussions scientifiques et a aussi révisé le manuscrit. Dr. Vu a participé aux
2279 discussions scientifiques et a révisé le manuscrit. Mr. Salmieri m'a aidé dans la rédaction
2280 du manuscrit en plus d'avoir participé à quelques discussions scientifiques et a révisé le
2281 manuscrit. Jingcheng Zhao a participé à la réalisation des expériences. Dr. Lacroix,
2282 coordonnatrice et responsable du projet, a supervisé les discussions scientifiques entourant
2283 ce projet en plus d'avoir révisé le manuscrit.

2284

2285 **4.2. Résumé en français**

2286 Les propriétés chimiopréventives, antiradicalaires et antiprolifératives des huiles
2287 essentielles (HE) de *Boswellia carterri* (huile Frankincense) et de *B. sacra* (huile Sacrée)
2288 utilisées seules ou en combinaison avec des extraits de parois cellulaires de levures ont été
2289 investiguées en modèle *in vitro* contre le cancer colorectal (CCR). Les huiles essentielles
2290 ont été testées pour leur capacité à induire la NAD(P)H : quinone réductase (QR), à capter
2291 des radicaux libres et à inhiber la croissance de cellules cancéreuses humaine du CCR. Les
2292 résultats ont démontré que les HE de *B. sacra* et de *Boswellia carterri* sont en mesure de
2293 capter l'anion superoxide et inhibent de manière similaire la croissance de deux lignées
2294 cellulaires cancéreuses humaines du CCR. Cette étude a aussi mis en évidence pour la
2295 première fois que l'augmentation de l'activité de la QR est un mécanisme d'action de ces
2296 HE dans la prévention du cancer et a démontré que des extraits de parois cellulaires de
2297 levures améliorent la capacité de l'huile Frankincense à augmenter l'activité spécifique de
2298 la QR. Finalement, l'huile Sacrée a capté efficacement l'anion superoxide en plus
2299 d'exprimer une cytotoxicité spécifique aux cellules cancéreuses contrairement à l'huile
2300 Frankincense.

2301 **Mots clefs :** Huiles essentielles de *Boswellia*, chimioprévention, antiradicalaire,
2302 antiprolifératif, NAD(P)H : quinone réductase, β -glucanes, apoptose

2303

2304

2305 **4.3. Abstract**

2306 The *in vitro* chemopreventive, antiradical and antiproliferative effects of essential oils
2307 (EOs) from *Boswellia carterii* (Frankincense oil) and *B. sacra* (Sacred oil) used alone and
2308 in combination with yeast cell wall extracts on colorectal cancer (CRC) were investigated.
2309 Essential oils were assayed for their capacity to increase the specific activity of NAD(P)H:
2310 quinone reductase (QR), scavenge radicals and inhibit growth of human CRC cells. Results
2311 demonstrated that EOs from *B. sacra* and *B. carterii* scavenged superoxide anions and
2312 similarly inhibited growth of two human CRC cell lines. This study also reported the
2313 increase of QR activity as a novel mechanism of action of these EOs in cancer prevention
2314 and demonstrated that yeast cell wall extract enhanced the capacity of Frankincense oil to
2315 increase QR specific activity. Finally, Sacred oil efficiently scavenged superoxide anions
2316 and expressed cancerous cell-specific cytotoxicity when opposed to Frankincense oil.

2317

2318 **Keywords:** *Boswellia* essential oils, chemoprevention, antiradical, antiproliferative,
2319 NAD(P)H: quinone reductase, β -glucan, apoptosis

2320

2321

2322 **4.4. Introduction**

2323 The colorectal cancer (CRC) is the second most deadly cancer in males and the third for
2324 females (Canadian Cancer Society's Advisory *et al.*, 2014) and is the third most prevalent
2325 cancer in Canada (Canadian Digestive Health Foundation, 2016). The increase of CRC in
2326 Canada and USA has generated an increased interest in the consumption of natural products
2327 to prevent the development of this disease. Thus, prevention seems to be the most efficient
2328 approach since treatments for CRC can be expensive and invasive for patients.
2329 Chemoprevention consists of using natural or synthetic materials to prevent the progression
2330 of cancer (Czadek, 2016). Many essential oils (EOs) and their constituents have been
2331 reported to be chemopreventive agents due to their abilities to affect phase I and II
2332 enzymes, prevent lipid peroxidation, suppress cyclooxygenase-2 activity and exhibit
2333 anticancer properties such as *in vivo* antitumoral activities, apoptosis and cancerous cell
2334 specific cytotoxicity (Gautam *et al.*, 2014, Jayakumar *et al.*, 2012). More specifically, EOs
2335 from *Boswellia spp.* are well known for their tumor cell specific cytotoxicity and their
2336 capacity to induce apoptosis in cancerous cells (Dozmorov *et al.*, 2014, Frank *et al.*, 2009).
2337 In this aspect, the use of *Boswellia spp.* EOs as chemopreventive agents toward CRC
2338 appears to be relevant. Moreover, EOs exhibiting enhanced chemopreventive properties
2339 obtained by combination with known chemopreventive agents is also a relevant approach
2340 to reduce CRC development.

2341 EOs obtained from *Boswellia* trees have been used for many centuries in religious rituals
2342 and medicinal applications such as inflammation, immune support, skin health and more
2343 recently cancer treatment. As found with others EOs, the biological properties of
2344 Frankincense (obtained from *Boswellia carterii*) and Sacred (obtained from *B. sacra*) EOs

2345 vary according to many factors such as plant species, plant organs, extraction methods, soil
2346 composition, vegetative cycle stage, season and climate of harvesting (Bakkali *et al.*,
2347 2008). In this context, many scientists, botanists and governments tend to consider *B.*
2348 *carterii* and *B. sacra* as the same species whereas several studies tend to prove the opposite
2349 using chemical characterization (Woolley *et al.*, 2012). Despite these evidences, very few
2350 studies have investigated differences between EOs from *B. carterii* and *B. sacra* regarding
2351 their biological activities toward colorectal cancer (CRC).

2352 Yeast β -glucans found in the cell wall are known for their strong immunomodulatory
2353 properties (Samuelsen *et al.*, 2014) and can be easily extracted from spent yeast
2354 (Supphantharika *et al.*, 2003). In previous studies, the chemopreventive potential *in vitro*
2355 and *in vivo* of insoluble glucan from *S. boulardii* cell wall was demonstrated (Fortin *et al.*,
2356 2017a, Fortin *et al.*, 2017b). Notably, this specific extract appeared to be an inducer of
2357 NAD(P)H: quinone reductase (QR), a phase II detoxification enzyme (EC 1.6.99.2) *in vitro*
2358 and *in vivo* and could significantly reduce aberrant crypt count in 1,2-dimethylhydrazine-
2359 treated rats.

2360 To substantiate differences between EOs from *B. sacra* and *B. carterii*, this study
2361 investigated the differences and the mechanism of action of Frankincense and Sacred EOs
2362 regarding chemopreventive, antiradical and antiproliferative properties toward CRC. In
2363 this context, EOs were evaluated for their capacity to induce QR activity which has never
2364 been evaluated before and to scavenge superoxide anions (O_2^-) and DPPH radicals.
2365 Moreover, EOs were tested for their antiproliferative activities against cancerous and non-
2366 cancerous cells to reveal a cancerous cell specific cytotoxicity then an apoptosis assay was
2367 conducted to determine if this mechanism was involved. Finally, efforts were invested to

2368 enhance biological activities of EOs through addition of insoluble glucan to Frankincense
2369 and Sacred EOs.

2370 **4.5. Method**

2371 **4.5.1. Chemicals**

2372 Chemicals and media were obtained as follows: essential amino acids, sodium pyruvate,
2373 fetal bovine serum (FBS), minimum essential medium-Earle's balanced salt solution
2374 (MEM-EBSS), Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (MEMF/12),
2375 Ham's F-12 medium, Dulbecco's Modified Eagle Medium low glucose, Hank's balanced
2376 salt solutions (HBSS), trypsin, Pierce[®]BCA Protein assay, glycine, 25 cm² flask, 96-well
2377 and 6-well microplates were purchased from Fisher Scientific (Ottawa, ON, Canada).
2378 Activated carbon, digitonin, bovine serum albumin (BSA), glucose-6-phosphate, thiazolyl
2379 blue tetrazolium bromide (MTT), menadione, glucose-6-phosphate dehydrogenase,
2380 nicotinamide adenine dinucleotide phosphate (NADP) and flavin adenine dinucleotide
2381 (FAD), Tween-80, sodium azide, 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
2382 tetrazolium-5-carboxanilide inner salt (XTT), xanthine, sodium carbonate buffer (pH 10.2),
2383 xanthine oxidase, superoxide dismutase, N-methylpyrrolidone (NMP), α,α -diphenyl- β -
2384 picrylhydrazyl (DPPH) and 5-fluorouracil (5-FU) were purchased from Sigma-Aldrich
2385 (Oakville, ON, Canada). Lecithin was purchased from ADM (Calgary, AB, Canada).
2386 Frankincense and Sacred EOs were graciously provided by Young Living Essential Oils
2387 (Lehi, UT, USA). Annexin V-FITC/PI Dead Cell Apoptosis kit was purchased from
2388 Invitrogen (Burlington, ON, Canada). Polymethyl methacrylate (PMMA) was obtain from
2389 Agilent technologies (Mississauga, ON, Canada).

2390

2391 **4.5.2. EOs preparation**

2392 *Boswellia carterii* and *B. sacra* were harvested in Kenya and Oman respectively to obtain
2393 Frankincense and Sacred EOs using the steam distillation method and were kindly provided
2394 by Young Living Essential Oils (Lehi, UT, USA). Frankincense and Sacred EOs were
2395 prepared under oil-in-water emulsion (termed emulsifying solution) containing 1% (v/v)
2396 Tween-80 and 1% (w/v) lecithin as emulsifying agents. The EO emulsion was stirred until
2397 complete homogenization and then filtered through a 0.2 µm filter. For combined
2398 treatments containing EOs and insoluble β-glucan, an EO emulsion was prepared as
2399 mentioned above but without filtration through a 0.2 µm filter, and sodium azide (20 ppm)
2400 was added to prevent microbial contamination since an insoluble extract was used. For
2401 assays, EOs were serial diluted in anhydrous ethanol to a final concentration of 34400 ppm.

2402

2403 **4.5.3. Extraction of insoluble glucan from *S. boulardii* cell wall**

2404 Extraction of insoluble glucan was performed as described by Fortin *et al.* (2017a). Briefly,
2405 *S. boulardii* cells were grown in yeast peptone media containing 1% (w/v) dextrose and
2406 collected in early stationary phase. The cell suspension was centrifuged at 9000 x g for 10
2407 min at 4°C and the resulting biomass was washed twice with sterile phosphate buffer 50
2408 mM, pH 7.2. Then, the wet biomass was suspended in sterile water (15% w/v) and
2409 autolyzed for 24 h at 50°C under agitation at 200 rpm. The autolyzed biomass was then
2410 centrifuged at 9000 x g for 10 min at 4°C and 500 ml of 1 mol/l NaOH was mixed with 100
2411 g of wet autolyzed cells for 1 h at 90°C without agitation. Finally, the resulting suspension
2412 was centrifuged as described above and the precipitate was washed twice with distilled
2413 water and then freeze-dried.

2414

2415 **4.5.4. Cancerous cell lines and cells maintenance**

2416 Hepa 1c1c7 ATCC CRL-2026, HT-29 ATCC HTB-38, CHO-K1 and Caco-2 cell lines
2417 were purchased from American type culture collection (ATCC) (Manassas, VA, USA). All
2418 cell lines were cultivated in 25 cm² cellular flasks (Corning, NY, USA) at 37°C in a
2419 humidified incubator with an atmosphere of 5% CO₂ and 95% air. Hepa 1c1c7 and HT-29
2420 cells were grown in complete MEM-EBSS and complete MEMF/12 media, respectively
2421 (0.1% essential amino acids, 0.1% sodium pyruvate, 10% FBS). Caco-2 cells were grown
2422 in Dulbecco's Modified Eagle Medium low glucose (0.1% essential amino acids, 0.1%
2423 sodium pyruvate, 20% FBS) and CHO-K1 cells were grown in Ham's F-12 media (20%
2424 FBS). At a confluence of 80-90%, cells were treated with 1X trypsin-EDTA for 12 min at
2425 37°C in presence of 5% CO₂. Finally, trypsin was inactivated with 2 ml of respective media
2426 and 1 ml of the resulting suspension was used to inoculate 5 ml of fresh media.

2427

2428 **4.5.5. Antiradical assays (O₂⁻ and DPPH radicals scavenging activity)**

2429 The capacity of Frankincense and Sacred EOs to scavenge O₂⁻ anions was measured using
2430 the xanthine/xanthine oxidase (X/XO) system (XTT color assay) based on Gerhäuser *et al.*
2431 (2003) with modification. A 20 µl sample previously diluted in ethanol was loaded in a 96-
2432 well microplate and completed to 200 µl with reactional mix (1 mmol/l XTT, 1 mmol/l
2433 EDTA, 1 mmol/l xanthine, 50 mmol/l sodium carbonate buffer (pH 10.2) and 3 mU/ml
2434 xanthine oxidase). The optical density (OD) was read at 490 nm after 20 min. Negative and
2435 positive controls consisted of ethanol and 30 U/ml of superoxide dismutase respectively.
2436 Scavenging activity was calculated as follows:

2437

2438 Scavenging Activity (%)= [(*sample OD* - *Negative control OD*) / (*Positive control OD* -
2439 *Negative control OD*)] x 100 (Equation 1)

2440

2441 The capacity of Frankincense and Sacred EOs to scavenge DPPH was based on the method
2442 of Blois (1958) and Kedare *et al.* (2011) with some modifications. Briefly, 1 ml of 40 µM
2443 DPPH previously dissolved in anhydrous ethanol was added to 250 µl of serial diluted EOs
2444 (also diluted in anhydrous ethanol). The solution was mixed and kept at room temperature
2445 for 1 hour protected from lights then, optical density was read at 517 nm. The blank
2446 consisted of 1.25 ml anhydrous ethanol whereas control consisted of 250 µl of anhydrous
2447 ethanol and 1 ml of DPPH solution. The inhibition percentage (IP) of free radicals was
2448 measured by the equation proposed by Megdiche-Ksouri *et al.* (2015):

2449

2450 $IP (\%) = ([Control\ OD - Sample\ OD] / Control\ OD) * 100$ (Equation 2)

2451

2452 For both assays, concentrations that exhibited a scavenging activity of 50% (SC₅₀ values)
2453 were determined.

2454

2455 **4.5.6. NAD(P)H: QR assay**

2456 QR assay was based on methods from Prochaska *et al.* (1988a) and Talalay (1989) with
2457 some modifications. Hepa 1c1c7 cells were seeded at a density of 2 x 10³ cells/well in a
2458 96-well plate using complete MEM-EBSS media and were incubated at 37°C in a
2459 humidified incubator with 5% CO₂. Afterward, the media was removed using a
2460 multichannel micropipette and serial diluted samples were added, then the microplate was
2461 incubated for 48 h as mentioned above. Cells were washed with 200 µl HBSS solution and

2462 50 µl of 1.6% (w/v) digitonin were added to each well followed by a 20 min incubation.
2463 Then, 20 µl of samples were removed using a multichannel micropipette and used for total
2464 protein quantification whereas 200 µl of complete reaction mixture (0.25 mol/l Tris-HCl
2465 pH 7, 4.67% (w/v) BSA, 0.01% Tween-20, 5 mol/l FAD, 1 mmol/l glucose-6-phosphate,
2466 30 mol/l NADP, 34.8 µmol/l MTT, 50 µmol/l menadione and 2 mU/µl glucose-6-
2467 phosphate dehydrogenase) were added to each well then incubated at room temperature for
2468 5 min. The microplate was read at 595 nm. A protein assay was conducted using
2469 Pierce®BCA reagents using the manufacturer's instruction. Controls consisted of
2470 emulsifying solution whereas media was used as blank. Specific activity of QR was defined
2471 as nmol of blue formazan formed per mg protein per minute. Fold induction of QR was
2472 calculated as follows:

2473

2474 $QR \text{ Fold Induction (treated on control)} = \frac{\text{Specific Activity of QR in Treated Group}}{\text{Specific Activity of QR in Negative Control Group}}$ (Equation 3)

2476

2477 **4.5.7. Molecular weight determination by gel permeation** 2478 **chromatography (GPC)**

2479 Molecular weights (Mw) of insoluble glucan treated with Sacred EO was analyzed by gel
2480 permeation chromatography (GPC) (Agilent Technologies 1260 infinity series,
2481 Waldbronn, BW, Germany), equipped with a quaternary pump (Model G1311B), a manual
2482 injector with a sample loop of 20 µl and a refractive index detector (Model G1362A). Two
2483 identical PLgel 5 µm Mixed-D 300 X 7.5 mm columns were used in series and mobile
2484 phase consisted of 100% N-methylpyrrolidone (NMP) containing 5% (w/v) LiCl at a flow
2485 rate of 0.5 ml/min. Both columns and detector were set at 60°C. Insoluble glucan (5 mg)

2486 and EOs were suspended in 5 ml of emulsion as described in section 2.2. in a proportion
2487 of 5:1 for 48 h. Then, 2 ml of 100% NMP was added to obtain a relative concentration in
2488 insoluble glucan of 2.5 mg/ml and the suspension was stirred for 48 h at 60°C, filtered
2489 through a nylon 0.2-µm filter and injected in the column. Polymethyl methacrylate
2490 (PMMA) was used as a standard and was prepared as indicated by the manufacturer. The
2491 equation obtained by plotting M_w with retention times of standards was used to calculate
2492 M_w of insoluble glucan. All extracts were injected in triplicate (n=3).

2493

2494 **4.5.8. Antiproliferative assay**

2495 Antiproliferative properties were determined by the ability of the metabolic active cells to
2496 cleave the tetrazolium salt to purple formazan crystals based on Vistica *et al.* (1991).
2497 Different cell lines were seeded at 2×10^4 cells/well of media in a 96-well plate (200
2498 µl/well) and were incubated for 24 h at 37°C in 5% CO₂. Spent media were removed using
2499 a multichannel micropipette and 100 µl of fresh media containing 10 µl of sample
2500 previously serial diluted was added and microplate was then incubated for 48 h as
2501 mentioned above. Afterward, samples were removed using a multichannel micropipette
2502 and replaced with 225 µl of fresh media containing 25 µl 0.5% (w/v) MTT followed by
2503 incubation for 4 h at 37°C in 5% CO₂. Finally, the media was carefully removed using a
2504 multichannel micropipette and replaced with 225 µl of DMSO containing 25 µl of Sorensen
2505 buffer containing 0.1 mol/l glycine and 0.1 mol/l NaCl at a pH of 10.5. The microplate was
2506 then read at 562 nm. The negative control and blank consisted of emulsifying solution and
2507 media respectively. Growth inhibition was calculated as follows:

2508

2509 Cellular Growth Inhibition (%) = $100 - (([Sample\ OD] / Negative\ control\ OD) \times 100)$

2510 (Equation 4)

2511

2512 Equations obtained by plotting the linear portion of growth inhibition versus increasing
2513 concentrations of samples were used to calculate concentrations that inhibit 50% of cellular
2514 growth (IC₅₀ values). For combined treatments, concentrations corresponding to IC₅₀
2515 values when tested separately were serially diluted and assayed.

2516

2517 **4.5.9. Assessing interaction between EOs and insoluble glucan regarding** 2518 **antiproliferative and NAD(P)H: QR assays**

2519 The assessment of interactions in combined treatments regarding QR and antiproliferative
2520 assays differed due to the nature of measured effects. The determination of combined
2521 effects concerning antiproliferative assay was based on combination index (CI) as used by
2522 Hossain *et al.* (2016) with different upper and lower bounds suggested by Berenbaum
2523 (1977) following the equation:

2524

2525 $CI = [Dx / IC_{50x}] + [Dy / IC_{50y}]$ (Equation 5)

2526

2527 where *Dx* and *Dy* represent concentrations of components used in combination that reached
2528 IC₅₀ values whereas *IC_{50x}* and *IC_{50y}* represents concentrations of components x and y that
2529 reached IC₅₀ values when tested separately. Based on CI values, different combined effects
2530 can be classified: CI value < 1 was interpreted as a synergistic effect, a CI value equal to 1

2531 was interpreted as an additive effect and a $CI > 1$ was interpreted as an antagonistic effect.
2532 Concerning the QR assay, concentrations that exhibited an induction of 1.5 when tested
2533 separately were used for combined treatment assays. Determination of the combined effect
2534 was based on fold induction and assessed as follows: Fold induction of 1.5 to 3.0 was
2535 interpreted as an additive effect, fold induction ≈ 1.5 as no interactive effect and fold
2536 induction < 1.5 as an antagonistic effect. Fold induction calculated in combined treatments
2537 was obtained as described in equation 3.

2538

2539 **4.5.10. Apoptosis assay**

2540 HT-29 cells were seeded in a 6-well plate at 3×10^5 cells/well (3 ml/well) and incubated
2541 as described in section 2.8. for 24 h. Then, cells were incubated for 48 h at 37°C in 5% CO₂
2542 in the presence of 450, 900 and 1800 ppm of Frankincense or Sacred EOs in a final volume
2543 of 3 ml in order to surround IC₅₀ values obtained for this cell line. Cells present in the
2544 supernatant were harvested by centrifugation at 500 x g for 10 min at 4°C. Adhered cells
2545 were treated with 1 ml of 1X trypsin-EDTA for 12 min at 37°C. Then, 2 ml of complete
2546 MEM/F12 medium was added and cells were harvested by centrifugation as described
2547 previously. The cell-containing pellets (from the supernatant and the adhered cells) were
2548 washed twice with PBS containing 0.25% EDTA to avoid clumping and the apoptosis
2549 evaluation was performed by using Annexin V-FITC and PI double staining assays.
2550 Harvested cells were diluted in 1X binding buffer at 10^6 cells/ml and Annexin V-FITC/PI
2551 staining was performed according to the manufacturer's instructions with a total of 10,000
2552 events by flow cytometry (Coulter Epics XL-MCL, Beckman Coulter Canada, Inc.,
2553 Mississauga, ON, Canada). 5-fluouracil (5-FU) was used as positive control and
2554 emulsifying solution was used as negative control.

2555

2556 **4.5.11. Statistical analysis**

2557 All measurements were done in triplicate (n=3) and results are presented as average ±
2558 standard deviation. QR fold induction, IC₅₀ values and percentage of apoptotic and necrotic
2559 cells were analyzed by one-way analysis of variance (ANOVA) using PASW statistics 18
2560 software (IBM Corporation, Somers, NY, USA) and differences among treatments were
2561 analyzed with a post hoc Duncan's multiple-range test. Significance was considered at P ≤
2562 0.05.

2563

2564 **4.6. Results**

2565 **4.6.1. Evaluation of the antiradical properties of EOs**

2566 Antiradical properties of EOs from *Boswellia spp.* were investigated via their capacity to
2567 scavenge O₂⁻ and DPPH radicals and the results are presented in Fig. 4.1 Sacred and
2568 Frankincense EOs demonstrated a dose-dependent response in antiradical activities and
2569 were found to scavenge 50% of O₂⁻ anion at 4300 and 34400 ppm respectively in addition
2570 to demonstrate a dose-dependent response (Fig. 4.1a). These results suggest a strong
2571 capacity of Sacred EO to scavenge O₂⁻ anion known to be involved in CRC carcinogenesis
2572 (Wang *et al.*, 2016). In contrast, both EOs were not able to scavenge 50% of DPPH radical
2573 despite their high concentration ranging from 33.59 to 34400 ppm. However, a dose-
2574 dependent response was also observed suggesting a weak capacity of Sacred EO (18% at
2575 34400 ppm) to scavenge DPPH radical (Fig. 4.1b).

2576

2577 **4.6.2. Effect of EOs in combination with insoluble glucan on the**
2578 **induction of NAD(P)H: QR and molecular weight**
2579 To determine the chemopreventive potential of Frankincense and Sacred EOs, their effects
2580 on QR activity was evaluated and results are shown in Table 4.1 Cells treated with
2581 emulsifying solution (control) showed a 0.77-fold induction which corresponded to a basal
2582 expression of QR in Hepa 1c1c7 cells. Moreover, Frankincense and Sacred EOs reached
2583 maximum fold inductions of 1.50 and 1.39 at a concentration of 27 and 54 ppm
2584 respectively. In addition, both EOs tested separately demonstrated a maximum fold
2585 induction significantly higher than control (0.77-fold induction) ($P \leq 0.05$). Those results
2586 demonstrated that Frankincense EO (27 ppm) is twice as efficient as Sacred EO (54 ppm)
2587 to induce QR. In order to increase the chemopreventive potential of Frankincense and
2588 Sacred EOs, they were combined with insoluble glucan of *S. boulardii* which has
2589 demonstrated an excellent chemopreventive potential against colorectal cancer evaluated
2590 *in vitro* and *in vivo* (Fortin et al., 2017a, Fortin et al., 2017b). Concentrations in EOs and
2591 insoluble glucan that exhibited similar fold inductions were mixed to determine the
2592 combined effect of EO + insoluble glucan on QR activity and these results are also
2593 presented in Table 4.1 The combination of Sacred EO+ Frankincense EO showed a similar
2594 QR activity (1.39-fold induction) as compared to each EO tested separately, hence
2595 suggesting there was no interactive effect between two EOs. In contrast, the combination
2596 of Sacred EO + insoluble glucan revealed a QR activity (0.36-fold induction) which was
2597 significantly ($P \leq 0.05$) lower than of Sacred EO (1.39-fold induction) and insoluble glucan
2598 (1.52-fold induction at 250 ppm) alone, hence suggesting an antagonistic effect. The
2599 combination of Frankincense EO + insoluble glucan revealed a QR activity (1.99-fold
2600 induction) which was significantly ($P \leq 0.05$) higher than that of Frankincense EO (1.50-

2601 fold induction) or insoluble glucan (1.52-fold induction) alone, hence suggesting an
2602 additive effect. These results demonstrated that insoluble glucan improves the capacity of
2603 Frankincense EO in inducing QR activity. The antagonistic effect of Sacred EO when
2604 combined with insoluble glucan on QR activity led to a hypothesis that Sacred EO might
2605 degrade insoluble glucan. The hypothesis was verified by comparing the molecular weight
2606 (Mw) of insoluble glucan before and after addition of Sacred EO. Results demonstrated
2607 that insoluble glucan possessed a Mw (1921±13 kDa) similar as if it was combined with
2608 Sacred EO (1904±297 kDa), hence suggesting that EOs did not affect the yeast cell wall
2609 extract.

2610

2611 **4.6.3. Effect of EOs in combination with insoluble glucan on the cellular** 2612 **proliferation of different cell lines**

2613 The effect of Frankincense and Sacred EOs on the growth inhibition of human CRC HT-
2614 29 and Caco-2 cells as well as on non-cancerous Cho-K1 cells were evaluated and the
2615 results are presented in Table 4.2 Regarding HT-29 cells, IC₅₀ values of 1447 ppm and
2616 1348 ppm were found for Frankincense and Sacred EOs respectively. Against Caco-2 cells,
2617 IC₅₀ values of 1424 ppm and 1138 ppm were found for Frankincense and sacred EOs
2618 respectively. Concerning the non-cancerous CHO-K1 cells, Frankincense EO exhibited an
2619 IC₅₀ value of 1689 ppm whereas Sacred EO showed no effect on this non-cancerous cell
2620 line at tested concentrations ranging from 21.5 to 2752 ppm. The results hence suggest that
2621 Sacred EO exhibited cancerous cell-specific cytotoxicity. In addition, no significant
2622 difference between IC₅₀ values of Frankincense and Sacred EOs tested separately were
2623 observed regarding HT-29 and Caco-2 cell lines (P > 0.05).

2624 In order to increase the chemopreventive potential of Frankincense and Sacred EOs, these
2625 EOs and insoluble glucans were used in combination to evaluate their effect on the growth
2626 of different cell lines. Table 4.2 indicates that the combination of Frankincense and Sacred
2627 EOs against HT-29 cells exhibited a combination index (CI) of 1.05 and an IC₅₀ value in
2628 total EOs of 1465 ppm, thus suggesting an additive effect. In contrast, Sacred and
2629 Frankincense EOs in combination with insoluble glucan (which showed an IC₅₀ value of
2630 108 ppm when tested separately) presented a CI values of 2.61 and 1.75 respectively.
2631 However, combined treatments revealed that IC₅₀ values of insoluble glucan (93 ppm for
2632 both EOs) and EOs (1279 and 1282 ppm respectively) were not significantly different from
2633 IC₅₀ values obtained when tested separately ($P > 0.05$). Those results suggest that EOs
2634 combined with insoluble glucan generated antagonistic effects against HT-29 cells.

2635 In case of the Caco-2 cells, combination of Frankincense and Sacred EOs exhibited a CI
2636 value of 0.82 and an IC₅₀ value in total EOs of 1032 ppm, hence suggesting an additive
2637 effect which is congruent with results observed with HT-29 cells. However, Sacred and
2638 Frankincense EOs in combination with insoluble glucan (which showed an IC₅₀ value of
2639 634 ppm when tested separately) presented CI values of 0.97 and 1.06 respectively.
2640 However, Sacred and Frankincense EOs in combination with insoluble glucan showed that
2641 IC₅₀ values of insoluble glucan (307 and 337 ppm respectively) and EOs (551 and 756 ppm
2642 respectively) are lower than IC₅₀ values obtained when tested separately. Those results
2643 suggest that EOs combined with insoluble glucan demonstrated additive effects against
2644 Caco-2 cells.

2645 Table 4.2 also indicates that the combination of Frankincense and Sacred EOs against
2646 CHO-K1 cells exhibited an IC₅₀ value in total EOs of 704 ppm, hence suggesting a

2647 synergistic effect. Moreover, Sacred and Frankincense EOs in combination with insoluble
2648 glucan revealed IC₅₀ values of insoluble glucan (611 and 796 ppm respectively) and EOs
2649 (561 and 448 ppm respectively), hence suggesting a synergistic effect since insoluble
2650 glucan and Sacred EOs assayed separately showed no IC₅₀ values against CHO-K1 at tested
2651 concentrations ranging from 21.5 to 2752 ppm. These results suggest that CHO-K1 cells
2652 revealed to be highly sensitive to a combination of insoluble glucan and EOs, possibly due
2653 to an important cytotoxic effect on non-cancerous cells and the loss of cancerous cell-
2654 specific cytotoxicity.

2655

2656 **4.6.4. Effect of essential oils on the level of apoptosis in human colorectal** 2657 **cancer cells**

2658 Since a cancerous cell-specific cytotoxicity was observed with Sacred EO tested separately,
2659 Annexin V-FITC/PI double staining was performed to determine was apoptosis is involved
2660 in the growth inhibition of cancerous cells by EOs. HT-29 cells were chosen for this test
2661 since IC₅₀ values of Sacred and Frankincense EOs were not significantly ($P > 0.05$)
2662 different against HT-29 and Caco-2 cell lines (Table 4.2). Further, the effect of
2663 Frankincense and Sacred EOs on apoptosis induction in HT-29 cells has never been
2664 investigated previously. Data shown in Fig. 4.2a demonstrated that at the tested
2665 concentrations (450, 900 and 1800 ppm), neither Sacred EO (percentage of apoptotic cells
2666 of 2.38%, 2.96% and 3.90%, respectively) nor Frankincense EO (percentage of apoptotic
2667 cells of 4.70%, 4.06% and 4.34%, respectively) were able to significantly ($P > 0.05$) induce
2668 apoptosis (Annexin V⁺ PI⁻ cells) in HT-29 cells at concentrations surrounding IC₅₀ values
2669 compared to the negative control (percentage of apoptotic cells of 2.61%). In contrast, data

2670 shown in Fig. 4.2b demonstrated that at the tested concentrations (450, 900 and 1800 ppm),
2671 Sacred EO (percentage of apoptotic cells of 18.43%, 25.02% and 24.76%, respectively)
2672 and Frankincense EO (percentage of apoptotic cells of 24.11%, 22.62% and 26.17%,
2673 respectively) were able to significantly ($P \leq 0.05$) increase the percentage of necrotic cells
2674 as compared to negative control (percentage of necrosis cells of 7.57%) which corresponds
2675 to annexin V⁺PI⁺ cells. Those results suggests that Frankincense and Sacred EOs induced
2676 cytotoxicity in HT-29 cells via necrosis rather than apoptosis, based on the analysis of
2677 externalization of phosphatidylserine on the surface of the cell membrane using Annexin
2678 V-FITC and PI double staining.

2679

2680 **4.7. Discussion**

2681 **4.7.1. Evaluation of the antiradical properties of EOs**

2682 Antiradical assays revealed that Sacred EO was more efficient than Frankincense EO to
2683 scavenge O₂⁻ anion. This fact underlies the differences between biological activities
2684 between them even if both EOs were ineffective to scavenge DPPH radical. Many studies
2685 reported the weak capacity of EOs obtained from *B. sacra* and *B. carterii* to scavenge
2686 DPPH radical, which is in congruence with our results (Ali *et al.*, 2013, Mohamed *et al.*,
2687 2015, Wang *et al.*, 2008). Indeed, Wang *et al.* (2008) found that *B. carterii* EO reached
2688 approximately 12% scavenging activity at 10000 ppm whereas Ali *et al.* (2013) found that
2689 *B. sacra* EO reached 8% scavenging activity at 1000 ppm. Moreover, Mohamed *et al.*
2690 (2015) reported that an EO from *B. carterii* scavenged 50% of DPPH radical at 15210 ppm
2691 (15.21 mg/ml), which is at very high concentration. In addition, Al-Harrasi *et al.* (2013)
2692 reported that an EO from *B. sacra* exhibited a greater capacity to scavenge O₂⁻ anion (56.40

2693 %) as compared to DPPH radical (16.30 %) at tested concentrations, similarly to results
2694 obtained in the present study. This difference in capacity to scavenge O₂⁻ anion more
2695 efficiently than DPPH radical can be explained by the lower reactivity of DPPH radical
2696 compared to reactive oxygen species (ROS) such as O₂⁻ anion (Dizhbite *et al.*, 2004).
2697 Likewise, it is generally accepted that ROS, especially the O₂⁻ anion, are the most important
2698 free radicals in many diseases including cancer (Nishikawa, 2008, Young *et al.*, 2001).
2699 Such O₂⁻ anion scavenging activity of Sacred EO may be due to its high content of terpenes
2700 as compared to Frankincense EO, such as α-pinene (Woolley *et al.*, 2012), as reported by
2701 Singh *et al.* (2009).

2702 Although, Sacred and Frankincense EOs were harvested in two geographical regions, may
2703 vary according to soil composition, climate and season (Bakkali *et al.*, 2008). Al-Saidi *et*
2704 *al.* (2012) obtained four EOs from *B. sacra* harvested in different geographical regions in
2705 Oman. Despite the fact that α-pinene was the main compound in all EOs, the authors
2706 observed important variations in their amounts ranging from 46.8 to 76 %. Moreover, their
2707 results suggested that EOs exhibited different MIC values against gram-negative bacteria
2708 which meant that the geographical location of harvesting may influence the biological
2709 activities of EOs from *Boswellia spp.*

2710

2711 **4.7.2. Effect of EOs in combination with insoluble glucan on the** 2712 **induction of NAD(P)H: QR and Mw determination**

2713 The QR assays results showed that Sacred and Frankincense EOs were able to induce QR
2714 activity at low concentrations (54 and 26 ppm respectively). An increase of the QR specific
2715 activity by *Boswellia spp.* EOs has never been reported, hence revealing a novel

2716 chemopreventive property of these EOs. Thus, mechanisms by which EOs from *Boswellia*
2717 *spp.* induce QR are worthy further discussion. The increase of gene transcription coding
2718 for phase II enzymes depends on the destabilization of Keap1/Nrf cytoplasmic complex
2719 which triggers antioxidant response element (ARE) release. This destabilization is related
2720 to an α,β -unsaturated ketone moiety of an inducer reacting with the cysteine thiol of Keap1
2721 (Dinkova-Kostova *et al.*, 2002). Unsaturated ketones (enones) are known to be present in
2722 EOs from *Boswellia spp.* Indeed, Niebler *et al.* (2016) detected traces of rotundone and
2723 mustakone, two sesquiterpene ketones (aromatic enones), in *B. sacra* EO. Moreover, EOs
2724 from *Boswellia spp.* contain keto- β -boswellic acid (K-BA) and acetyl-keto- β -boswellic
2725 acid (AK-BA) which also possess aromatic enone functional groups (Suhail *et al.*, 2011).
2726 Thus, such molecules in Frankincense and Sacred EOs might explain the increase of QR
2727 activity observed in the present study especially since other organic acids were proven to
2728 be QR inducers such as fumaric acid derivatives and coussaric acid A (Kang *et al.*, 2004,
2729 Spencer *et al.*, 1990).

2730 In order to increase the chemopreventive potential of Frankincense and Sacred EOs, they
2731 were combined with insoluble glucan of *S. boulardii*'s cell wall. In previous studies, this
2732 insoluble glucan showed the most relevant chemopreventive properties *in vitro* and *in vivo*
2733 (Fortin *et al.*, 2017a, Fortin *et al.*, 2017b). The combination of yeast cell wall extract and
2734 *Boswellia* EOs as potential chemopreventive agents has never been tested before. Our
2735 results showed that insoluble glucan enhanced QR activity induced by Frankincense EO
2736 whereas a similar was not observed for Sacred EO. The degradation of β -glucan by Sacred
2737 EO was found not to be responsible for the observed differences between EOs since the
2738 Mw of insoluble glucan was similar despite mixing with Sacred EO. Moreover, many

2739 studies demonstrated that EOs may be encapsulated in polysaccharide-based gels without
2740 negatively affecting their properties (Ahmed *et al.*, 2016, Anchisi *et al.*, 2006, Beyki *et al.*,
2741 2014), which rejects the hypothesis of glucan degradation. However, divergence of
2742 combinatory effect between EOs regarding the QR assay may be due to an increased
2743 sensitivity of Hepa 1c1c7 cells toward Sacred EO leading to a weak induction. Thus, future
2744 studies on this aspect are necessary.

2745

2746 **4.7.3. Effect of EOs in combination with insoluble glucan on the cellular** 2747 **proliferation of different cell lines**

2748 Many studies demonstrated that EOs from *Boswellia spp.* exhibit cytotoxic effects
2749 (antiproliferative activity) toward different cancerous cell lines. Suhail *et al.* (2011)
2750 demonstrated that an EO from *B. sacra* exhibited IC₅₀ values varying from 1:1680 (1264
2751 ppm) to 1:1800 (477 ppm) toward human breast cancer cells. Moreover, Ni *et al.* (2012)
2752 obtained 4 EO fractions from *B. sacra* exhibiting IC₅₀ values varying from 1:270 (3185
2753 ppm) to 1:1560 (551 ppm) toward human pancreatic cancer cells. Finally, Dozmorov *et al.*
2754 (2014) demonstrated that an EO from *B. carterii* exhibited an IC₅₀ value of 1:1250 (688
2755 ppm) toward human bladder cancer cells whereas Frank *et al.* (2009) obtained an IC₅₀ value
2756 of 1:600 (1433 ppm) against the same cell line. These investigations confirm the
2757 congruence of IC₅₀ values obtained in the present study with the scientific literature.

2758 It is largely accepted that *B. carterii* is merely a synonym for *B. sacra* (Woolley *et al.*,
2759 2012). However, Woolley *et al.* (2012) observed significant differences in the composition
2760 of EOs obtained from these plants. The authors reported that EOs from *B. sacra* differed
2761 from EOs from *B. carterii* on higher optical rotation values (+30.1 and -13.3° respectively),

2762 enantiomeric ratios values and α -pinene content (79.0 and 48.2% respectively), which
2763 confirmed that both species are distinct. Terpenes contained in EOs from *Boswellia spp.*
2764 are known to influence cancerous cell-specific cytotoxicity. Indeed, Suhail *et al.* (2011)
2765 extracted 2 EOs from *B. sacra* and observed that EOs with higher boswellic acid (BA)
2766 content exhibited higher cancerous cell-specific cytotoxicity in breast cancer cells. Hakkim
2767 *et al.* (2015) extracted an EO from *B. sacra* containing a high concentration of α -pinene
2768 (62%) and α -amyrin (21%) which exhibited a more efficient antiproliferative effect on a
2769 human breast cancer cell line as compared to a similar EO containing less α -amyrin, hence
2770 suggesting a combined effect of terpenes. Moreover, enantiomeric ratios can influence
2771 biological activities of EOs. Indeed, Rivas da Silva *et al.* (2012) demonstrated that α and
2772 β -(+)-pinenes, which are the most abundant terpenes in EOs from *Boswellia spp.*, exhibited
2773 minimal inhibitory concentration (MIC) values against *Candida albicans*, *Cryptococcus*
2774 *neoformans*, *Rhizopus oryzae* and Methicillin-resistant *Staphylococcus aureus* whereas α
2775 and β -(-)-pinenes showed no effect at tested concentrations. Those investigations might
2776 explain the divergence in biological activities between EOs observed in the present study
2777 notably regarding cancerous cells specific cytotoxicity of Sacred EO.

2778 Combined treatments demonstrated that the effect of EOs and insoluble glucan had
2779 different effects on the viability of Caco-2 and HT-29 cell lines whereas no difference (P
2780 > 0.05) was observed when tested separately. Since no study has investigated the combined
2781 effect of EOs and yeast cell wall extracts on cell viability, it may be hypothesized that
2782 combining these compounds might create different chemical species that acted differently
2783 on cell lines. Since it was confirmed that EOs did not affect the Mw of insoluble glucan,
2784 further investigation will be necessary to understand such an effect. Finally, results showed

2785 that all combinations exhibited IC₅₀ values toward CHO-K1 cells, hence suggesting that
2786 combinations affected the growth of non-cancerous cells since insoluble glucan and Sacred
2787 EO exhibited cancerous cell-specific cytotoxicity when tested separately. Such synergistic
2788 effects in CHO-K1 cells might be due to multiple mechanisms triggered by combined
2789 treatments in non-cancerous cells, which suggests important side effects of these
2790 combinations.

2791

2792 **4.7.4. Effect of EOs on the level of apoptosis in human colorectal cancer** 2793 **cells**

2794 Cytotoxic activities of EOs from *Boswellia spp.* are known to be mainly due to pro-
2795 apoptotic properties (Dozmorov *et al.*, 2014, Frank *et al.*, 2009, Ni *et al.*, 2012, Suhail *et*
2796 *al.*, 2011). However, it is interesting that no apoptotic activity was detected in the present
2797 study. Such divergence with the scientific literature may be explained by the fact that no
2798 study investigated the apoptosis activities of whole *Boswellia* EOs (which contains many
2799 bioactive compounds) on HT-29 cells. However, Liu *et al.* (2002) demonstrated that
2800 boswellic acid (BA), keto- β -boswellic acid (K-BA) and acetyl-keto- β -boswellic acid (AK-
2801 BA) induced apoptosis in a dose-dependent manner in HT-29 cells, hence suggesting that
2802 Frankincense and Sacred EOs used in the present study did not contain sufficient amounts
2803 of those specific triterpenes to induce apoptosis in HT-29 cells. Indeed, BA and its
2804 derivatives have been frequently reported to correlate with apoptotic activity depending on
2805 cell lines and concentrations used. Suhail *et al.* (2011) measured BA content of two EOs
2806 from *B. sacra* obtained at different temperatures and investigated their apoptotic activity
2807 in human breast cancer cells. Extracts obtained at 100°C exhibited the highest content in

2808 BA (30.1 mg/ml) and showed the most relevant results regarding DNA fragmentation,
2809 caspase activation and cell cycle arrest as compared to EOs obtained at 78°C (19.6 mg/ml
2810 boswellic acid). Moreover, Ni *et al.* (2012) obtained 4 EO fractions from *B. sacra* gum
2811 resins and reported that fractions (III and IV) containing high content in BA exhibited
2812 apoptosis activity in four different human pancreatic cancer cells. The authors also noticed
2813 that expression patterns in time function of pAkt, cdk4 and cyclin D1 proteins differ among
2814 those four human pancreatic cancer cell lines using cell cycle arrest assay upon treatment
2815 with fractions III and IV. Those studies revealed that induction of apoptosis by EOs from
2816 *Boswellia spp.* may vary upon terpene composition and cancerous cell lines.

2817

2818 **4.8. Conclusion**

2819 This study confirmed that EOs from *B. sacra* and *B. carterii* exhibited different
2820 chemopreventive, antiradical and antiproliferative properties toward CRC. This study also
2821 reported for the first time that Frankincense and Sacred EOs could induce QR activity
2822 which is one of the important mechanisms in cancer chemoprevention. Frankincense EO
2823 was more effective than Sacred EO in increasing QR specific activity and combining
2824 Frankincense EO with insoluble glucan obtained from cell walls of *S. boulardii* enhanced
2825 the capacity of this EO to increase QR specific activity. Moreover, Sacred EO efficiently
2826 scavenged O₂⁻ anion and demonstrated cancerous cell-specific cytotoxicity as opposed to
2827 Frankincense EO. Also, additive antiproliferative effects were observed by combining
2828 Frankincense and Sacred EOs toward human colorectal cancer cells and by combining EOs
2829 with insoluble glucans toward Caco-2 cells. It is worth noting that even Sacred EO or
2830 insoluble glucan alone expressed the cancerous cell-specific cytotoxicity effects, their

2831 combinations were found to be more efficient in affecting the viability of CHO-K1. Finally,
2832 based on the Annexin V-FITC/PI double staining assay, the induction of apoptosis in
2833 colorectal cancer cells might not be responsible for the cell growth inhibitory effect
2834 observed by both EOs.

2835

2836 **4.9. Acknowledgements**

2837 We acknowledge Young Living Essential Oils for kindly providing
2838 Frankincense and Sacred EOs. We also acknowledge Young Living Essential
2839 Oils, the Fondation Armand-Frappier and the Ministère de l'Économie, de
2840 l'Innovation et de l'Exportation du Québec (MEIE) for their financial
2841 contribution to this project. Olivier Fortin is a scholarship recipient of the
2842 Fondation Armand-Frappier.


2843

2844 **Conflict of Interest**


2845 The authors have no conflict of interest to declare.

2846

(A)



(B)



2847

2848 **Figure 4.1:** Effect of increasing concentration of Frankincense and Sacred EOs

2849 on the percentage of (A) O_2^- and (B) DPPH radical inhibition using

2850 xanthine/xanthine oxidase (X/XO) and DPPH methods respectively. Asterisk (*)

2851 indicates the concentration that scavenged 50% of radicals formed (SC_{50} value)

2852 above respective EO. Error bars represent the standard deviation of the mean of

2853 at least 3 independent experiments.

2854 **Table 4.1:** Effect of EOs used separately and in combination with insoluble glucan on the
 2855 induction of QR

Samples	Concentration (ppm)		Fold Induction	Effect
	Insoluble glucan	Total EOs		
Control	NA	NA	0.77±0.32 ^b	NA
Sacred EO	NA	54	1.39±0.11 ^c	NA
Frankincense EO	NA	27	1.50±0.15 ^c	NA
Insoluble glucan	250	NA	1.52±0.22 ^c	NA
Frankincense EO + Sacred EO †	NA	81	1.39±0.23 ^c	I
Insoluble glucan + Sacred EO	250	54	0.36±0.24 ^a	A
Insoluble glucan + Frankincense EO	250	27	1.99±0.52 ^d	AD

2856 For essential oils (EOs) tested separately, tested concentrations ranged from 3 to 1720 ppm.

2857 † 27 ppm of Frankincense and 54 ppm of Sacred EOs were combined. Concentrations for
 2858 combined treatments were chosen based on the highest induction of each compounds tested
 2859 separately. Additive effect (AD): 1.5 <Fold induction >3.0. No interactive effect (I): Fold
 2860 induction ≈ 1.5. Antagonistic effect (A): 1.5 >Fold induction. NA: Not applicable. Means
 2861 followed by different letters are significantly different ($p \leq 0.05$). Results are presented as
 2862 average ± standard deviation of at least 3 independent experiments.

2863

2864 **Table 4.2:** Effect of EOs used separately and in combination with insoluble glucan on the
 2865 cellular proliferation of different cell lines

Samples	IC ₅₀ (ppm)											
	HT-29				Caco-2				CHO-K1			
	Insoluble glucan	Total EOs	CI	CE	Insoluble glucan	Total EOs	CI	CE	Insoluble glucan ‡	Total EOs ‡	CI	CE
Sacred EO	NA	1348±107 ^B	NA	NA	NA	1138±57 ^B	NA	NA	NA	NR	NA	NA
Frankincense EO	NA	1447±86 ^B	NA	NA	NA	1424±206 ^{A,B}	NA	NA	NA	1689±22 ^B	NA	NA
Insoluble glucan	108±33 ^a	NA	NA	NA	634±242 ^{a,b,c}	NA	NA	NA	NR	NA	NA	NA
Frankincense EO + Sacred EO	NA	1465±276 ^{A,B}	1.05	AD	NA	1032±8 ^{A,B}	0.82	AD	NA	704±108 ^A	CI<1.0	S
Insoluble glucan + Sacred EO	93±6 ^a	1279±87 ^B	2.61	A	307±36 ^b	551±65 ^A	0.97	AD	611±49 ^c	561±45 ^A	CI<1.0	S
Insoluble glucan + Frankincense EO	93±6 ^a	1282±76 ^B	1.75	A	337±54 ^{a,b}	756±122 ^A	1.06	AD	796±279 ^{a,b,c}	448±157 ^A	CI<1.0	S

2866 EOs: Essential oils. IC₅₀: Concentration that inhibits 50% of the cellular growth. CI:

2867 Combination Index. CE: Combinatory effect. NR: Not reached. NA: Not applicable.

2868 Concentrations were chosen according with IC₅₀ values of each component tested

2869 separately. ‡: The highest concentration of insoluble glucan and Sacred EO were selected


2870 for combination treatments against CHO-K1 cells since no IC₅₀ values were observed when

2871 tested separately. Additive effect (AD): CI ≈ 1.0. Antagonistic effect (A): CI > 1.0.

2872 Synergistic effect (S): CI < 1.0. Results are presented as average ± standard deviation of at

2873 least 3 independent experiments. IC₅₀ values of insoluble glucan bearing different

- 2874 lowercase letters are significantly different ($p \leq 0.05$). IC_{50} values of total EOs bearing
- 2875 different uppercase letters are significantly different ($p \leq 0.05$).



2876

2877 **Figure 4.2:** Effect of increasing concentration of Frankincense and Sacred EOs
 2878 surrounding IC_{50} values on the percentage of **(A)** apoptotic cells (Annexin V^+ PI $^-$ cells) and
 2879 **(B)** necrotic cells (Annexin V^+ PI $^+$ cells) in human colorectal cancer HT-29 cells
 2880 determined by flow cytometry using Annexin V-FITC and PI double staining method after
 2881 48 h of treatment. Positive control (PC) and Negative control (NC) consisted in cells treated
 2882 with 500 μ g/ml of 5-fluorouracil and emulsifying solution respectively. Error bars

2883 represent the standard deviation of the mean of at least 3 independent experiments. Means
2884 followed by different letters are significantly different ($p \leq 0.05$).

2885

2886

2887

2888

CHAPITRE 5 – DISCUSSION ET CONCLUSION GÉNÉRALES

2889

2890 **5.1. Discussion générale**

2891 L'objectif global de cette étude était de démontrer le potentiel chimiopréventif et anticancer
2892 d'extraits de parois cellulaires de levures envers le CCR. Selon l'hypothèse de départ, les β -
2893 glucanes et les mannoprotéines contribuent significativement à l'activité biologique des parois de
2894 levures. Le premier sous-objectif fût de sélectionner une méthode d'extraction permettant d'obtenir
2895 des extraits ayant une activité biologique intéressante. La séparation des différents polymères
2896 retrouvés dans les parois cellulaires de levures est simple et peu couteuse. Par contre, obtenir un
2897 extrait d'une grande pureté (>60%) peut s'avérer couteux et difficile pour le secteur industriel
2898 (Kwiatkowski *et al.*, 2012). En ce sens, l'extraction des β -glucanes et des mannoprotéines à partir
2899 des parois cellulaires de levures est normalement réalisée via des méthodes alcalines, acides,
2900 alcooliques, enzymatiques ou à partir de différentes combinaisons de ces dernières (Ahmad *et al.*,
2901 2012). Des tests préliminaires ont montré qu'une méthode d'extraction dite crue était en mesure
2902 d'induire la QR de manière plus efficace qu'une méthode d'extraction dite fine démontrant que le
2903 respect de l'intégrité des parois cellulaires est un facteur important à prendre en compte dans
2904 l'activité biologique. Alors que la méthode d'extraction fine était composée d'un grand nombre
2905 d'étapes de purification (deux traitements alcalins, deux traitements acides, une précipitation à
2906 l'alcool, deux traitements enzymatiques et l'élimination des β -glucanes de haut poids moléculaire),
2907 la méthode d'extraction crue était composée d'un traitement alcalin et d'une précipitation à l'alcool
2908 ce qui affectait probablement moins l'architecture des parois et de ses composantes (par exemple,
2909 l'hélice triple des β -glucanes). De plus, l'obtention des extraits des parois cellulaires de levures
2910 nécessite une étape de destruction cellulaire qui peut être réalisée par autolyse, cisaillement à billes,
2911 sonication ou microfluidisation (Geciova *et al.*, 2002). Encore une fois, des tests préliminaires ont
2912 montré que l'autolyse permettait d'obtenir des extraits pouvant induire la QR plus efficacement
2913 que les méthodes de cisaillement à billes ou de microfluidisation alors que la sonication n'a pas été
2914 en mesure de briser les parois cellulaires. Mentionnons que la suspension cellulaire non diluée et
2915 obtenue après autolyse fût inoculée sur pétri pour confirmer la perte de viabilité des levures par
2916 autolyse. En ce sens, la méthode d'extraction crue précédée d'une étape d'autolyse s'est avérée
2917 plus adaptée pour une application potentielle à l'industrie en plus de démontrer une meilleure
2918 induction de la QR lors de tests préliminaires. Suite à la sélection d'une méthode d'extraction, il a
2919 été confirmé que la biomasse de levures fût collectée en phase stationnaire dans l'optique d'imiter
2920 l'état cellulaire des levures après leurs utilisations en milieu industriel (par exemple, industrie
2921 brassicole). Cette étape s'est avérée cruciale dans le but de comparer l'activité biologique des

2922 espèces de levures étudiées puisque la phase de croissance influence grandement la composition
2923 des parois cellulaires et donc leurs activités biologiques.

2924 L'extraction alcaline a résulté en l'obtention de trois extraits de parois cellulaires tel que présenté
2925 dans le chapitre 2. Il est connu que l'extrait insoluble contient majoritairement du (1→3)-β-D-
2926 glucanes à fort poids moléculaire et de la chitine alors que l'extrait soluble est connu pour être
2927 majoritairement constitué de (1→3)-β-D-glucanes avec ramifications (1→6)-β-D-glucanes.
2928 L'extrait de mannoprotéines serait quant à lui constitué de protéines couplées aux mannanes avec
2929 présence de β-glucanes en raison de l'absence d'étape de purification subséquente (Kwiatkowski
2930 *et al.*, 2012, Mantovani *et al.*, 2008). Puisque la solubilité des extraits est non seulement fonction
2931 du type de β-D-glucanes mais aussi de différents paramètres chimiques (degré de ramification et
2932 de polymérisation), il serait pertinent d'investiguer la nature chimique des β-D-glucanes obtenues.

2933 L'étude du potentiel chimiopréventif et anticancer des extraits de parois cellulaires de levures a été
2934 réalisée en modèle *in vitro* et *in vivo* dans le but de déterminer les meilleurs extraits de β-glucanes
2935 et de mannoprotéines tel que présenté aux chapitres 2 et 3. L'extrait insoluble obtenu de la paroi
2936 cellulaire de *S. boulardii* s'est avéré être le meilleur extrait de par sa capacité à inhiber efficacement
2937 les cellules humaines du cancer colorectal, à augmenter l'activité spécifique de la quinone réductase
2938 *in vitro* ainsi qu'à diminuer le nombre de foyers de cryptes aberrantes chez le rat via la diminution
2939 de l'activité de la β-glucuronidase au niveau du caecum et l'augmentation de l'activité spécifique
2940 de la QR au niveau du foie. La caractérisation des extraits a montré qu'une forte teneur en β-
2941 glucanes, des ratios élevés en β-glucanes/sucre totaux ainsi que des ratios faibles en chitine/β-
2942 glucanes ont un impact important sur la mise en valeur de leur potentiel chimiopréventif.

2943 Ces résultats confirment le caractère probiotique de *S. boulardii* (Czerucka *et al.*, 2007, Kelesidis
2944 *et al.*, 2012). De plus, il semble que les β-glucanes constituent les principales composantes
2945 polysaccharidiques responsables de l'activité biologique observée tant *in vitro* que *in vivo* ce qui
2946 est conforme à plusieurs autres études (Aguilar *et al.*, 2012, Bohn *et al.*, 1995, Chan *et al.*, 2009,
2947 Falch *et al.*, 2000, Luhm *et al.*, 2006, Rand *et al.*, 2010, Stier *et al.*, 2014). La structure des β-
2948 glucanes est connue pour avoir un impact majeur sur son activité immunomodulatoire et anticancer.
2949 En effet, l'augmentation du poids moléculaire des β-glucanes est proportionnelle avec un fort degré
2950 de polymérisation (DP) et un fort degré de ramification (Mantovani *et al.*, 2008). Sachant que les
2951 β-glucanes insolubles de *S. boulardii* présentent un fort poids moléculaire, il est possible d'avancer
2952 que les β-glucanes contenus dans cet extrait possèdent un DP supérieur à 100 en plus d'être
2953 constitués d'une structure (1→3)-β-D-glucanes avec un degré de ramification modéré en (1→6)-
2954 β-D-glucanes. Ces dernières caractéristiques chimiques ont été rapportées comme étant

2955 déterminantes dans l'activité biologique des β -glucanes (Zekovic *et al.*, 2005). De plus, des β -
2956 glucanes à fort poids moléculaire sont connus pour avoir une meilleure affinité pour le récepteur
2957 dectin-1 à la surface des macrophages permettant ainsi l'augmentation de l'infiltration des cellules
2958 T activées dans l'environnement tumoral en plus de favoriser l'activité tumoricide des cellules
2959 tueuses naturelles (Adams *et al.*, 2008). Il est possible qu'un tel mécanisme ait contribué en partie
2960 à l'excellent potentiel chimiopréventif des β -glucanes insolubles en modèle *in vivo*. De plus, il est
2961 possible que les β -glucanes aient adopté une structure en hélice triple. En ce sens, le schizophyllan,
2962 un homopolysaccharide de glucose de source fongique, possède une telle structure et démontre des
2963 capacités anticancer et antitumorales. Cependant, un fort traitement alcalin induit une structure en
2964 hélice simple et réduit l'activité biologique du schizophyllan démontrant l'importance de la
2965 structure triple des β -glucanes (Ooi *et al.*, 2000, Ren *et al.*, 2012). Zhang *et al.* (2005) ont proposé
2966 que l'effet d'une telle structure cause une conformation rigide de la chaîne des β -glucanes leur
2967 conférant de meilleures propriétés à inhiber la croissance de cellules cancéreuses (Zhang *et al.*,
2968 2005).

2969 La quantification des composantes polysaccharidiques a permis de démontrer que les extraits ne
2970 contenaient pas seulement des polysaccharides. Puisque cette étude se concentrait sur les sucres
2971 des parois cellulaires, les autres composantes n'ont pas été quantifiées. Or, les proportions relatives
2972 entre les polysaccharides et les protéines ont été plusieurs fois rapportées comme étant un facteur
2973 important dans l'explication de propriétés anticancer des parois cellulaires (Moharib *et al.*, 2014,
2974 Wang *et al.*, 1995). Les mécanismes *in vitro* et *in vivo* aboutissant à une diminution des masses
2975 tumorales et à une inhibition de croissance de cellules cancéreuses induite par des composés
2976 polysaccharidiques purifiés diffèrent de ceux des complexes polysaccharide-protéines (CPP).
2977 Typiquement, les polysaccharides purifiés tendent à agir sur l'activation des macrophages et les
2978 cellules T alors que les CPP ne tendent pas à induire des effets immunomodulateurs (Ooi *et al.*,
2979 2000). Une faible activité immunomodulatrice des CPP pourrait être en partie responsable de
2980 l'absence de potentiel chimiopréventif *in vivo* de l'extrait de mannoprotéines de *S. boulardii* en
2981 comparaison à sa forte activité biologique observée en modèle *in vitro*.

2982 L'induction de la quinone réductase par des extraits de parois cellulaires de levures est une
2983 découverte réalisée au cours de cette étude (chapitre 2 et 3). Le mécanisme d'induction de cette
2984 enzyme dépend de la présence d'un inducteur mono ou bifonctionnel. Alors que les inducteurs
2985 monofonctionnels augmentent l'activité enzymatique spécifiquement des enzymes de phase II telle
2986 que la quinone réductase, les inducteurs bifonctionnels augmentent l'activité des enzymes de
2987 phases II et de phases I (exemples, cytochromes P-450). Les inducteurs monofonctionnels pénètrent

2988 dans le milieu intracellulaire où ils génèrent un signal électrophilique stimulant la transcription de
2989 gènes codant pour les enzymes de phase II seulement. En contrepartie, les inducteurs bifonctionnels
2990 se lient aux récepteurs d'hydrocarbure aryle ce qui active ensuite les gènes codants pour les
2991 enzymes de phase I. La forte activité des récepteurs d'hydrocarbure aryle catalyse la métabolisation
2992 de l'inducteur bifonctionnel en composé analogue aux propriétés électrophiliques expliquant alors
2993 l'activation des gènes codants aussi pour les enzymes de phase II (Prochaska *et al.*, 1988b). Des
2994 études antérieures ont montré que les β -glucanes de source fongique présentaient la capacité
2995 d'inhiber les isoenzymes de phase I de la famille du cytochrome P-450 infirmant leur nature
2996 bifonctionnelle (Hashimoto *et al.*, 2002, Okamoto *et al.*, 2004). En ce sens, il est possible que les
2997 β -glucanes insolubles obtenus dans le cadre de cette présente étude consistent en un inducteur
2998 monofonctionnel. Par contre, des analyses subséquentes sont de mises pour confirmer cette
2999 hypothèse.

3000

3001 Un second point saillant de cette étude concerne la capacité des β -glucanes insolubles de *S.*
3002 *boulardii* à diminuer le nombre de cryptes aberrantes chez des rats traités au 1,2-diméthylhydrazine
3003 (DMH). Il a été déterminé que l'induction de la quinone réductase et la diminution de l'activité de
3004 la β -glucuronidase sont les mécanismes sous-jacents à la diminution du nombre de cryptes
3005 aberrantes. Ce faisant, un tel patron d'activité enzymatique aurait pu réduire le temps de transit
3006 intestinal des carcinogènes ce qui limite la carcinogénèse du CCR (Chapitre 4). Alors que le
3007 mécanisme d'induction de la quinone réductase au niveau du foie des rats traités par aux β -glucanes
3008 insolubles de *S. boulardii* mérite d'être investigué dans des études supplémentaires, la diminution
3009 de l'activité enzymatique de la β -glucuronidase dans le contenu caecal est probablement due aux
3010 propriétés prébiotiques de cet extrait. Tel que suggéré dans le chapitre 3, cet extrait aurait pu agir
3011 négativement sur la croissance des bactéries excréant cette enzyme fécale ou agir positivement sur
3012 d'autres bactéries bénéfiques (*Bifidobacteria* et *Lactobacilli*) créant un phénomène d'exclusion
3013 compétitive. D'ailleurs, il a déjà été rapporté que les (1 \rightarrow 3)- β -D-glucanes administrés oralement
3014 ne sont pas digérables chez les rats (Chan *et al.*, 2009). Or, il est connu que les β -glucanes insolubles
3015 sont majoritairement constitués de (1 \rightarrow 3)- β -D-glucanes (Mantovani *et al.*, 2008), suggérant une
3016 modification de la composition du microbiote intestinal des rats. De plus, la composition du
3017 microbiote peut aussi être modifiée par l'accumulation d'acide gras à courte chaîne (AGCC) par
3018 certaines bactéries pouvant être provoqué par la capacité des β -glucanes insolubles de *S. boulardii*
3019 à agir comme prébiotique. En effet, Louis *et al.* (2014) ont discuté du fait que les carbohydrates
3020 non-digestibles, tels que les β -glucanes, peuvent agir sur la production microbienne d'AGCC

3021 favorisant une modulation du microbiote. En ce sens, ce mécanisme est peut-être responsable de la
3022 diminution des populations microbiennes responsables de la production de la β -glucuronidase. Par
3023 contre, la nature prébiotique des β -glucanes insolubles de *S. boulardii* devra être confirmée dans
3024 des études subséquentes.

3025 Considérant l'importante littérature concernant les propriétés immunomodulatrices des β -glucanes
3026 de levures, il est possible qu'un mécanisme immunitaire soit aussi impliqué dans le potentiel
3027 chimiopréventif *in vivo* observé au chapitre 3. Par exemple, les (1 \rightarrow 3)- β -D-glucanes sont reconnus
3028 pour moduler IL-6, ce qui démontre une propriété anti-inflammatoire (Luhm *et al.*, 2006).
3029 L'implication d'un mécanisme immunitaire devra faire l'objet d'une étude à part entière d'autant
3030 plus que les β -glucanes insolubles de *S. boulardii* n'ont pas été purifiés et que plusieurs mécanismes
3031 immunitaires devront être investigués. De plus, Qi *et al.* (2011) ont extrait des β -glucanes solubles
3032 de levures et leur étude montre que ces constituants ne présentent aucun effet thérapeutique lorsque
3033 utilisé seul alors que sa contrepartie insoluble présentait une forte capacité à ralentir la croissance
3034 de tumeur cancéreuse. Les auteurs ont démontré que ces différences étaient dues à la capacité des
3035 β -glucanes insolubles à activer les cellules dendritiques et les macrophages via le récepteur dectin-
3036 1 ce qui démontre l'importance de la préparation des composantes de la paroi cellulaire de levures
3037 et de sa composition dans son activité immunomodulatoire.

3038 En plus de l'excellent potentiel chimiopréventif *in vitro* de l'extrait insoluble de *S. boulardii*, les
3039 tests antiprolifératifs effectués sur des cellules non cancéreuses (CHO-K1) ont démontré que cet
3040 extrait semble spécifique aux cellules cancéreuses (chapitre 4). En effet, l'extrait insoluble de *S.*
3041 *boulardii* a présenté des valeurs d'IC₅₀ lorsque testé envers les cellules cancéreuses HT-29 et Caco-
3042 2 alors qu'aucune valeur n'a été obtenue envers les cellules CHO-K1. Ces données suggèrent aussi
3043 une faible cytotoxicité de l'extrait insoluble de *S. boulardii* envers les cellules non-cancéreuses ce
3044 qui est fort intéressant dans un contexte de thérapeutique. Cette conclusion n'est pas inattendue
3045 considérant l'appellation *Generally Recognized as Safe* de *S. cerevisiae* et de l'idée généralement
3046 accepté que les bêta-glucanes sont connus comme étant sécuritaire (Czerucka *et al.*, 2007, Kelesidis
3047 *et al.*, 2012). En effet, le *European Food Safety Authority* a conduit une étude testant la toxicité
3048 chronique, l'allergénicité, la toxicité animale ainsi que la capacité d'absorption/métabolisation et
3049 d'extraction de différents bêta-glucanes industriels extrait de *S. cerevisiae* en modèle humain
3050 (hommes et femmes âgés entre 1 et 64 ans) et animal en utilisant de fortes doses (jusqu'à 15g/jour
3051 chez l'humain et jusqu'à 2g/kg chez le rat). Les conclusions du *European Food Safety Authority*
3052 dévoilent que le bêta-glucane de levure, considéré comme un nouvel ingrédient alimentaire, est

3053 sécuritaire à la consommation dans les conditions observées, soit à de très fortes doses ((EFSA),
3054 2011).

3055

3056 En parallèle aux études concernant les parois cellulaires de levures (chapitres 2 et 3), le potentiel
3057 chimiopréventif de deux HE considérées par plusieurs auteurs comme étant identiques a aussi été
3058 déterminé. Il a été observé au chapitre 4 que l'HE de *B. carterii* était deux fois plus efficace à
3059 induire la QR alors que l'HE de *B. sacra* possède une cytotoxicité spécifique aux cellules
3060 cancéreuses en plus de présenter de meilleure capacité antiradicalaire. Puisque que les HE sont des
3061 mélanges complexes de composés chimiques, les différences dans l'activité biologique de ces deux
3062 HE émanent de leurs compositions. En effet, les propriétés antiradicalaires et antiprolifératives des
3063 huiles de *Boswellia* ont souvent été associées aux teneurs en terpènes tels que l'acide boswellique,
3064 l' α -amyrine et l' α -pinène (Hakkim *et al.*, 2015, Singh *et al.*, 2009, Suhail *et al.*, 2011). Sachant que
3065 l'huile de *B. sacra* a été rapporté pour contenir de plus fortes teneurs en terpènes en comparaison
3066 avec l'huile de *B. carterii* (Woolley *et al.*, 2012), il est possible que cette différence soit responsable
3067 de la divergence entre les deux HE concernant les tests antiradicalaires et antiprolifératifs. Par
3068 contre, la divergence dans l'induction de la QR pourrait être due à une plus grande teneur en
3069 composés possédant une fonction cétone α/β -insaturée. Des tests supplémentaires devront être
3070 menés pour valider ces hypothèses.

3071 Les tests d'apoptose effectués sur les cellules HT-29 ont suggéré qu'aucune des deux huiles n'a été
3072 en mesure d'induire ce phénomène (chapitre 4). Considérant que les terpènes sont les composantes
3073 majoritaires des huiles de *Boswellia* qui induisent l'apoptose (Liu *et al.*, 2002, Ni *et al.*, 2012), il
3074 est possible que les cellules HT-29 soient plus résistantes aux terpènes (par exemple, acide
3075 boswellique) que d'autres lignées cellulaires puisque la présente étude est la première à investiguer
3076 l'effet apoptotique des huiles de *Boswellia* sur des cellules HT-29. Il a déjà été montré qu'à l'AK-
3077 BA induit l'apoptose dans les cellules HT-29 via une voie moléculaire passant par les protéines
3078 PI3K/AKT (Li *et al.*, 2013). Or, il se peut aussi que les teneurs en acide boswellique et ces dérivés
3079 retrouvés dans les huiles de *B. sacra* et de *B. carterii* soient inférieurs à ceux utilisées par Li *et al.*
3080 (2013). Par contre, il est aussi possible que l'effet apoptotique des huiles de *Boswellia* provienne
3081 d'un effet synergique entre ses composantes terpéniques. Des tests supplémentaires s'imposent
3082 pour répondre à cette question, notamment une quantification des teneurs en acide boswellique et
3083 ces dérivées sur les HE de *B. sacra* et *B. carterii*. Les résultats présentés au chapitre 4 suggèrent
3084 que les l'huile de *B. sacra* et de *B. carterii* démontrent un potentiel chimiopréventif différent entre
3085 eux ce qui apporte une évidence que ces derniers végétaux n'appartiennent pas à la même espèce.

3086 Considérant l'excellent potentiel chimiopréventif des parois cellulaires de *S. boulardii* dévoilé dans
3087 la présente étude (chapitre 2 et 3), ces résultats suggèrent que l'extrait insoluble de cette espèce soit
3088 en mesure d'augmenter l'activité biologique des HE. Cette combinaison peut être considérée
3089 comme innovatrice et audacieuse puisqu'à notre connaissance, aucune étude n'a investigué l'effet
3090 chimiopréventif et anticancéreux d'un extrait de paroi cellulaire de levures combinée à des HE.

3091 Il s'est avéré que la combinaison entre l'huile essentielle de *B. carterii* et les β -glucanes insolubles
3092 de *S. boulardii* a été en mesure d'augmenter davantage le niveau d'induction de la quinone
3093 réductase en comparaison au niveau d'induction de chaque composé testé seul (Chapitre 4). Par
3094 contre, l'huile de *B. sacra* n'a pas montré un tel effet. Ces résultats sont congruents avec la capacité
3095 des huiles testées séparément. En effet, l'huile Frankincense a été deux fois plus efficace que l'huile
3096 Sacrée pour l'induction de cette enzyme. De plus, l'huile Sacrée possède une plus grande capacité
3097 que l'huile Frankincense à affecter la viabilité des cellules Hepa 1c1c7 qui est basée sur la réduction
3098 du niveau d'induction de la quinone réductase à forte concentration (108 ppm) ce qui pourrait
3099 expliquer la divergence de l'effet observé dans les traitements combinés.

3100 Les tests antiprolifératifs ont démontré que l'effet des différentes combinaisons semble fonction de
3101 la lignée cellulaire utilisée puisque chacune d'elles révèle un effet combinatoire différent. Les
3102 résultats suggèrent que les différentes combinaisons démontrent une capacité accrue à affecter la
3103 viabilité des cellules non-cancéreuses (CHO-K1), ce qui laisse croire que combiner les HE de
3104 *Boswellia* avec un extrait de paroi cellulaire de levures est peu favorable quant aux tests
3105 antiprolifératifs. Il est peu probable que les huiles aient affecté la structure des β -glucanes contenus
3106 dans l'extrait insoluble de *S. boulardii* (considéré comme le composé contribuant significativement
3107 à l'activité biologique, voir Chapitre 2). En effet, Carneiro *et al.* (2013) ont démontré que
3108 l'encapsulation d'huile de lin avec de la maltodextrine en combinaison avec de la gomme
3109 d'arabique ou du concentré de protéine de lactosérum a été en mesure de réduire grandement
3110 l'oxydation de l'huile et de démontrer une grande stabilité (taux de cisaillement, densité et humidité
3111 interne) des polymères utilisés pour l'encapsulation dans le temps. De plus, plusieurs études ont
3112 démontré que des HE peuvent être encapsulées dans un gel à base de polysaccharide sans affecter
3113 la fonction biologique des huiles (Ahmed *et al.*, 2016, Anchisi *et al.*, 2006, Beyki *et al.*, 2014). Or,
3114 après avoir confirmé que les HE utilisées dans cette étude n'affectaient pas le poids moléculaire de
3115 l'extrait insoluble (Chapitre 4), ces résultats pourraient être expliqués par un changement de l'effet
3116 synergique intrinsèque des huiles. En effet, les HE sont souvent considérées comme un mélange
3117 chimique complexe au sein duquel les différentes composantes peuvent œuvrer de concert pour
3118 fournir des propriétés biologiques supérieures à celles de chaque composante testée séparément.

3119 En ce sens, il est possible que l'activité de(s) la composante(s) majoritaire(s) des huiles de
3120 *Boswellia* soit modulée par la présence de molécules minoritaires au sein de l'huile ce qui forme
3121 un équilibre dans les teneurs des différents composés chimiques (Bakkali *et al.*, 2008). Au cours de
3122 cette présente étude, il peut être juste d'avancer que la perte de la cytotoxicité spécifique aux
3123 cellules cancéreuses soit due à une déstabilisation de l'équilibre chimique de l'huile Sacrée par
3124 l'ajout de l'huile Frankincense et des β -glucanes insolubles causé par une réduction de la
3125 disponibilité des groupements fonctionnelles dû aux mélanges. Cette déstabilisation a peut-être
3126 engendré des effets antiprolifératifs différents selon la sensibilité de la lignée cellulaire utilisée.
3127 Toutefois, les traitements combinés ont permis de mettre en lumière que les β -glucanes insolubles
3128 de *S. boulardii* possèdent une cytotoxicité spécifique aux cellules cancéreuses (Chapitre 4)
3129 renforçant davantage le potentiel chimiopréventif de cet extrait.

3130

3131 **5.2. Conclusion générale**

3132 Malgré l'importante quantité d'études utilisant une approche thérapeutique envers le CCR, cette
3133 maladie reste encore un enjeu important au Canada puisqu'il représente le troisième cancer le plus
3134 répandu au pays. De plus, les traitements typiquement utilisés contre ce cancer sont souvent très
3135 invasifs en plus d'être accompagnés d'une large gamme d'effets secondaires. En ce sens, une
3136 approche préventive via des moyens naturels semble être nécessaire pour enrayer ce cancer.

3137 Dans ce contexte, ce projet de maîtrise aura permis de dévoiler un excellent potentiel
3138 chimiopréventif et anticancéreux *in vitro* et *in vivo* des parois cellulaires de levures et, dans une
3139 moindre mesure, celui des HE de *B. sacra* et de *B. carterii*. De plus, ce projet aura permis d'élucider
3140 un nouveau mécanisme chimiopréventif (induction de la quinone réductase) des parois cellulaires
3141 de levures en plus d'amener des preuves de l'importance cruciale des β -glucanes dans leurs activités
3142 biologiques. De surcroît, ce projet aura permis de mettre en évidence la non-toxicité (toxicité
3143 spécifique aux cellules cancéreuses) de l'extrait insoluble de *S. boulardii* qui s'est d'ailleurs
3144 démarqué des autres extraits par son excellent potentiel chimiopréventif. Cette étude a aussi permis
3145 de démontrer un effet additif entre les β -glucanes insolubles de *S. boulardii* et l'huile de *B. carterii*
3146 à ce qui attrait à l'induction de la quinone réductase en modèle *in vitro*. Les β -glucanes insolubles
3147 extraient de la paroi cellulaire de *S. boulardii*, souche de levure considérée comme probiotique et
3148 à fort potentiel industriel, pourraient être utilisés dans la fabrication d'un produit nutraceutique ou
3149 comme ingrédient fonctionnel dans une optique de prévention du CCR humain ou même sous la

3150 forme de fibre naturelle. Pour faire suite à cette étude, plusieurs perspectives de recherche sont
3151 envisageables. En premier lieu, la détermination du potentiel chimiopréventif d'un composé est
3152 basée sur une accumulation de preuves obtenues par plusieurs tests d'activités biologiques de
3153 différentes natures. En ce sens, il serait intéressant de déterminer si les β -glucanes insolubles de *S.*
3154 *boulardii* sont en mesure : d'induire l'apoptose, de moduler négativement le gène pro-
3155 inflammatoire *cox-2* ainsi que d'investiguer son potentiel immunomodulateur. En second lieu, il
3156 serait possible d'approfondir la connaissance de la structure chimique exacte des β -glucanes
3157 contenus dans l'extrait insoluble de *S. boulardii*, notamment en ce qui a trait à la nature des liaisons
3158 glycosidiques ((1 \rightarrow 3) et (1 \rightarrow 6)- β -D-glucanes), le degré de polymérisation et de ramification ainsi
3159 que la nature des impuretés (lipides, protéines, etc)). Ces informations seront utiles pour affiner la
3160 caractérisation de cet extrait et ainsi mieux comprendre les relations structures-fonctions.
3161 D'ailleurs, dans l'optique d'établir une corrélation solide entre les teneurs absolues et relatives en
3162 β -glucanes et l'activité biologique, il serait intéressant de comparer le potentiel chimiopréventif *in*
3163 *vitro* des parois cellulaires de *S. boulardii* en phase exponentielle avec ceux de la présente étude
3164 collectée en phase stationnaire. Finalement, il serait intéressant d'améliorer le potentiel
3165 chimiopréventif via une modification chimique des β -glucanes purifiés de l'extrait insoluble de *S.*
3166 *boulardii*. Pour ce faire, différentes approches sont connues dans la littérature telles que la
3167 sulphatation, la méthylation, la carboxyméthylation, l'hydroxylation, l'aminoéthylation et la
3168 formylméthylation (Mantovani *et al.*, 2008, Ooi *et al.*, 2000).

- 3170 (EFSA) EFSA (2011) Scientific Opinion on the safety of 'yeast beta-glucans' as a Novel Food
3171 ingredient. *EFSA Journal* 9(5):2137-2159.
- 3172 Adams EL, Rice PJ, Graves B, Ensley HE, Yu H, Brown GD, Gordon S, Monteiro MA, Papp-Szabo E,
3173 Lowman DW, Power TD, Wempe MF & Williams DL (2008) Differential high-affinity
3174 interaction of dectin-1 with natural or synthetic glucans is dependent upon primary
3175 structure and is influenced by polymer chain length and side-chain branching. *J.*
3176 *Pharmacol. Exp. Ther.* 325(1):115-123.
- 3177 Aggarwal B, Prasad S, Sung B, Krishnan S & Guha S (2013) Prevention and Treatment of
3178 Colorectal Cancer by Natural Agents from Mother Nature. *Current Colorectal Cancer*
3179 *Reports* 9(1):37-56.
- 3180 Aguilar-Uscanga B & Francois JM (2003) A study of the yeast cell wall composition and structure
3181 in response to growth conditions and mode of cultivation. *Let. Appl. Microbiol.*
3182 37(3):268-274.
- 3183 Aguilar B, Solís J, Viveros JM, López Z & Knauth P (2012) Characterization of Cell Wall Extracts
3184 from *Saccharomyces cerevisiae* with Immunological Activity. *Food Biotechnol.* 26(4):326-
3185 338.
- 3186 Ahmad A, Anjum FM, Zahoor T, Nawaz H & Dilshad SM (2012) Beta glucan: a valuable functional
3187 ingredient in foods. *Crit. Rev. Food Sci. Nutr.* 52(3):201-212.
- 3188 Ahmed TA & Aljaeid BM (2016) Preparation, characterization, and potential application of
3189 chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug
3190 delivery. *Drug Des Devel Ther* 10:483-507.
- 3191 Akramiene D, Kondrotas A, Didziapetriene J & Kevelaitis E (2007) Effects of beta-glucans on the
3192 immune system. *Medicina (Kaunas)* 43(8):597-606.
- 3193 Al-Harrasi A, Ali L, Ceniviva E, Al-Rawahi A, Hussain J, Hussain H, Rehman NU, Abbas G & Al-
3194 Harrasi R (2013) Antiglycation and antioxidant activities and HPTLC analysis of *Boswellia*
3195 *sacra* Oleogum resin: the sacred frankincense. *Tropical Journal of Pharmaceutical*
3196 *Research* 12(4):597-602.
- 3197 Al-Saidi S, Rameshkumar KB, Hisham A, Sivakumar N & Al-Kindy S (2012) Composition and
3198 antibacterial activity of the essential oils of four commercial grades of Omani luban, the
3199 oleo-gum resin of *Boswellia sacra* FLUECK. *Chem. Biodivers.* 9(3):615-624.
- 3200 Ali SK, Hamed AR, Soltan MM, Hegazy UM, Elgorashi EE, El-Garf IA & Hussein AA (2013) In-vitro
3201 evaluation of selected Egyptian traditional herbal medicines for treatment of alzheimer
3202 disease. *BMC Complementary and Alternative Medicine* 13(1):1-10.
- 3203 Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG,
3204 Shoemaker RH & Boyd MR (1988) Feasibility of drug screening with panels of human
3205 tumor cell lines using a microculture tetrazolium assay. *Cancer Res.* 48(3):589-601.
- 3206 Anchisi C, Meloni MC & Maccioni AM (2006) Chitosan beads loaded with essential oils in
3207 cosmetic formulations. *J Cosmet Sci* 57(3):205-214.
- 3208 Anderson P, McNeil K & Watson K (1986) High-efficiency carbohydrate fermentation to ethanol
3209 at temperatures above 40 C by *Kluyveromyces marxianus* var. *marxianus* isolated from
3210 sugar mills. *Appl. Environ. Microbiol.* 51(6):1314-1320.
- 3211 Austin PR (1977) *Chitin solution*. Attribué.

3212 Backhaus K, Heilmann CJ, Sorgo AG, Purschke G, de Koster CG, Klis FM & Heinisch JJ (2010) A
3213 systematic study of the cell wall composition of *Kluyveromyces lactis*. *Yeast* 27(8):647-
3214 660.

3215 Bakkali F, Averbeck S, Averbeck D & Idaomar M (2008) Biological effects of essential oils—a
3216 review. *Food Chem. Toxicol.* 46(2):446-475.

3217 Baldwin C, Millette M, Oth D, Ruiz MT, Luquet FM & Lacroix M (2010) Probiotic *Lactobacillus*
3218 *acidophilus* and *L. casei* mix sensitize colorectal tumoral cells to 5-fluorouracil-induced
3219 apoptosis. *Nutr. Cancer* 62(3):371-378.

3220 Baran J, Allendorf DJ, Hong F & Ross GD (2007) Oral beta-glucan adjuvant therapy converts
3221 nonprotective Th2 response to protective Th1 cell-mediated immune response in
3222 mammary tumor-bearing mice. *Folia Histochem Cytobiol* 45(2):107-114.

3223 Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E,
3224 Clarke AR, Sansom OJ & Clevers H (2009) Crypt stem cells as the cells-of-origin of
3225 intestinal cancer. *Nature* 457(7229):608-611.

3226 Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. A critical
3227 review. *Clin. Exp. Immunol.* 28(1):1-18.

3228 Beyki M, Zhavesh S, Khalili ST, Rahmani-Cherati T, Abollahi A, Bayat M, Tabatabaei M &
3229 Mohsenifar A (2014) Encapsulation of *Mentha piperita* essential oils in chitosan–
3230 cinnamic acid nanogel with enhanced antimicrobial activity against *Aspergillus flavus*.
3231 *Industrial Crops and Products* 54:310-319.

3232 Bhattacharjee B & Chatterjee J (2013) Identification of proapoptotic, anti-inflammatory, anti-
3233 proliferative, anti-invasive and anti-angiogenic targets of essential oils in cardamom by
3234 dual reverse virtual screening and binding pose analysis. *Asian Pac J Cancer Prev*
3235 14(6):3735-3742.

3236 Bird RP (1995) Role of aberrant crypt foci in understanding the pathogenesis of colon cancer.
3237 *Cancer Lett.* 93(1):55-71.

3238 Bland EJ, Keshavarz T & Bucke C (2004) The influence of small oligosaccharides on the immune
3239 system. *Carbohydr. Res.* 339(10):1673-1678.

3240 Blois MS (1958) Antioxidant Determinations by the Use of a Stable Free Radical. *Nature*
3241 181(4617):1199-1200.

3242 Bobek P & Galbavy S (2001) Effect of pleuran (beta-glucan from *Pleurotus ostreatus*) on the
3243 antioxidant status of the organism and on dimethylhydrazine-induced precancerous
3244 lesions in rat colon. *Br. J. Biomed. Sci.* 58(3):164-168.

3245 Bohn JA & BeMiller JN (1995) (1→3)-β-d-Glucans as biological response modifiers: a review of
3246 structure-functional activity relationships. *Carbohydr. Polym.* 28(1):3-14.

3247 Boyd MR (1997) The NCI In Vitro Anticancer Drug Discovery Screen. *Anticancer Drug*
3248 *Development Guide: Preclinical Screening, Clinical Trials, and Approval*, Teicher BA (Édit.)
3249 Humana Press, Totowa, NJ10.1007/978-1-4615-8152-9_2. p 23-42.

3250 Burt S (2004) Essential oils: their antibacterial properties and potential applications in foods—a
3251 review. *Int. J. Food Microbiol.* 94(3):223-253.

3252 Caillet S, Lorenzo G, Côté J, Doyon G, Sylvain JF & Lacroix M (2012) Cancer chemopreventive
3253 effect of fractions from cranberry products. *Food Res. Int.* 45(1):320-330.

3254 Canadian Cancer Society (2017a) *How radiation therapy works.*,
3255 <http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/radiation-therapy/how-radiation-therapy-works/?region=qc> (Consulté le March 2017)

3256 Canadian Cancer Society (2017b) *Treatments for colorectal cancer.*,
3257 <http://www.cancer.ca/en/cancer-information/cancer-type/colorectal/treatment/?region=qc> (Consulté le March 2017)

3260 Canadian Cancer Society's Advisory & Committee on Cancer Statistics, Canadian Cancer Statistics
3261 2015. (2014) Canadian Cancer Statistics 2014. Toronto, ON), p 132.

3262 Canadian Digestive Health Foundation (2016) *Colon Cancer Overview.*,
3263 <http://www.cdhf.ca/en/disorders/details/id/7> (Consulté le April 20th 2016)

3264 Carneiro HCF, Tonon RV, Grosso CRF & Hubinger MD (2013) Encapsulation efficiency and
3265 oxidative stability of flaxseed oil microencapsulated by spray drying using different
3266 combinations of wall materials. *J. Food Eng.* 115(4):443-451.

3267 Chakrabandhu Y, Pochat-Bohatier C, Vachoud L, Bouyer D & Desfours JP (2008) Control of
3268 elaboration process to form chitin-based membrane for biomedical applications.
3269 *Desalination* 233(1-3):120-128.

3270 Chan GC, Chan WK & Sze DM (2009) The effects of beta-glucan on human immune and cancer
3271 cells. *J Hematol Oncol* 2:25.

3272 Chang PV, Hao L, Offermanns S & Medzhitov R (2014) The microbial metabolite butyrate
3273 regulates intestinal macrophage function via histone deacetylase inhibition. *Proceedings*
3274 *of the National Academy of Sciences* 111(6):2247-2252.

3275 Chen W, Liu Y, Li M, Mao J, Zhang L, Huang R, Jin X & Ye L (2015) Anti-tumor effect of alpha-
3276 pinene on human hepatoma cell lines through inducing G2/M cell cycle arrest. *J*
3277 *Pharmacol Sci* 127(3):332-338.

3278 Chen Y, Zhou C, Ge Z, Liu Y, Liu Y, Feng W, Li S, Chen G & Wei T (2013) Composition and potential
3279 anticancer activities of essential oils obtained from myrrh and frankincense. *Oncol Lett*
3280 6(4):1140-1146.

3281 Colorectal Cancer Association of Canada (2017) *Treatments options.*, [http://www.colorectal-](http://www.colorectal-cancer.ca/en/treating-cancer/treatment-cancer/)
3282 [cancer.ca/en/treating-cancer/treatment-cancer/](http://www.colorectal-cancer.ca/en/treating-cancer/treatment-cancer/) (Consulté le March 2017)

3283 Cuendet M, Oteham CP, Moon RC & Pezzuto JM (2006) Quinone reductase induction as a
3284 biomarker for cancer chemoprevention. *J. Nat. Prod.* 69(3):460-463.

3285 Czadek P (2016) Chemoprevention of colorectal cancer. *Polish Annals of Medicine* 23(1):75-79.

3286 Czerucka D, Piche T & Rampal P (2007) Review article: yeast as probiotics -- *Saccharomyces*
3287 *bouardii*. *Aliment Pharmacol Ther* 26(6):767-778.

3288 Dabek M, McCrae SI, Stevens VJ, Duncan SH & Louis P (2008) Distribution of beta-glucosidase
3289 and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic
3290 bacteria. *FEMS Microbiol. Ecol.* 66(3):487-495.

3291 Dadrass M, Nejati V, Tukmechi A & Hobbenaghi R (2014) The Protective Effect of Cell Wall and
3292 Cytoplasmic Fraction of Selenium Enriched Yeast on 1, 2-Dimethylhydrazine-induced
3293 Damage in Liver. *Research in Molecular Medicine* 2(1):39-45.

3294 de Moreno de LeBlanc A & Perdigon G (2005) Reduction of beta-glucuronidase and
3295 nitroreductase activity by yoghurt in a murine colon cancer model. *Biocell* 29(1):15-24.

3296 Denizot F & Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to
3297 the tetrazolium dye procedure giving improved sensitivity and reliability. *J. Immunol.*
3298 *Methods* 89(2):271-277.

3299 Desrouillères K, Millette M, Vu KD, Touja R & Lacroix M (2015) Cancer preventive effects of a
3300 specific probiotic fermented milk containing *Lactobacillus acidophilus* CL1285, *L. casei*
3301 *LBC80R* and *L. rhamnosus* CLR2 on male F344 rats treated with 1,2-dimethylhydrazine.
3302 *Journal of Functional Foods* 17:816-827.

3303 Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M &
3304 Talalay P (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors
3305 regulating induction of phase 2 enzymes that protect against carcinogens and oxidants.
3306 *Proc Natl Acad Sci U S A* 99(18):11908-11913.

3307 Dizhbite T, Telysheva G, Jurkjaņe V & Viesturs U (2004) Characterization of the radical
3308 scavenging activity of lignins—natural antioxidants. *Bioresour. Technol.* 95(3):309-317.
3309 dos Santos Mathias TR, de Mello PPM & ervulo EFC (2014) Solid wastes in brewing process: A
3310 review. *Journal of Brewing and Distilling* 5(1):1-9.
3311 Dozmorov MG, Yang Q, Wu W, Wren J, Suhail MM, Woolley CL, Young DG, Fung KM & Lin HK
3312 (2014) Differential effects of selective frankincense (Ru Xiang) essential oil versus non-
3313 selective sandalwood (Tan Xiang) essential oil on cultured bladder cancer cells: a
3314 microarray and bioinformatics study. *Chin Med* 9:18.
3315 Dubois M, Gilles KA, Hamilton JK, Rebers PA & Smith F (1956) Colorimetric Method for
3316 Determination of Sugars and Related Substances. *Anal. Chem.* 28(3):350-356.
3317 Fahey JW, Dinkova-Kostova AT, Stephenson KK & Talalay P (2004) The "Prochaska" microtiter
3318 plate bioassay for inducers of NQO1. *Methods Enzymol.* 382:243-258.
3319 Falcão Moreira R, Fernandes PA & Moradas-Ferreira P (1998) Kluyveromyces marxianus
3320 flocculence and growth at high temperature is dependent on the presence of the
3321 protein p37. *Microbiology* 144(3):681-688.
3322 Falch BH, Espevik T, Ryan L & Stokke BT (2000) The cytokine stimulating activity of (1-->3)-beta-
3323 D-glucans is dependent on the triple helix conformation. *Carbohydr. Res.* 329(3):587-
3324 596.
3325 Fiala ES (1977) Investigations into the metabolism and mode of action of the colon carcinogens
3326 1,2-dimethylhydrazine and azoxymethane. *Cancer* 40(5 Suppl):2436-2445.
3327 Fonseca GG, Heinzle E, Wittmann C & Gombert AK (2008) The yeast Kluyveromyces marxianus
3328 and its biotechnological potential. *Appl. Microbiol. Biotechnol.* 79(3):339-354.
3329 Fontaine T, Simenel C, Dubreucq G, Adam O, Delepierre M, Lemoine J, Vorgias CE, Diaquin M &
3330 Latge JP (2000) Molecular organization of the alkali-insoluble fraction of Aspergillus
3331 fumigatus cell wall. *J. Biol. Chem.* 275(36):27594-27607.
3332 Fortin O, Aguilar-Uscanga B, Vu KD, Salmieri S & Lacroix M (2017a) Cancer chemopreventive,
3333 antiproliferative and superoxide anion scavenging properties of Kluyveromyces
3334 marxianus and Saccharomyces cerevisiae var. boulardii cell wall components. *Nutr.*
3335 *Cancer* (submitted).
3336 Fortin O, Aguilar-Uscanga B, Vu KD, Salmieri S & Lacroix M (2017b) Effect of β -glucan and
3337 mannoprotein extracted from cell wall of Saccharomyces boulardii on colon cancer
3338 prevention in male F344 rats treated with 1,2-dimethylhydrazine. *Nutr. Cancer*
3339 (submitted).
3340 Frank MB, Yang Q, Osban J, Azzarello JT, Saban MR, Saban R, Ashley RA, Welter JC, Fung KM &
3341 Lin HK (2009) Frankincense oil derived from Boswellia carteri induces tumor cell specific
3342 cytotoxicity. *BMC Complement Altern Med* 9:6.
3343 Fung K, Suhail M, McClendon B, Woolley C, Young D & Lin H (2013) Management of basal cell
3344 carcinoma of the skin using frankincense (Boswellia sacra) essential oil: a case report.
3345 *OA Alternative Medicine* 1(2):1-5.
3346 Fung KY, Cosgrove L, Lockett T, Head R & Topping DL (2012) A review of the potential
3347 mechanisms for the lowering of colorectal oncogenesis by butyrate. *Br J Nutr*
3348 108(5):820-831.
3349 Gautam N, Mantha AK & Mittal S (2014) Essential oils and their constituents as anticancer
3350 agents: a mechanistic view. *Biomed Res Int* 2014:154106.
3351 Geciova J, Bury D & Jelen P (2002) Methods for disruption of microbial cells for potential use in
3352 the dairy industry—a review. *Int. Dairy J.* 12(6):541-553.
3353 Gerhäuser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauff J, Liu G-Y, Sitthimonchai S &
3354 Frank N (2003) Mechanism-based in vitro screening of potential cancer

3355 chemopreventive agents. *Mutation Research/Fundamental and Molecular Mechanisms*
3356 *of Mutagenesis* 523-524:163-172.

3357 Giavasis I (2014) Bioactive fungal polysaccharides as potential functional ingredients in food and
3358 nutraceuticals. *Curr. Opin. Biotechnol.* 26:162-173.

3359 Gill CI & Rowland IR (2002) Diet and cancer: assessing the risk. *Br J Nutr* 88 Suppl 1:S73-87.

3360 Hagggar FA & Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival,
3361 and risk factors. *Clin Colon Rectal Surg* 22(4):191-197.

3362 Hakama M (1998) Chemoprevention of cancer. *Acta Oncol* 37(3):227-230.

3363 Hakkim FL, Al-Buloshi M & Al-Sabahi J (2015) Frankincense derived heavy terpene cocktail
3364 boosting breast cancer cell (MDA-MB-231) death in vitro. *Asian Pacific Journal of*
3365 *Tropical Biomedicine* 5(10):824-828.

3366 Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144(5):646-674.

3367 Hashimoto T, Nonaka Y, Minato K, Kawakami S, Mizuno M, Fukuda I, Kanazawa K & Ashida H
3368 (2002) Suppressive effect of polysaccharides from the edible and medicinal mushrooms,
3369 *Lentinus edodes* and *Agaricus blazei*, on the expression of cytochrome P450s in mice.
3370 *Biosci Biotechnol Biochem* 66(7):1610-1614.

3371 Hossain F, Follett P, Dang Vu K, Harich M, Salmieri S & Lacroix M (2016) Evidence for synergistic
3372 activity of plant-derived essential oils against fungal pathogens of food. *Food Microbiol.*
3373 53, Part B:24-30.

3374 Hudson LE, Fasken MB, McDermott CD, McBride SM, Kuiper EG, Guiliano DB, Corbett AH & Lamb
3375 TJ (2014) Functional heterologous protein expression by genetically engineered
3376 probiotic yeast *Saccharomyces boulardii*. *PLoS One* 9(11):e112660.

3377 Jaehrig SC, Rohn S, Kroh LW, Fleischer LG & Kurz T (2007) In vitro potential antioxidant activity of
3378 (1→3),(1→6)-beta-D-glucan and protein fractions from *Saccharomyces cerevisiae* cell
3379 walls. *J. Agric. Food Chem.* 55(12):4710-4716.

3380 Jaehrig SC, Rohn S, Kroh LW, Wildenauer FX, Lisdat F, Fleischer L-G & Kurz T (2008) Antioxidative
3381 activity of (1→3), (1→6)-β-d-glucan from *Saccharomyces cerevisiae* grown on different
3382 media. *LWT - Food Science and Technology* 41(5):868-877.

3383 Jayakumar S, Madankumar A, Asokkumar S, Raghunandhakumar S, Gokula dhas K, Kamaraj S,
3384 Divya MG & Devaki T (2012) Potential preventive effect of carvacrol against
3385 diethylnitrosamine-induced hepatocellular carcinoma in rats. *Mol. Cell. Biochem.* 360(1-
3386 2):51-60.

3387 Kang YH & Pezzuto JM (2004) Induction of quinone reductase as a primary screen for natural
3388 product anticarcinogens. *Methods Enzymol.* 382:380-414.

3389 Karoui M, Tresallet C, Brouquet A, Radvanyi H & Penna C (2007) [Colorectal carcinogenesis. 2.
3390 Underlying epigenetic and genetic alterations and molecular classification of colorectal
3391 cancers]. *J Chir (Paris)* 144(2):97-104.

3392 Kedare SB & Singh RP (2011) Genesis and development of DPPH method of antioxidant assay. *J*
3393 *Food Sci Technol* 48(4):412-422.

3394 Kelesidis T & Pothoulakis C (2012) Efficacy and safety of the probiotic *Saccharomyces boulardii*
3395 for the prevention and therapy of gastrointestinal disorders. *Therap Adv Gastroenterol*
3396 5(2):111-125.

3397 Kelly GE (2001) *Process for glucan preparation and therapeutic uses of glucan*. Brevet 6,242,594
3398 (United States) Attribué le June 5 2001.

3399 Ketudat Cairns JR & Esen A (2010) beta-Glucosidases. *Cell. Mol. Life Sci.* 67(20):3389-3405.

3400 Kim DH & Jin YH (2001) Intestinal bacterial beta-glucuronidase activity of patients with colon
3401 cancer. *Arch Pharm Res* 24(6):564-567.

3402 Kim MJ, Hong SY, Kim SK, Cheong C, Park HJ, Chun HK, Jang KH, Yoon BD, Kim CH & Kang SA
3403 (2009) beta-Glucan enhanced apoptosis in human colon cancer cells SNU-C4. *Nutr Res*
3404 *Pract* 3(3):180-184.

3405 Klis FM, Boorsma A & De Groot PW (2006) Cell wall construction in *Saccharomyces cerevisiae*.
3406 *Yeast* 23(3):185-202.

3407 Klis FM, Mol P, Hellingwerf K & Brul S (2002) Dynamics of cell wall structure in *Saccharomyces*
3408 *cerevisiae*. *FEMS Microbiol. Rev.* 26(3):239-256.

3409 Kobayashi H, Yoshida R, Kanada Y, Fukuda Y, Yagyu T, Inagaki K, Kondo T, Kurita N, Suzuki M,
3410 Kanayama N & Terao T (2005) Suppressing effects of daily oral supplementation of beta-
3411 glucan extracted from *Agaricus blazei* Murill on spontaneous and peritoneal
3412 disseminated metastasis in mouse model. *J. Cancer Res. Clin. Oncol.* 131(8):527-538.

3413 Krizkova L, Zitnanova I, Mislovicova D, Masarova J, Sasinkova V, Durackova Z & Krajcovic J (2006)
3414 Antioxidant and antimutagenic activity of mannan neoglycoconjugates: mannan-human
3415 serum albumin and mannan-penicillin G acylase. *Mutat. Res.* 606(1-2):72-79.

3416 Kusuhara M, Urakami K, Masuda Y, Zangiaccomi V, Ishii H, Tai S, Maruyama K & Yamaguchi K
3417 (2012) Fragrant environment with alpha-pinene decreases tumor growth in mice.
3418 *Biomed Res* 33(1):57-61.

3419 Kwiatkowski S & Kwiatkowski SE (2012) Yeast (*Saccharomyces cerevisiae*) Glucan
3420 Polysaccharides – Occurrence, Separation and Application in Food, Feed and Health
3421 Industries.

3422 Lahouar L, Pochart P, Salem HB, El Felah M, Mokni M, Magne F, Mangin I, Suau A, Pereira E,
3423 Hammami M & Achour L (2012) Effect of dietary fibre of barley variety 'Rihane' on
3424 azoxymethane-induced aberrant crypt foci development and on colonic microbiota
3425 diversity in rats. *Br J Nutr* 108(11):2034-2042.

3426 Laroche C & Michaud P (2007) New developments and prospective applications for beta (1,3)
3427 glucans. *Recent Pat Biotechnol* 1(1):59-73.

3428 Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC & Yan J (2010) Orally administered particulate
3429 beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell
3430 responses in cancer. *Clin. Cancer. Res.* 16(21):5153-5164.

3431 Li J, Zhu L, Zheng ZY, Zhan XB, Lin CC, Zong Y & Li WJ (2013) A new effective process for
3432 production of curdolan oligosaccharides based on alkali-neutralization treatment and acid
3433 hydrolysis of curdolan particles in water suspension. *Appl. Microbiol. Biotechnol.*
3434 97(19):8495-8503.

3435 Liu H-Z, Wang Q & He Y (2011) Immunoactivities and antineoplastic activities of *Saccharomyces*
3436 *cerevisiae* mannoprotein. *Carbohydr. Polym.* 83(4):1690-1695.

3437 Liu J-J, Nilsson Å, Oredsson S, Badmaev V, Zhao W-Z & Duan R-D (2002) Boswellic acids trigger
3438 apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas
3439 ligand interaction in colon cancer HT-29 cells. *Carcinogenesis* 23(12):2087-2093.

3440 Louis P, Hold GL & Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal
3441 cancer. *Nat. Rev. Microbiol.* 12(10):661-672.

3442 Luhm J, Langenkamp U, Hensel J, Frohn C, Brand JM, Hennig H, Rink L, Koritke P, Wittkopf N,
3443 Williams DL & Mueller A (2006) Beta-(1-->3)-D-glucan modulates DNA binding of nuclear
3444 factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1
3445 receptor antagonist ratio. *BMC Immunol.* 7:5.

3446 Machová E & Bystrický S (2013) Antioxidant capacities of mannans and glucans are related to
3447 their susceptibility of free radical degradation. *Int. J. Biol. Macromol.* 61:308-311.

3448 Mantovani MS, Bellini MF, Angeli JP, Oliveira RJ, Silva AF & Ribeiro LR (2008) beta-Glucans in
3449 promoting health: prevention against mutation and cancer. *Mutat. Res.* 658(3):154-161.

3450 Manzano A & Perez-Segura P (2012) Colorectal cancer chemoprevention: is this the future of
3451 colorectal cancer prevention? *TheScientificWorldJournal* 2012:327341.

3452 Margaritis A & Bajpai P (1983) Effect of Sugar Concentration in Jerusalem Artichoke Extract on
3453 *Kluyveromyces marxianus* Growth and Ethanol Production. *Appl. Environ. Microbiol.*
3454 45(2):723-725.

3455 Matsuzawa A & Ichijo H (2001) Molecular mechanisms of the decision between life and death:
3456 regulation of apoptosis by apoptosis signal-regulating kinase 1. *J. Biochem.* 130(1):1-8.

3457 McBain AJ & Macfarlane GT (1998) Ecological and physiological studies on large intestinal
3458 bacteria in relation to production of hydrolytic and reductive enzymes involved in
3459 formation of genotoxic metabolites. *J. Med. Microbiol.* 47(5):407-416.

3460 Megdiche-Ksouri W, Trabelsi N, Mkadmini K, Bourgou S, Noumi A, Snoussi M, Barbria R,
3461 Tebourbi O & Ksouri R (2015) Artemisia campestris phenolic compounds have
3462 antioxidant and antimicrobial activity. *Industrial Crops and Products* 63:104-113.

3463 Misico RI, Song LL, Veleiro AS, Cirigliano AM, Tettamanzi MC, Burton G, Bonetto GM, Nicotra VE,
3464 Silva GL, Gil RR, Oberti JC, Kinghorn AD & Pezzuto JM (2002) Induction of quinone
3465 reductase by withanolides. *J. Nat. Prod.* 65(5):677-680.

3466 Mitterdorfer G, Kneifel W & Viernstein H (2001) Utilization of prebiotic carbohydrates by yeasts
3467 of therapeutic relevance. *Lett. Appl. Microbiol.* 33(4):251-255.

3468 Mohamed AA, Ali SI, Kabiell HF, Hegazy AK, Kord MA & EL-Baz FK (2015) Assessment of
3469 antioxidant and antimicrobial activities of essential oil and extracts of *Boswellia carteri*
3470 resin. *International Journal of Pharmacognosy and Phytochemical Research* 7:502-509.

3471 Moharib SA, El Maksoud NA, Ragab HM & Shehata M (2014) Anticancer activities of mushroom
3472 polysaccharides on chemically-induced colorectal cancer in rats. *Journal of Applied*
3473 *Pharmaceutical Science* 4(7):54.

3474 Mork AC, Helmke RJ, Martinez JR, Michalek MT, Patchen ML & Zhang GH (1998) Effects of
3475 particulate and soluble (1-3)-beta-glucans on Ca²⁺ influx in NR8383 alveolar
3476 macrophages. *Immunopharmacology* 40(1):77-89.

3477 Mroczynska M, Galecka M, Szachta P, Kamoda D, Libudzisz Z & Roszak D (2013) Beta-
3478 glucuronidase and Beta-glucosidase activity in stool specimens of children with
3479 inflammatory bowel disease. *Pol J Microbiol* 62(3):319-325.

3480 Nakamura J, Kubota Y, Miyaoka M, Saitoh T, Mizuno F & Benno Y (2002) Comparison of four
3481 microbial enzymes in Clostridia and Bacteroides isolated from human feces. *Microbiol.*
3482 *Immunol.* 46(7):487-490.

3483 National Library of Medicine (2003) *NCBI-Bookshelf, Holland-Frei Cancer Medicine 6th edition,*
3484 *Combinaison Chemotherapy* Bethesda MD),
3485 <http://www.ncbi.nlm.nih.gov/books/NBK13955/>

3486 Nguyen TH, Fleet GH & Rogers PL (1998) Composition of the cell walls of several yeast species.
3487 *Appl. Microbiol. Biotechnol.* 50(2):206-212.

3488 Ni X, Suhail MM, Yang Q, Cao A, Fung KM, Postier RG, Woolley C, Young G, Zhang J & Lin HK
3489 (2012) Frankincense essential oil prepared from hydrodistillation of *Boswellia sacra* gum
3490 resins induces human pancreatic cancer cell death in cultures and in a xenograft murine
3491 model. *BMC Complement Altern Med* 12:253.

3492 Niebler J, Zhuravlova K, Minceva M & Buettner A (2016) Fragrant Sesquiterpene Ketones as
3493 Trace Constituents in Frankincense Volatile Oil of *Boswellia sacra*. *J. Nat. Prod.*
3494 79(4):1160-1164.

3495 Nishikawa M (2008) Reactive oxygen species in tumor metastasis. *Cancer Lett.* 266(1):53-59.

3496 Okamoto T, Kodoi R, Nonaka Y, Fukuda I, Hashimoto T, Kanazawa K, Mizuno M & Ashida H
3497 (2004) Lentinan from shiitake mushroom (*Lentinus edodes*) suppresses expression of
3498 cytochrome P450 1A subfamily in the mouse liver. *BioFactors* 21(1-4):407-409.

3499 Oliveira RJ, Salles MJ, da Silva AF, Kanno TY, Lourenco AC, Leite Vda S, Matiazi HJ, Pesarini JR,
3500 Ribeiro LR & Mantovani MS (2013) In vivo evaluation of the antimutagenic and
3501 antigenotoxic effects of beta-glucan extracted from *Saccharomyces cerevisiae* in acute
3502 treatment with multiple doses. *Genet. Mol. Biol.* 36(3):413-424.

3503 Ooi VE & Liu F (2000) Immunomodulation and anti-cancer activity of polysaccharide-protein
3504 complexes. *Curr. Med. Chem.* 7(7):715-729.

3505 Park HY, Bae EA, Han MJ, Choi EC & Kim DH (1998) Inhibitory effects of *Bifidobacterium* spp.
3506 isolated from a healthy Korean on harmful enzymes of human intestinal microflora. *Arch*
3507 *Pharm Res* 21(1):54-61.

3508 Pérez P, García I & Durán A (1983) Effect of Papulacandin B on the Cell Wall and Growth of
3509 *Geotrichum lacti*. *Microbiology* 129(1):245-250.

3510 Pinto M, Coelho E, Nunes A, Brandão T & Coimbra MA (2014) Valuation of brewers spent yeast
3511 polysaccharides: A structural characterization approach. *Carbohydr. Polym.*

3512 Prochaska HJ & Santamaria AB (1988a) Direct measurement of NAD(P)H:quinone reductase from
3513 cells cultured in microtiter wells: A screening assay for anticarcinogenic enzyme
3514 inducers. *Anal. Biochem.* 169(2):328-336.

3515 Prochaska HJ & Talalay P (1988b) Regulatory mechanisms of monofunctional and bifunctional
3516 anticarcinogenic enzyme inducers in murine liver. *Cancer Res.* 48(17):4776-4782.

3517 Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR &
3518 Yan J (2011) Differential pathways regulating innate and adaptive antitumor immune
3519 responses by particulate and soluble yeast-derived beta-glucans. *Blood* 117(25):6825-
3520 6836.

3521 Rand TG, Sun M, Gilyan A, Downey J & Miller JD (2010) Dectin-1 and inflammation-associated
3522 gene transcription and expression in mouse lungs by a toxic (1,3)-beta-D glucan. *Arch.*
3523 *Toxicol.* 84(3):205-220.

3524 Ren L, Perera C & Hemar Y (2012) Antitumor activity of mushroom polysaccharides: a review.
3525 *Food Funct* 3(11):1118-1130.

3526 Rivas da Silva AC, Lopes PM, Barros de Azevedo MM, Costa DC, Alviano CS & Alviano DS (2012)
3527 Biological activities of alpha-pinene and beta-pinene enantiomers. *Molecules*
3528 17(6):6305-6316.

3529 Rodrussamee N, Lertwattanasakul N, Hirata K, Suprayogi, Limtong S, Kosaka T & Yamada M
3530 (2011) Growth and ethanol fermentation ability on hexose and pentose sugars and
3531 glucose effect under various conditions in thermotolerant yeast *Kluyveromyces*
3532 *marxianus*. *Appl. Microbiol. Biotechnol.* 90(4):1573-1586.

3533 Roncero C, Valdivieso MH, Ribas JC & Duran A (1988) Effect of calcofluor white on chitin
3534 synthases from *Saccharomyces cerevisiae*. *J. Bacteriol.* 170(4):1945-1949.

3535 Rosenberg DW, Giardina C & Tanaka T (2009) Mouse models for the study of colon
3536 carcinogenesis. *Carcinogenesis* 30(2):183-196.

3537 Saiki S, Nagasawa N, Hiroki A, Morishita N, Tamada M, Kudo H & Katsumura Y (2011) ESR study
3538 on radiation-induced radicals in carboxymethyl cellulose aqueous solution. *Radiat. Phys.*
3539 *Chem.* 80(2):149-152.

3540 Saitô H, Yoshioka Y, Uehara N, Aketagawa J, Tanaka S & Shibata Y (1991) Relationship between
3541 conformation and biological response for (1→3)-β-d-glucans in the activation of
3542 coagulation Factor G from limulus amebocyte lysate and host-mediated antitumor

3543 activity. Demonstration of single-helix conformation as a stimulant. *Carbohydr. Res.*
3544 217:181-190.

3545 Samuelsen AB, Schrezenmeir J & Knutsen SH (2014) Effects of orally administered yeast-derived
3546 beta-glucans: a review. *Mol. Nutr. Food Res.* 58(1):183-193.

3547 Shen RL, Dang XY, Dong JL & Hu XZ (2012) Effects of oat beta-glucan and barley beta-glucan on
3548 fecal characteristics, intestinal microflora, and intestinal bacterial metabolites in rats. *J.*
3549 *Agric. Food Chem.* 60(45):11301-11308.

3550 Simon GL & Gorbach SL (1986) The human intestinal microflora. *Dig. Dis. Sci.* 31(9 Suppl):147S-
3551 162S.

3552 Singh HP, Mittal S, Kaur S, Batish DR & Kohli RK (2009) Characterization and antioxidant activity
3553 of essential oils from fresh and decaying leaves of *Eucalyptus tereticornis*. *J. Agric. Food*
3554 *Chem.* 57(15):6962-6966.

3555 Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN & Garrett
3556 WS (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell
3557 homeostasis. *Science* 341(6145):569-573.

3558 Spencer SR, Wilczak CA & Talalay P (1990) Induction of glutathione transferases and
3559 NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues.
3560 *Cancer Res.* 50(24):7871-7875.

3561 Stevens RG, Swede H & Rosenberg DW (2007) Epidemiology of colonic aberrant crypt foci:
3562 review and analysis of existing studies. *Cancer Lett.* 252(2):171-183.

3563 Stier H, Ebbeskotte V & Gruenwald J (2014) Immune-modulatory effects of dietary Yeast Beta-
3564 1,3/1,6-D-glucan. *Nutr J* 13:38.

3565 Suhail MM, Wu W, Cao A, Mondalek FG, Fung KM, Shih PT, Fang YT, Woolley C, Young G & Lin
3566 HK (2011) *Boswellia sacra* essential oil induces tumor cell-specific apoptosis and
3567 suppresses tumor aggressiveness in cultured human breast cancer cells. *BMC*
3568 *Complement Altern Med* 11:129.

3569 Suphantharika M, Khunrae P, Thanardkit P & Verduyn C (2003) Preparation of spent brewer's
3570 yeast beta-glucans with a potential application as an immunostimulant for black tiger
3571 shrimp, *Penaeus monodon*. *Bioresour. Technol.* 88(1):55-60.

3572 Talalay P (1989) Mechanisms of induction of enzymes that protect against chemical
3573 carcinogenesis. *Adv. Enzyme Regul.* 28:237-250.

3574 Tsiapali E, Whaley S, Kalbfleisch J, Ensley HE, Browder IW & Williams DL (2001) Glucans exhibit
3575 weak antioxidant activity, but stimulate macrophage free radical activity. *Free Radic Biol*
3576 *Med* 30(4):393-402.

3577 Tsoni SV & Brown GD (2008) β -Glucans and Dectin-1. *Ann. N. Y. Acad. Sci.* 1143(1):45-60.

3578 Turgis M, Han J, Millette M, Salmieri S, Borsa J & Lacroix M (2009) Effect of selected
3579 antimicrobial compounds on the radiosensitization of *Salmonella Typhi* in ground beef.
3580 *Lett. Appl. Microbiol.* 48(6):657-662.

3581 van Meerloo J, Kaspers GJ & Cloos J (2011) Cell sensitivity assays: the MTT assay. *Methods Mol*
3582 *Biol* 731:237-245.

3583 Van Vuuren SF, Kamatou GPP & Viljoen AM (2010) Volatile composition and antimicrobial
3584 activity of twenty commercial frankincense essential oil samples. *S. Afr. J. Bot.*
3585 76(4):686-691.

3586 Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A & Boyd MR (1991) Tetrazolium-based
3587 assays for cellular viability: a critical examination of selected parameters affecting
3588 formazan production. *Cancer Res.* 51(10):2515-2520.

3589 Volman JJ, Ramakers JD & Plat J (2008) Dietary modulation of immune function by beta-glucans.
3590 *Physiol. Behav.* 94(2):276-284.

- 3591 Wang HF, Wang YK & Yih KH (2008) DPPH free-radical scavenging ability, total phenolic content,
 3592 and chemical composition analysis of forty-five kinds of essential oils. *J Cosmet Sci*
 3593 59(6):509-522.
- 3594 Wang HX, Liu WK, Ng TB, Ooi VE & Chang ST (1995) Immunomodulatory and antitumor activities
 3595 of a polysaccharide-peptide complex from a mycelial culture of *Tricholoma* sp., a local
 3596 edible mushroom. *Life Sci.* 57(3):269-281.
- 3597 Wang Y, Zhang L, Li Y, Hou X & Zeng F (2004) Correlation of structure to antitumor activities of
 3598 five derivatives of a beta-glucan from *Poria cocos sclerotium*. *Carbohydr. Res.*
 3599 339(15):2567-2574.
- 3600 Wang Z, Li S, Cao Y, Tian X, Zeng R, Liao D-F & Cao D (2016) Oxidative Stress and Carbonyl
 3601 Lesions in Ulcerative Colitis and Associated Colorectal Cancer. *Oxidative Medicine and*
 3602 *Cellular Longevity* 2016:15.
- 3603 Watanabe T, Shimada R, Matsuyama A, Yuasa M, Sawamura H, Yoshida E & Suzuki K (2013)
 3604 Antitumor activity of the beta-glucan paramylon from *Euglena* against preneoplastic
 3605 colonic aberrant crypt foci in mice. *Food Funct* 4(11):1685-1690.
- 3606 Woolley CL, Suhail MM, Smith BL, Boren KE, Taylor LC, Schreuder MF, Chai JK, Casabianca H, Haq
 3607 S, Lin HK, Al-Shahri AA, Al-Hatmi S & Young DG (2012) Chemical differentiation of
 3608 *Boswellia sacra* and *Boswellia carterii* essential oils by gas chromatography and chiral
 3609 gas chromatography-mass spectrometry. *J. Chromatogr. A* 1261:158-163.
- 3610 Xia D, Lou W, Fung KM, Wolley CL, Suhail MM & Lin HK (2016) Cancer Chemopreventive Effects
 3611 of *Boswellia sacra* Gum Resin Hydrodistillates on Invasive Urothelial Cell Carcinoma:
 3612 Report of a Case. *Integr Cancer Ther* 10.1177/1534735416664174.
- 3613 Yilmaz E & Bengisu M (2003) Preparation and characterization of physical gels and beads from
 3614 chitin solutions. *Carbohydr. Polym.* 54(4):479-488.
- 3615 Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW & Lee KH (2008) Anti-tumor
 3616 metastatic activity of β -glucan purified from mutated *Saccharomyces cerevisiae*. *Int.*
 3617 *Immunopharmacol.* 8(1):36-42.
- 3618 Young I & Woodside J (2001) Antioxidants in health and disease. *J. Clin. Pathol.* 54(3):176-186.
- 3619 Zekovic DB, Kwiatkowski S, Vrvic MM, Jakovljevic D & Moran CA (2005) Natural and modified (1-
 3620 ->3)-beta-D-glucans in health promotion and disease alleviation. *Crit. Rev. Biotechnol.*
 3621 25(4):205-230.
- 3622 Zhang L, Li X, Xu X & Zeng F (2005) Correlation between antitumor activity, molecular weight,
 3623 and conformation of lentinan. *Carbohydr. Res.* 340(8):1515-1521.
- 3624 Zhang M, Zhang L, Cheung PCK & Ooi VEC (2004) Molecular weight and anti-tumor activity of the
 3625 water-soluble polysaccharides isolated by hot water and ultrasonic treatment from the
 3626 sclerotia and mycelia of *Pleurotus tuber-regium*. *Carbohydr. Polym.* 56(2):123-128.

3627

3628

3629 **ANNEXE I : VERSION SOUMISE DE LA PUBLICATION 1**

3630 **Cancer Chemopreventive, Antiproliferative and Superoxide Anion**

3631 **Scavenging Properties of *Kluyveromyces marxianus* and *Saccharomyces***

3632 ***cerevisiae var. boulardii* Cell Wall Components**

3633 Olivier Fortin¹, Blanca Aguilar-Uscanga², Khanh Dang Vu¹, Stephane
3634 Salmieri¹ and Monique Lacroix¹

3635

3636 ¹ *INRS-Institut Armand-Frappier, Research Laboratories in Sciences Applied to Food, 531*

3637 *boul. des Prairies, Laval, QC, Canada.*

3638 ² *Laboratorio de Microbiología Industrial, Centro Universitario de Ciencias Exactas e*

3639 *Ingenierías, Universidad de Guadalajara (UdG). 1425 Blvd. Marcelino García Barragan*

3640 *Guadalajara, Jalisco, Mexico.*

3641

3642 Address correspondence to Monique Lacroix. INRS-Institut Armand-Frappier,

3643 Research Laboratories in Sciences Applied to Food, Canadian Irradiation Centre,

3644 The Institute of Nutraceutical and Functional Foods (INAF), 531, Boulevard des

3645 Prairies, Laval, Québec, Canada H7V 1B7. Tel.: +450 687 5010 #4489; fax:

3646 +450 686 5501. E-mail address: monique.lacroix@iaf.inrs.ca (M. Lacroix).

3647 **Abstract**

3648 This study investigated the cancer chemopreventive, the antiradical and the
3649 antiproliferative properties of polysaccharides extracts from cell wall of
3650 *Saccharomyces boulardii* and *Kluyveromyces marxianus*. β -glucan, mannan and
3651 chitin were also quantified to identify the most important extract responsible for
3652 these biological properties. Soluble and insoluble glucans as well as
3653 mannoprotein were extracted from cell wall using single hot-alkaline method.
3654 Superoxide anion scavenging (antiradical capacity), NAD(P)H: quinone
3655 reductase (QR) (EC 1.6.99.2) induction and antiproliferative assays were done
3656 for the evaluation of biological properties of those extracts. The insoluble glucan
3657 from *S. boulardii* revealed the most relevant biological properties by increasing
3658 QR activity and exhibiting the highest growth inhibition against colorectal
3659 cancer cells. Moreover, high amount of glucan, high glucan/total sugars ratios
3660 and low chitin/glucan ratios were shown to have an impact on enhancing cancer
3661 chemopreventive and antiproliferative properties. To our knowledge, this is the
3662 first study that demonstrates QR activity by yeast cell wall components.

3663

3664 Keywords: yeast, cell wall, β -glucan, chemoprevention, experimental

3665 **Introduction**

3666 Colorectal cancer (CRC) is the second leading cause of deaths due to cancer in
3667 males and the third in females (Canadian Cancer Society's Advisory *et al.*,
3668 2014). It is also the third most prevalent cancer in Canada (Canadian Digestive
3669 Health Foundation, 2016). Since treatment for CRC can be expensive and
3670 invasive for patients, prevention methods still seem to be the most efficient
3671 approach. It has been shown that life style plays an important role in the
3672 incidence of many cancers and diet has been related to almost 70 % of CRC
3673 incidence (Aggarwal *et al.*, 2013). Thus, consumption of diet containing agents
3674 with CRC preventive properties could reduce the risks of CRC incidence. The
3675 impact of CRC on the health of the population in Canada and USA triggered a
3676 demand of natural products with CRC preventive properties to prevent or reduce
3677 the development of this disease. Among natural agents, yeast cell wall
3678 components have been interesting due to their anticancer and
3679 immunomodulatory properties which can be utilized in nutrition, in
3680 pharmaceutical and in medical applications (Laroche *et al.*, 2007).

3681

3682 Yeasts are largely used in industrial domains especially in food industry.
3683 However, cell wall of spent yeasts are often discarded after fermented broth
3684 collected or used in many applications such as yeast extract or nutraceutical food
3685 supplements (dos Santos Mathias *et al.*, 2014, Giavasis, 2014). Many studies
3686 have investigated the natural properties of yeast cell wall and demonstrated that
3687 there are strong immunomodulatory properties of yeast glucan in *in vitro* and *in*

3688 *vivo* models (Karoui *et al.*, 2007, Oliveira *et al.*, 2013). Those properties depend
3689 on physicochemical nature and integrity of the glucan structure which vary
3690 according to growth conditions, extraction methods and yeast species (Aguilar-
3691 Uscanga *et al.*, 2003, Mantovani *et al.*, 2008, Pinto *et al.*, 2014).

3692

3693 Yeast cell walls are organized with approximatively the same polysaccharides
3694 which mainly consist of mannoprotein, chitin and (1→3)-β-D-glucan with
3695 (1→6)-β-D-glucan ramifications (Klis *et al.*, 2006). The sugar composition of
3696 the cell walls is mainly responsible for their biological and chemical properties
3697 (Aguilar *et al.*, 2012).

3698

3699 *Saccharomyces boulardii* (*S. cerevisiae* var. *boulardii*) and *Kluyveromyces*
3700 *marxianus* are well-known yeasts with diverse industrial applications and
3701 relevant biological properties. Indeed, *S. boulardii* is considered as a probiotic
3702 strain known to generate preventive effects on the occurrence of antibiotic-
3703 associated diarrhoea, beneficial effects against different enteric pathogens and to
3704 produce different anti-inflammatory molecules including *Saccharomyces* anti-
3705 inflammatory factor (Czerucka *et al.*, 2007, Kelesidis *et al.*, 2012). *K. marxianus*
3706 is known to possess a relevant potential in biotechnology due to its capacity to
3707 synthesis β-galactosidase and pectinase in addition to reducing lactose content
3708 in food products. Furthermore, *K. marxianus* exhibits an higher ethanol
3709 production as compare to *S. cerevisiae* due to its highly thermotolerant properties
3710 (Anderson *et al.*, 1986, Fonseca *et al.*, 2008).

3711

3712 Since the immunomodulatory properties of cell wall extracts (glucan, chitin and
3713 mannoprotein) of *S. cerevisiae* are well characterized, this study focused on the
3714 chemopreventive, antiradical and antiproliferative properties of cell wall extracts
3715 of *S. boulardii* and *K. marxianus*. The content, the relative concentrations and
3716 the molecular weight of the polysaccharides typically found in yeast cell wall
3717 were determined. Then, the cancer chemopreventive potential of the extracts was
3718 investigated and compared with commercial insoluble glucans of *S. cerevisiae*.
3719 Nicotinamide adenine dinucleotide phosphate hydrogen: quinone reductase
3720 (QR) assay has been selected as cancer chemopreventive test for its direct role
3721 in protection against toxic electrophilic metabolites directly involved in the very
3722 first stage of carcinogenesis process whereas superoxide (O_2^-) anion was selected
3723 since it is one of the most important reactive oxygen species (ROS) due to its
3724 ability to generate hydrogen peroxide and $OH\cdot$ radicals (Young *et al.*, 2001).
3725 Finally, structure-function relationships between the cell wall composition and
3726 their biological activities were revealed.

3727

3728 **Materials and Methods**

3729 ***Chemicals***

3730 Chemicals and media were obtained as follows: dextrose, essential amino acids,
3731 sodium pyruvate, fetal bovine serum (FBS), minimum essential medium-Earle's
3732 balanced salt solution (MEM-EBSS), Dulbecco's Modified Eagle Medium:
3733 Nutrient Mixture F-12 (MEMF/12), Hank's balanced salt solutions (HBSS),

3734 trypsin (EC 3.4.21.4), Pierce[®]BCA Protein assay, glycine, N-methylpyrrolidone
3735 (NMP) and 96-wells microplates were purchased from Fisher Scientific (Ottawa,
3736 ON, Canada). Commercial insoluble β -glucan, activated carbon, digitonin,
3737 bovine serum albumin (BSA), glucose-6-phosphate, thiazolyl blue tetrazolium
3738 bromide (MTT), menadione, glucose-6-phosphate deshydrogenase (EC
3739 1.1.1.49), 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
3740 carboxanilide inner salt (XTT), xanthine, sodium carbonate buffer (pH 10.2),
3741 xanthine oxydase (EC 1.1.3.22), superoxide dismutase (EC 1.15.1.1) , phenol,
3742 sulphuric acid, N-acetylglucosamine, mannan, lithium chloride (LiCl),
3743 nicotinamide adenine dinucleotide phosphate (NADP), dimethyl sulfoxide
3744 DMSO) and flavin adenine dinucleotide (FAD) were purchased from Sigma-
3745 Aldrich (Oakville, ON, Canada). Yeast extract, bacterial peptone and agar were
3746 purchased from Alpha Bioscience (Baltimore, MD, USA). Polyethylene glycol
3747 and polymethyl methacrylate (PMMA) were purchased from Agilent
3748 technologies (Mississauga, ON, Canada).

3749

3750 ***Yeast Strains and Growth Conditions***

3751 *Kluyveromyces marxianus* ATCC 10022 and *Saccharomyces cerevisiae* var.
3752 *boulardii* ATCC MYA-796 were purchased from American type culture
3753 collection (ATCC) (Manassas, VA, USA). The yeast strains were stored at -80°C
3754 in sterile yeast peptone dextrose (YPD) (10 M dextrose, 5 M yeast extract, 3 M
3755 bacterial peptone, 0.8 M MgSO₄, 1 M KH₂PO₄) containing 10% (w/v) sterile
3756 glycerol. One ml of culture cells in cryovial (10⁸ cells/ml) from each strain were

3757 thawed and inoculated in a 125 ml Erlenmeyer containing 25 ml of YPD medium
3758 then incubated for 18 h at 30°C at 200 rpm (Forma Scientific, Orbital shaker,
3759 Model; EQ-069, USA). A quantity of 2.5 ml of the resulting cell suspension was
3760 inoculated in a 250 Erlenmeyer containing a final volume of 50 ml of YPD
3761 medium for 24 h at 30°C under agitation. Finally, 12.5 ml of this second cell
3762 suspension was inoculated in a 1L Erlenmeyer containing a final volume of 250
3763 ml of YPD medium for 24 h at 30°C under agitation. At the end of second and
3764 third growth, 1 ml of fermented broth was serially diluted in sterile peptone water
3765 and plated on YPD agar in order to confirm lack of contamination in cell
3766 suspension. To obtain sufficient cell wall extract, this procedure was repeated in
3767 triplicate (n=3) for each strain.

3768

3769 ***Growth Kinetics***

3770 To determine the growth phase of yeast species, optical density and dry biomass
3771 weight were monitored for 24 h. The growth was conducted using the same
3772 conditions as mentioned above except that 1 ml of cell suspension was collected
3773 every 2 h and diluted in sterile medium, to measure growth by optical density at
3774 600 nm (Varian Canada Inc., Mississauga, ON, Canada). In parallel, 1 ml of cell
3775 suspension was also collected every 2 h and placed in sterile pre-weight tubes
3776 then centrifuged at 2000 g for 10 min at 4°C. Supernatant was discarded and
3777 pellet was washed with sterile water. Finally, washed biomass was dried at 60°C
3778 for 48 h and tubes were weighted. Linear relation (equation) of dry biomass
3779 weight and optical density was established and the resulting equation was used

3780 to estimate the dry biomass in time function. For both strains, kinetic were made
3781 in triplicates (n=3).

3782

3783 ***Biomass Collect and Cell Wall Preparation***

3784 Fermented broths were centrifuged at 9000 g for 10 min at 4°C. The resulting
3785 pellet (biomass) was washed twice with sterile phosphate buffer 50 mmol/l, pH
3786 7.2. The wet biomass was suspended in 15% (w/v) sterile water and was
3787 autolyzed for 24 h at 50°C with agitation at 200 rpm. Autolyzed cells were then
3788 centrifuged at 9000 g for 10 min at 4°C. The supernatant was discarded and the
3789 autolyzed cells were entirely used for glucan and mannoprotein extraction.

3790

3791 ***Extraction of Yeast Glucan and Mannoprotein Extracts***

3792 Method of extraction of β -glucan and mannoprotein was based on work of
3793 Nguyen *et al.* (1998) and Supphantharika *et al.* (2003) with some modifications.
3794 The autolyzed cells were mixed with 1 mol/l NaOH (20% w/v) for 1 h at 90°C
3795 without stirring in order to avoid glucan degradation. Then, the suspension was
3796 centrifuged at 9000 g for 10 min at 4°C. The precipitate was washed twice with
3797 distilled water, freeze-dried and the resulting extract was considered as insoluble
3798 glucan. The supernatant was mixed with 95% ethanol in 1:4 proportions, left
3799 overnight at 4°C and centrifuged. The resulting pellet was washed twice with
3800 distilled water, then freeze-dried and the obtained extract was referred as soluble
3801 glucan. Finally, ethanol in the supernatant was evaporated using a vacuum
3802 concentrator (Savant, Automatic environmental speedVac® system, Model;

3803 AES1010, Farmingdale, NY, USA) under Full vacuum, low speed and at
3804 ambient temperature for 8 h and then freeze-dried to obtain mannoprotein
3805 extract. For both strains, extraction was made in triplicate (n=3).

3806

3807 ***Total Sugars, Glucan, Mannan and Chitin Quantifications***

3808 The total sugars content in each extract was determined following a method of
3809 Dubois *et al.* (1956) using a mixture of 40% mannose and 60% dextrose (ranging
3810 from 0.02 to 0.1 M) as a standard curve. Glucan and mannan were quantified by
3811 HPLC (Varian Pro Star 210) equipped with a refractive index detector (RID)
3812 using a method established for analysis of polysaccharides in Industrial
3813 Microbiology laboratory of CUCEI-UdG (México). Polysaccharides were
3814 separated in a Metacarb CA-PLUS (30 cm X 7.8 mm) isothermal column at
3815 90°C, using water as mobile phase and a flow rate of 0.6 ml/min. A calibration
3816 curve was performed at concentrations between 1 to 0.1 M of glucan and
3817 mannan. The quantification of chitin in cell wall extracts was done using a
3818 modified method of Pérez *et al.* (1983) and Roncero *et al.* (1988) using a
3819 standard curve of N-acetylglucosamine ranging from 20 to 100 mmol/l. Results
3820 were expressed as average \pm standard deviation (SD).

3821

3822 ***Molecular Weight Determination by Gel Permeation Chromatography (GPC)***

3823 The molecular weights (Mw) of polysaccharides was analysed by gel permeation
3824 chromatography (GPC) using an Agilent HPLC (Agilent Technologies 1260
3825 infinity series, Waldbronn, BW, Germany), equipped with a quaternary pump

3826 (Model G1311B), a manual injector with a sample loop of 20 μ l and a refractive
3827 index detector (Model G1362A). Insoluble glucan was treated separately from
3828 soluble glucan and mannoprotein extracts. For soluble glucan and mannoprotein
3829 extracts, two identical PL Aquagel-OH mixed-M 8 μ m 300 X 7.5 mm columns
3830 were used in series to increase resolution. Water containing 20 ppm sodium azide
3831 was used as mobile phase with a flow rate of 1 ml/min and both columns and
3832 detector were set at 30°C. Freeze-dried mannoprotein and soluble glucan were
3833 rehydrated by solubilizing 2.5 mg/ml in mobile phase and filtered through a 0.2-
3834 μ m filter. Polyethylene glycol was used as a standard and prepared as
3835 recommended by the manufacturer. Concerning insoluble glucan, 2 identical
3836 PLgel 5 μ m Mixed-D 300 X 7.5 mm columns were used in series as explained
3837 above. Mobile phase consisted of 100% NMP containing 5% (w/v) LiCl. A flow
3838 rate of 0.5 ml/min was used and both columns and detector were set at 60°C.
3839 Method for preparation of insoluble glucan for injection was mainly based on
3840 Austin (1977), Yilmaz *et al.* (2003) and on Chakrabandhu *et al.* (2008) with
3841 some modifications due to the insoluble properties of chitin. Freeze-dried
3842 insoluble glucan was mixed in NMP at a concentration of 2.5 mg/ml into a glass
3843 bottle. The suspension was stirred for 48 h at 60°C and filtered through a nylon
3844 0.2- μ m filter. PMMA was used as a standard for insoluble glucan and was
3845 prepared as indicated by the manufacturer. The equation obtained by plotting
3846 Mw with retention times of standards was used to calculate the Mw of each peak
3847 obtained by GPC of the extracts. All extracts were injected in triplicate (n=3)
3848 and expressed as Mw range.

3849

3850 ***Cancerous Cell Lines and Cells Maintenance***

3851 Hepa 1c1c7 (ATCC CRL-2026) and HT-29 (ATCC HTB-38) cell lines were
3852 purchased from American type culture collection (ATCC) (Manassas, VA,
3853 USA). The cell lines were cultivated in 25 cm² cellular flasks (Corning,
3854 Manassas, VA, USA) in a humidified incubator at 37°C in an atmosphere of 5%
3855 CO₂ and 95% air. Hepa 1c1c7 cells and HT-29 cells were grown in complete
3856 MEM-EBSS and complete MEMF/12 media respectively containing 0.1%
3857 essential amino acids, 0.1% sodium pyruvate, 10% (v/v) FBS. The maintenance
3858 of cells was performed at a confluence of 80-90% by washing adherent cells with
3859 HBSS solution. Then, cells were treated with 1X trypsin for exactly 12 min in a
3860 humidified incubator as mentioned above and inoculated into 5 ml of fresh
3861 completed medium.

3862

3863 ***NAD(P)H: quinone reductase (QR) Assay***

3864 QR assay was based on study of Prochaska *et al.* (1988a) with some
3865 modifications. The aim of this assay was to determine the concentration of
3866 extracts required to double the QR induction (CD) in Hepa 1c1c7 cells. The
3867 induction of QR can be easily detected by using this cell line since it possesses
3868 the capacity for carcinogen activation and xenobiotic metabolism in addition to
3869 possessing a high inducible aryl hydrocarbon hydrolase consequently facilitating
3870 metabolic activation of xenobiotics (Fahey *et al.*, 2004). Freeze-dried extracts
3871 were rehydrated in 10% (v/v) dimethyl sulfoxide (DMSO) containing 20 ppm of

3872 sodium azide (as antimicrobial agent) in order to avoid sterilization of extract
3873 solution by filtration or by heating which could lead to a loss of biological
3874 activities. A 96-well plate was seeded with Hepa 1c1c7 cells at a density of 10^4
3875 cells/ml (200 μ l per well) in completed MEM-EBSS medium and incubated in a
3876 humidified incubator as mentioned above. Afterward, different concentrations
3877 of extracts (20 μ l) previously serial diluted were added and each well was
3878 completed to 200 μ l with carbon activated MEM-EBSS media for 48 h. Cells
3879 were then washed with HBSS solution and 50 μ l of 1.6% (w/v) digitonin were
3880 added in each well. The microplate was incubated for 20 min at 37°C on an
3881 orbital shaker. A sample of 20 μ l of this suspension was collected for further
3882 total protein determination. Then, 200 μ l of complete reaction mixture (0.25
3883 mol/l Tris-HCl pH 7, 4.67% (w/v) BSA, 0.01% tween-20, 5 mol/l FAD, 1 mmol/l
3884 glucose-6-phosphate, 30 mol/l NADP, 34.8 μ mol/l MTT, 50 μ mol/l menadione
3885 and 2 mU/ μ l glucose-6-phosphate deshydrogenase) were added in each well and
3886 optical densities were read after 5 min at 595 nm using a microplate reader
3887 (Biotek, Model EL800, Winooski, VT, USA). Protein assay was made using
3888 Pierce[®]BCA reagents and was performed as suggested by the manufacturer.
3889 Control consisted of 1% (v/v) DMSO containing 20 ppm sodium azide whereas
3890 medium was used as blank. Specific activity of QR was defined as nmol of blue
3891 formazan formed per mg protein per minute. Fold inductions of QR were
3892 presented as average \pm SD and were calculated as follow:
3893

3894 QR Fold Induction (treated on control) = Specific activity of QR in treated group / Specific
3895 activity of QR in negative control group (Equation 1)

3896

3897 ***Antiradical Assay (O₂⁻ Anion Scavenging Activity)***

3898 The capacity of samples to scavenge O₂⁻ was measured using xanthine/xanthine
3899 oxydase (X/XO) system (XTT color assay) based on method of Gerhäuser *et al.*
3900 (2003). This assay aims to determine whether soluble extracts possess radical
3901 scavenging properties by quantified their activity to scavenge O₂⁻ anion. Freeze-
3902 dried samples of yeast cell wall extracts were rehydrated in 10% (v/v) DMSO at
3903 desired concentrations. Then, serial dilutions of extracts were performed in 10%
3904 (v/v) DMSO and 20 µl of those extracts were loaded in 96-well microplate. Each
3905 well was completed to 200 µl with reactional mix (1 mmol/l XTT, 1 mmol/l
3906 EDTA, 1 mmol/l xanthine, 50 mmol/l sodium carbonate buffer (pH 10.2) and 3
3907 mU/ml xanthine oxydase) and optical density was read at 490 nm (Biotek) after
3908 20 min. Negative control consisted of DMSO 1% (v/v) whereas positive control
3909 corresponded to 30 U/ml of superoxide dismutase. Scavenging activity (%) was
3910 calculated as follow:

3911

3912 % Scavenging Activity = [(sample OD - Negative control OD) / (Positive control
3913 OD - Negative control OD)] x 100 (Equation 2)

3914

3915 Concentrations exhibiting a scavenging activity of 50% referred as SC₅₀ values.
3916 Insoluble glucan was not used for this assay since perfectly soluble samples were
3917 required. Scavenging activities were presented as average ± SD.

3918

3919 *Antiproliferative Assay*

3920 The antiproliferative effect of different yeast cell wall extracts was measured
3921 using MTT color assay based on method of Vistica *et al.* (1991). The cell
3922 proliferation was determined by the ability of the metabolic active cells to cleave
3923 the tetrazolium salt to purple formazan crystals. Human CRC HT-29 cells were
3924 chosen for antiproliferative assay since this study focus on CRC. In a 96-well
3925 plate, HT-29 cells were seeded at 2×10^4 cells per 200 µl of complete MEMF/12
3926 medium. After 24 h as mentioned above, the medium was replaced with 100 µl
3927 of fresh medium containing 10 µl of each extract previously serial diluted.
3928 Negative control consisted of 1% (v/v) DMSO containing 20 ppm sodium azide
3929 and blank consisted of 100µl of fresh medium. After 48 h of incubation, culture
3930 medium was decanted and replaced with 200 µl of fresh MEMF/12 media
3931 containing 25 µl of 0.5% (w/v) MTT. The microplate was incubated for 4 h as
3932 described above. Then, medium was carefully eliminated and 200 µl of DMSO
3933 plus 25 µl of Sorensen buffer pH 10.5 (0.1 mol/l glycine, 0.1 mol/l NaCl) were
3934 added in each well. Absorbencies were measured at 562 nm (Biotek) and the
3935 cellular growth inhibition was calculated as follow:

3936

3937 $\% \text{ Growth Inhibition} = 100 - \left(\left(\frac{[\text{Sample OD}]}{\text{Negative control OD}} \right) \times 100 \right)$
3938 (Equation 3)

3939

3940 Equations obtained by plotting the linear portion of growth inhibition versus
3941 concentrations of extracts were used to determinate concentrations that inhibit
3942 50% of the cellular growth (IC₅₀ values). Results were presented as average ±
3943 SD.

3944

3945 ***Statistical Analysis***

3946 All quantifications and assays were replicated at least 3 times (n=3). Amounts
3947 of total sugar content, chitin, glucan and mannan in extracts as well as QR fold
3948 inductions, O₂⁻ anion scavenging activities and IC₅₀ values were analyzed by
3949 one-way analysis of variance (ANOVA) using PASW statistics 18 software
3950 (IBM Corporation, Somers, NY, USA) and differences between samples were
3951 analyzed with post hoc Duncan's multiple-range test. Significance was
3952 considered at $P \leq 0.05$.

3953

3954 **Results**

3955 ***Growth Kinetics***

3956 Growth kinetics of yeasts was performed to collect yeast biomass in stationary
3957 phase in order to reflect spent yeast at the end of industrial fermentation
3958 processes. As presented in Fig. A.1, the initial amounts of biomass from *K.*
3959 *marxianus* (0.8 g/l) and *S. boulardii* (1.0 g/l) were similar. Afterwards, dry

3960 biomass of both *K. marxianus* and *S. boulardii* was increased to 1.5 g/l after 8 h
3961 and 10 h respectively, indicating that *K. marxianus* presented a shorter latency
3962 phase than *S. boulardii*. Despite the fact that *K. marxianus* produced more
3963 biomass than *S. boulardii* (6.3 and 3.2 g/l respectively), both species biomass
3964 was collected in stationary phase after 24 h growth.

3965

3966 ***Solubility and Visual Appearances of Yeast Cell Wall Extracts***

3967 The solubility of those extracts is briefly described in Table A.1 Results showed
3968 that insoluble glucan and commercial glucan were partially soluble in high
3969 concentrations of DMSO whereas they were totally soluble in pure NMP after
3970 stirring and heating for 48 h in presence of 5% (w/v) lithium chloride. Soluble
3971 glucan and mannoprotein were readily soluble in water and at all concentrations
3972 of DMSO. In 10% DMSO, insoluble glucan yielded a white and turbid
3973 suspension; soluble glucan yielded a transparent solution whereas mannoprotein
3974 yielded a transparent and yellow solution.

3975

3976 ***Quantification of Total Sugars, Chitin, Glucan, Mannan in the Extracts and***

3977 ***Mw Determination***

3978 The quantification of total sugars is presented in Table A.2 Results showed that
3979 the content of insoluble glucan, soluble glucan and mannoprotein of *S. boulardii*
3980 (42.73%, 39.13% and 0.45% respectively) are similar to their respective
3981 counterparts in *K. marxianus* (51.38%, 32.55% and 0.52% respectively)
3982 suggesting that both species possessed a similar amount of total sugars in cell

3983 walls. Results also showed that insoluble glucan from both species contain
3984 significantly more total sugars than all other extracts evaluated in this study ($P \leq$
3985 0.05). Also, insoluble extracts of both species contained the highest amounts of
3986 glucan (49.17 and 40.54% for *K. marxianus* and *S. boulardii* respectively)
3987 whereas the soluble glucan of *S. boulardii* contained the lowest amount of glucan
3988 (23.99%). Furthermore, combined amounts of glucan in soluble and insoluble
3989 extracts represented 65% and 80% for *S. boulardii* and *K. marxianus*
3990 respectively, which demonstrate a noticeable difference in their cell wall
3991 composition. The content of mannoprotein are presented in Table A.2 The results
3992 showed that the content of mannoprotein of *S. boulardii* contained significantly
3993 less mannan (3.17%) than their *K. marxianus* counterparts (9.14%) ($P \leq 0.05$).
3994 Moreover, each extract contained 4-10 times less mannan than glucan. These
3995 observations may be due to the presence of mannan covalently bound to glucan
3996 despite the extraction. The total content of chitin found in the three extracts of *S.*
3997 *boulardii* (1.51%) is higher than content found in all extracts of *K. marxianus*
3998 (0.89%), which also demonstrate typical differences in cell wall composition
3999 between each strain. Finally, higher chitin contents were found in both soluble
4000 and insoluble extracts of *S. boulardii* (0.66 and 0.58% respectively) as compared
4001 to 0.30 and 0.35% in *K. marxianus*. The GPC analysis showed that the Mw
4002 range in insoluble glucan of *S. boulardii* is 1921 kDa and 2085kDa in *K.*
4003 *marxianus* showing higher Mw than soluble glucan and mannoprotein extracts,
4004 which corroborates the fact that solubility partially depends on Mw (Table A.2).
4005 Mannoprotein extracts of *K. marxianus* showed a Mw from 0.48-77 kDa and

4006 from (0.72-87 kDa) in *S. boulardii*. Also, data shown in Table A.2 indicated that
4007 insoluble glucan in both strains showed a high amounts of total sugars and
4008 glucan in addition to showed high Mw.

4009

4010 ***Determination of Relative Concentrations in Total Sugars, Chitin, Glucan and***
4011 ***Mannan Contents in the Extracts***

4012 Determination of relative concentration using ratios may lead to a better analysis
4013 of extracts composition and to a better understanding of structure-function
4014 relationship. Table A.3 showed that insoluble glucan of *S. boulardii* possess a
4015 glucan/total sugars ratio (0.94) that was significantly higher ($P \leq 0.05$) then their
4016 soluble counterparts (0.61) whereas no differences ($P > 0.05$) in the glucan/total
4017 sugar ratios were observed between insoluble and soluble glucan of *K.*
4018 *marxianus*. Mannan/total sugars ratios were higher in mannoprotein of *S.*
4019 *boulardii* (7.03) and *K. marxianus* (10.55) whereas mannan/glucan ratios
4020 showed no significant differences ($P > 0.05$) between soluble and insoluble
4021 glucan of both strains. In addition, chitin/total sugars ratios in insoluble glucans
4022 of both yeast strains (6.83×10^{-3} and 13.66×10^{-3} for *S. boulardii* and *K.*
4023 *marxianus* respectively) were the lowest as compared to other extracts whereas
4024 these ratios in mannoprotein of both strains were the highest (470.85×10^{-3} and
4025 685.14×10^{-3} for *S. boulardii* and *K. marxianus* respectively). More importantly,
4026 insoluble glucan of both strains exhibited low chitin/glucan ratios compared to
4027 other extracts whereas this ratio was significantly higher ($P \leq 0.05$) regarding
4028 soluble glucan of *S. boulardii* (27.40×10^{-3}), hence suggesting that soluble

4029 extract of *S. boulardii* possessed more chitin and less glucan than both insoluble
4030 extracts. Also, chitin/mannan ratios suggest that insoluble glucan of both strains
4031 contain high amounts of chitin whereas soluble glucan of *S. boulardii* exhibited
4032 the highest chitin/mannan ratio, which is congruent with Table A.2. Analysis of
4033 all ratios for each extract and each strain suggests that insoluble glucan possess
4034 high glucan/total sugars ratios, low chitin/total sugars ratio and low chitin/glucan
4035 ratios for both strains. Contrastingly, soluble glucan of *S. boulardii* exhibited the
4036 lowest glucan/total sugars ratio and the highest chitin/glucan ratio therefore
4037 suggesting a low proportion of glucan in this extract.

4038

4039 ***Cancer Chemopreventive, Antiradical and Antiproliferative Activities of Yeast***

4040 ***Cell Wall Extracts***

4041 Biological activities of yeast cell wall extracts are presented in Table A.4.
4042 Results showed that only insoluble glucan from both yeast species could induced
4043 QR activity and reached CD values of 500 µg/ml. Also, CD value (125 µg/ml
4044 corresponding to 1.96-Fold Induction) of the commercial insoluble glucan is 4
4045 times lower than those obtained for the insoluble extracts of *S. boulardii* (500
4046 µg/ml corresponding to 1.97-Fold induction) and *K. marxianus* (500 µg/ml
4047 corresponding to 2.08-Fold Induction), which might be explained by a higher
4048 purity of the commercial glucan. Also, fold inductions of insoluble glucan from
4049 both yeast strains were significantly higher than fold inductions of water-soluble
4050 extracts (soluble glucan and mannoprotein extracts) ($P \leq 0.05$). Those results
4051 showed that insoluble glucan of *S. boulardii* and *K. marxianus* are relevant

4052 toward QR induction assay since significant CD values were obtained for those
4053 extracts. The capacity of water-soluble extracts of yeast cell walls to scavenge
4054 O_2^- anion was determined and presented in Table A.4. Results showed that
4055 soluble glucan of *K. marxianus* reached a SC_{50} value of 3000 $\mu\text{g/ml}$ (Scavenging
4056 activity of 55.47 %) as opposed to soluble glucan of *S. boulardii* that did not
4057 reached a SC_{50} value. Mannoprotein of *K. marxianus* reached a SC_{50} value (1500
4058 $\mu\text{g/ml}$ corresponding to a scavenging activity of 51.53 %) twice as low as found
4059 for mannoproteins of *S. boulardii* (3000 $\mu\text{g/ml}$ corresponding to a scavenging
4060 activity of 56.03 %). Also, soluble glucan of *S. boulardii* showed a O_2^-
4061 scavenging activity (Scavenging activity of 6.52 %) significantly lower than all
4062 other extracts ($P \leq 0.05$). Those results demonstrate that mannoprotein and
4063 soluble glucan of *K. marxianus* scavenged more efficiently the O_2^- species as
4064 compared to their *S. boulardii* counterparts. The antiproliferative activities of
4065 cell wall extracts of *S. boulardii* and *K. marxianus* against HT-29 cells are also
4066 presented in Table A.4. Results showed that all extracts were able to reach 50%
4067 of growth inhibition whereas extracts of *S. boulardii* showed lower IC_{50} values
4068 than their *K. marxianus* counterparts. Indeed, insoluble extract of *S. boulardii*
4069 possessed the lowest IC_{50} value (108.28 $\mu\text{g/ml}$) among glucan extracts whereas
4070 mannoprotein of *S. boulardii* possessed the lowest IC_{50} value (250.98 $\mu\text{g/ml}$)
4071 among mannoprotein extracts. In fact, only insoluble glucan of *S. boulardii*
4072 exhibited an IC_{50} value significantly ($P \leq 0.05$) lower than the commercial
4073 insoluble glucan (344.18 $\mu\text{g/ml}$) whereas soluble glucan and mannoprotein of *K.*

4074 *marxianus* were found to possess the highest IC₅₀ values (856.05 and 1402.96
4075 µg/ml respectively) as compared to all extracts.

4076

4077 ***Relationship Between the Contents of Yeast Cell Wall Polysaccharide and***
4078 ***their Biological Activities***

4079 Table A.4 also indicates that insoluble glucan from both yeast strains constitute
4080 the most relevant extracts regarding biological activities. The insoluble glucan
4081 of *S. boulardii* is the most relevant extract based on its QR inductive activity
4082 with the CD value of 500 µg/ml and its antiproliferative activity against HT-29
4083 cells with the lowest IC₅₀ values of 108.28 µg/ml. In contrast, soluble glucan of
4084 *S. boulardii* exhibited the lowest biological activities based on an IC₅₀ value of
4085 356.11 µg/ml against HT-29 cells as the unique detected biological activity.

4086

4087 Determining the combination of polysaccharides found in yeast cell wall that are
4088 potentially responsible for cancer chemopreventive, antiradical and
4089 antiproliferative properties is essential to understand the major components
4090 involved in the biological activities of extracts. Results from the characterization
4091 of biological activities suggested that insoluble glucan possessed the most
4092 relevant biological activities which correspond to high contents in total sugars,
4093 glucan and chitin as well as a high Mw, a high glucan/total sugars ratio, low
4094 chitin/total sugars and chitin/glucan ratios. In contrast, soluble extract of *S.*
4095 *boulardii* presented the weakest biological activity and corresponded to a low
4096 content in glucan, low glucan/total sugars ratio and high chitin/glucan ratio.

4097 These assessments suggest a typical relationship between biological activities
4098 and sugars quantification that aims to determine the relative importance of each
4099 polysaccharide in biological activities: % chitin < % glucan \approx % total sugars.
4100 This relation shows that extracts mainly need to contain glucan to possess
4101 biological properties whereas chitin seems to be statistically less influent on
4102 chemopreventive and anticancer properties against CRC *in vitro*.

4103

4104 **Discussion**

4105 Since growth phase can modulate the yeast cell wall composition drastically,
4106 biomass was collected in stationary phase in this study in order to reflect cellular
4107 state of spent yeasts. Mitterdorfer *et al.* (2001) demonstrated that a strain of *S.*
4108 *boulardii* reached the early stationary phase after approximately 25 h of growth
4109 using Sabouraud media containing 1% dextrose which is also comparable with
4110 our results. Similarly, the growth kinetics of *K. marxianus* obtained in this study
4111 is comparable with Falcão Moreira *et al.* (1998) considering growth conditions.
4112 The authors reported that *K. marxianus* ATCC 10022 cells entered in stationary
4113 phase after approximately 28 h of growth using YPD medium containing 2%
4114 dextrose and a growth temperature of 26°C. It has been demonstrated that growth
4115 temperature and dextrose concentration lower than 30°C and 2% can lead to a
4116 decrease of biomass and thus to a reduction of the time needed to enter stationary
4117 phase (Margaritis *et al.*, 1983, Rodrussamee *et al.*, 2011). Consequently, time
4118 needed for *K. marxianus* to enter stationary phase as found in the present study
4119 is considered congruent with scientific literature.

4120

4121 In general, yeast cell wall collected in stationary phase consists mainly of 3
4122 biopolymers: chitin, mannan and (1→3)-β-D-glucan and (1→6)-β-D-glucan.
4123 Their proportion change according to many parameters such as strains, growth
4124 conditions, growth phase, method of cell wall preparation, extraction and
4125 chemical derivatization of natural biopolymers (Aguilar-Uscanga *et al.*, 2003,
4126 Zekovic *et al.*, 2005). Glucan amounts found in soluble and insoluble extracts
4127 obtained in this study are similar to those obtained by Supphantharika *et al.*
4128 (2003). The authors used a single hot alkaline extraction approach to recover
4129 glucan from bakery yeast's cell wall and obtained insoluble extracts constituted
4130 of approximately 50% of glucan. Moreover, the theoretical amount of total β-
4131 glucans represents between 58 to 72% of yeast cell wall dry weight, which is in
4132 accordance with total amount of β-glucan obtained in this study. In contrast, total
4133 amount of mannans in extracts was inferior for both yeast strains as compared to
4134 mannoprotein complex found in the literature (35 to 40%) (Klis *et al.*, 2002,
4135 Kwiatkowski *et al.*, 2012). This divergence might be due to the relatively
4136 important content of proteins in the complex which was not quantified since this
4137 study focused on polysaccharides characterization. Klis *et al.* (2006) reviewed
4138 that *S. cerevisiae*'s cell wall contains between 1 and 6% of chitin which is
4139 congruent with our results. The presence of chitin in soluble and insoluble
4140 glucans extracts might be due to residual N-acetyl-glucosamine branched to
4141 (1→3)-β-D-glucan and (1→6)-β-D-glucan.

4142

4143 The content of chitin, glucan and mannan revealed the divergence in cell wall
4144 composition of *S. boulardii* and *K. marxianus* which has already been reported
4145 elsewhere (Backhaus *et al.*, 2010). The authors concluded that *S. cerevisiae* tends
4146 to decrease the amount of glucan in cell wall under stress condition whereas a
4147 *Kluyveromyces spp.* member tends to unchanged glucan content under the same
4148 condition. Those observations seem to be in agreement with our results, since
4149 amounts of glucan and glucan/total sugars ratios were significantly higher for *K.*
4150 *marxianus*.

4151

4152 The Mw of glucan between 100 and 200 kDa are known to exhibit important
4153 biological activities such as tumor growth inhibition *in vivo* and antiproliferative
4154 effect on cancerous cells *in vitro* (Mantovani *et al.*, 2008). In the present study,
4155 the Mw of insoluble glucan from *S. boulardii* (1921 kDa) and *K. marxianus*
4156 (2085 kDa) possessed higher Mw as compared to other extracts in addition to
4157 exhibit the most relevant biological activities. β -glucan with high Mw glucan
4158 have been reported as possessing biological activities. Using hot-alkaline
4159 extraction, Mork *et al.* (1998) produced a soluble β -glucan that exhibited Mw of
4160 approximately 1000 kDa and showed capacity in activating macrophages. In
4161 addition, Kelly (2001) described an insoluble glucan that presented a Mw range
4162 of 1000-3000 kDa and exhibited a capacity to heal skin wounds in rats. Those
4163 studies confirmed that insoluble glucan with Mw higher than 1000 kDa possess
4164 biological activities and thus corroborates findings made in the present study.

4165

4166 The determination of polysaccharides mainly responsible for biological
4167 activities observed in this study revealed that β -glucan was the principal
4168 component of yeast cell walls that exhibited important biological activities
4169 whereas chitin and mannan were important to a lesser extent. Those results
4170 corroborate results obtained by others investigations. Indeed, yeast β -glucan are
4171 known to exhibit antimutagenic and antigenotoxic effects *in vivo* (Oliveira *et al.*,
4172 2013) and to inhibit the cellular growth of colorectal cancer cells both *in vitro*
4173 and *in vivo* (Kim *et al.*, 2009, Yoon *et al.*, 2008).

4174

4175 Chitin covalently bound to glucan in soluble/insoluble extracts might have led
4176 to a decrease of glucan biological function. Indeed, glucan branched to chitin or
4177 mannan above certain proportions might cause a decrease in glucan's biological
4178 properties, which could explain the importance of high chitin/glucan ratio in
4179 soluble glucan of *S. boulardii*. However, content of chitin was proven to be high
4180 in insoluble glucan which demonstrated the importance of relative concentration
4181 of chitin and glucan. In this regard, those results are congruent with findings of
4182 Zhang *et al.* (2004). Indeed, the authors observed that extracts with higher
4183 glucose/total sugars ratios and lower N-acetyl glucosamine/glucose ratios
4184 exhibited the most relevant anti-cancer properties both *in vivo* and *in vitro*.

4185

4186 The capacity of cell wall extracts obtained from *S. boulardii* and *K. marxianus*
4187 to induce QR activity seems to be a novel biological activity highlighted in the
4188 present study. Despite the fact that compounds exhibiting a CD value below 10

4189 $\mu\text{g/ml}$ are considered as highly relevant inducers (Kang *et al.*, 2004), high CD
4190 values obtained by insoluble glucan (500 $\mu\text{g/ml}$) can be considered as medium
4191 and even low inducers for *in vivo* studies using yeast cell wall compound (Li *et*
4192 *al.*, 2010, Samuelsen *et al.*, 2014). Further studies will be needed to determine
4193 the mechanism of QR induction by insoluble glucan.

4194

4195 As opposed to QR assay, several studies demonstrated the antiradical scavenging
4196 activity of polysaccharides from fungal and yeast sources (Jaehrig *et al.*, 2007,
4197 Krizkova *et al.*, 2006). The antiradical activity of yeast cell wall extracts might
4198 be explained by a hydrogen atom transfer (HAT) mechanism of anomeric
4199 hydrogen. Indeed, antiradical activities of glucan are higher than dextrose and
4200 mannose most probably due to the greater abstraction lability of the anomeric
4201 hydrogen from internal glucose units rather than from the reducing end (Tsiapali
4202 *et al.*, 2001). Our results also demonstrated that mannoprotein of *K. marxianus*
4203 exhibited the most relevant SC_{50} value. This observation might be due to a higher
4204 presence of aromatic amino acids and thiol groups in mannoprotein which are
4205 known to exhibit high antioxidant activities (Jaehrig *et al.*, 2007). In contrast, all
4206 soluble extracts obtained in the present study revealed relatively high SC_{50}
4207 values and thus can be considered to possess a low antiradical potential, which
4208 is in accordance with literature since sugar compounds were reported to exhibit
4209 low antiradicals properties (Machová *et al.*, 2013, Tsiapali *et al.*, 2001). Finally,
4210 it has been reported that yeast glucan possess a weaker antiradical scavenging

4211 capacity compare to mannoprotein extracts (Jaehrig *et al.*, 2007, Jaehrig *et al.*,
4212 2008), which is congruent with ours results.

4213

4214 Proliferation of cancerous cells can be inhibited through different mechanisms
4215 including cell cycle arrest, apoptosis and necrosis (Ren *et al.*, 2012). Although
4216 further study will be necessary to investigate whether necrosis or apoptosis was
4217 involved in growth inhibition of HT-29 cells observed in this study, the fact that
4218 all extracts exhibited antiproliferative activities is in agreement with literature
4219 (Zekovic *et al.*, 2005). Indeed, lentinan, a well-known β -glucan from fungi, was
4220 reported to inhibit 50% of the growth of sarcoma 180 solids tumors *in vitro* at a
4221 concentration of approximately 500 $\mu\text{g/ml}$ (Zhang *et al.*, 2005). Moreover, β -
4222 glucan derived from a mutant strain of *Aureobasidium* inhibited 52.6% of the
4223 cellular growth of human colon cancer cells SNU-C4 at a concentration of 150
4224 $\mu\text{g/ml}$ and triggered apoptosis at 100 $\mu\text{g/ml}$ (Kim *et al.*, 2009). These biological
4225 activities can be linked to β -glucan insolubility, molecular weight, nature of
4226 branching, presence of glycoprotein bound to glucan and triple-helix structure of
4227 glucan. Thus, further studies on the structure of glucan to find relation with
4228 biological properties are necessary.

4229

4230 **Conclusion**

4231 This study demonstrated that extracts obtained via a simple and fast extraction
4232 method from cell wall of *S. boulardii* and *K. marxianus* suitable for industrial
4233 application exhibited cancer chemoprevention, antiradical and antiproliferative

4234 properties. In addition, this study also revealed for the first time the capacity of
4235 insoluble glucan from *S. boulardii* and *K. marxianus* to induce QR activity.
4236 Results suggested that insoluble glucan and mannoprotein extracts from *S.*
4237 *boulardii* exhibited relevant biological activities toward CRC. Finally,
4238 characterization of extracts allowed revealing that high amount of glucan, high
4239 glucan/total sugars ratios and low chitin/glucan ratios in extracts have a major
4240 impact in biological properties of yeast cell wall extracts. In perspective,
4241 insoluble glucan and mannoprotein extracts of *S. boulardii* could be used in
4242 animal models in order to investigate their CRC chemopreventive properties and
4243 ultimately employ those extracts as food supplements in cancer prevention.

4244

4245 **Acknowledgments**


4246 This work was supported by the Ministère de l'Économie, de l'Innovation et de
4247 l'Exportation du Québec (MEIE). Olivier Fortin is a scholarship recipient of
4248 Fondation Armand-Frappier.

4249

4250 **Conflict of Interest**

4251 The authors have no conflict of interest to declare.

4252



4253

4254 **Fig A.1.** Growth kinetics of *S. boulardii* and *K. marxianus* based on dry biomass in time

4255 function. (■) *S. boulardii*, (□) *K. marxianus*.

4256

4257 **Table A.1** Solubility and visual appearance of yeast cell wall extracts obtained
 4258 after single hot-alkaline extraction for both strains.

Extracts	Solubility in solvents						Appearance in 10% DMSO
	Water	DMSO	DMSO	DMSO	DMSO	NMP*	
		10%	50%	75%	100%	100%	
Insoluble	-	-	-	+/-	+/-	+	White, high turbidity
Soluble	+	+	+	+	+	ND	Transparent
Manno	+	+	+	+	+	ND	Transparent, yellow
Commercial glucan	-	-	-	-	+/-	+	White, high turbidity

4259 *; 48 h with agitation at 60°C and additioned with 5% lithium chloride. -;

4260 Insoluble. +/-; Partially soluble. +; completely soluble. ND; Not determined.

4261 NMP; 1-methyl-2-pyrrolidone. Soluble, insoluble and manno extracts refer to

4262 soluble glucan, insoluble glucan and mannoprotein respectively.

4263

4264 **Table A.2** Sugars quantification and Mw range of yeast cell wall extracts
 4265 determined by spectrophotometric method and gel permeation
 4266 chromatography.

Strain	Extracts	Total sugars (%)	Glucan (%)	Mannan (%)	Chitin (%)	Mw range (kDa)
	Insoluble	51.38±6.02 ^b	49.17±0.13 ^d	3.14±2.78 ^{a,b}	0.35±0.08 ^{a,b}	2085
<i>K. marxianus</i>	Soluble	32.55±2.42 ^b	30.38±0.30 ^b	8.49±3.75 ^{a,b}	0.30±0.03 ^b	0.74-165
	Manno	0.52±0.38 ^a	ND	9.14±0.94 ^b	0.24±0.02 ^a	0.48-77
	Insoluble	42.73±7.64 ^b	40.54±0.07 ^c	9.72±1.96 ^{a,b}	0.58±0.03 ^c	1921
<i>S. boulardii</i>	Soluble	39.13±5.63 ^b	23.99±0.29 ^a	3.99±3.46 ^{a,b}	0.66±0.02 ^c	0.73-160
	Manno	0.45±0.03 ^a	ND	3.17±0.11 ^a	0.27±0.01 ^b	0.72-87

4267 ND; Not determined. Soluble, insoluble and manno extracts refer to soluble
 4268 glucan, insoluble glucan and mannoprotein respectively. Within each column,
 4269 means bearing a different lowercase letter are significantly different ($P \leq 0.05$).
 4270

4271 **Table A.3** Ratios in glucan, mannan and chitin regarding all yeast cell wall
 4272 extracts.

Strains	Extracts	Glucan / total sugars	Mannan / total sugars	Mannan / glucan	Chitin / total sugars (10 ⁻³)	Chitin / glucan (10 ⁻³)	Chitin / mannan
<i>K. marxianus</i>	Insoluble	0.96±0.11 ^b	0.06±0.01 ^a	0.06±0.05 ^a	6.83±1.54 ^a	7.12±1.62 ^a	0.112±0.025 ^{c, d}
	Soluble	0.93±0.07 ^b	0.26±0.02 ^b	0.28±0.01 ^a	9.34±0.82 ^a	10.03±0.88 ^{a, b}	0.036±0.003 ^b
	Manno	ND	10.55±1.07 ^c	ND	471.85±38.45 ^c	ND	0.026±0.002 ^a
<i>S. boulardii</i>	Insoluble	0.94±0.16 ^b	0.23±0.04 ^{a, b}	0.24±0.05 ^a	13.66±2.94 ^b	14.38±3.09 ^b	0.059±0.0129 ^{b, c}
	Soluble	0.61±0.09 ^a	0.10±0.01 ^a	0.16±0.14 ^a	16.81±0.48 ^b	27.40±0.79 ^c	0.165±0.005 ^d
	Manno	ND	7.03±0.53 ^c	ND	685.14±14.25 ^d	ND	0.086±0.002 ^c

4273 ND; Not determined. Soluble, insoluble and manno extracts refer to soluble
 4274 glucan, insoluble glucan and mannoprotein respectively. Within each column,
 4275 means bearing a different lowercase letter are significantly different (P≤0.05).
 4276

4277 **Table A.4** Effect of yeast cell wall extracts on quinone reductase induction,
 4278 superoxide anion scavenging capacity and antiproliferative property.

Strain	Extracts	QR Fold Induction (corresponding CD)†	O ₂ ⁻ Scavenging Activity (%) (corresponding SC ₅₀)†	Antiproliferative assay (IC ₅₀)†
<i>K. marxianus</i>	Insoluble	2.08±0.09 ^b (500)	ND	284.98±9.31 ^b
	Soluble	1.25±0.22 ^a (NR)	55.47±5.57 ^b (3000)	856.05±56.41 ^c
	Manno	1.26±0.07 ^a (NR)	51.53±2.48 ^b (1500)	1402.96±136.94 ^d
	Insoluble	1.97±0.16 ^b (500)	ND	108.28±32.87 ^a
<i>S. boulardii</i>	Soluble	1.12±0.03 ^a (NR)	6.52±2.83 ^a (NR)	356.11±2.82 ^b
	Manno	1.16±0.13 ^a (NR)	56.03±4.80 ^b (3000)	250.98±12.48 ^b
<i>S. cerevisiae</i> (Bakery strain)	Commercial glucan	1.96±0.24 ^b (125)	ND	344.18±24.90 ^b

4279 ND; Not determined. NR; CD or SC₅₀ values were not reached. Soluble,
 4280 insoluble and manno extracts refer to soluble glucan, insoluble glucan and
 4281 mannoprotein respectively. QR; Quinone reductase. O₂⁻; Superoxide anion. CD;
 4282 Concentration that double the specific activity of QR. SC₅₀; Concentration that
 4283 scavenges 50% of all O₂⁻. IC₅₀; Concentration that inhibits 50% of the cellular
 4284 growth. †; CD, IC₅₀ and SC₅₀ values are expressed in µg/ml. Means bearing a
 4285 different lowercase letter are significantly different (P≤0.05).

4286

ANNEXE II : COLLABORATION

- 4287 Desrouillères K, Millette M, Jamshidian M, Maherani B, **Fortin O** & Lacroix M (2016)
4288 Cancer preventive effect of a specific probiotic fermented milk components and cell
4289 walls extracted from a biomass containing *L. acidophilus* CL1285, *L. casei* LBC80R,
4290 and *L. rhamnosus* CLR2 on male F344 rats treated with 1,2-dimethylhydrazine.
4291 Journal of Functional Foods 26:373-38
4292